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Preface
Brucellosis is a major zoonotic disease. Elimination of human disease depends on
the prevention and control of animal infections. In endemic settings, brucellosis
typically affects rural communities with inadequate access to healthcare and 
preventative education. There is often a history of illness in the family, occupational 
exposure, or travel from an endemic area.
The clinical features are variable, most commonly presenting as nonspecific fever, 
accompanied by musculoskeletal pain in almost half of the patients. The most
important differential diagnosis is tuberculosis, especially in localized infections. 
Less common manifestations include prostatitis, cystitis, interstitial nephritis, 
or glomerulonephritis. Infection among children is generally more benign than
in adults with respect to likelihood and severity of complications and response
to treatment. Brucellosis in pregnancy is associated with the risk of spontaneous
abortion, premature delivery, miscarriage, and intrauterine infection with fetal 
death. The diagnosis should be confirmed by culture of blood or other sterile fluids, 
e.g. joint aspirates or by serological tests.
The microbiology laboratory should be warned if brucellosis is suspected, both to
optimize testing strategies and to reduce the significant risk of laboratory-acquired 
infection. Treatment regimens should include at least two antimicrobial agents for
at least 6 weeks, in order to prevent relapse. Aminoglycoside-containing regimens
are superior. More prolonged treatment with a triple antimicrobial combination
may be required for complicated infections.
The approach taken by the authors in this book is resolutely practical as they
have tried to introduce and discuss therapeutic trials in cattle, the brucella spp. 
vaccines and their possible implications to control programs, molecular targets, and 
methods for differentiation of species and biovars. In addition, the latest updates
of antibiotic therapy of brucellosis are described, which makes the book easier to
consult. Kidney involvement in brucellosis and neonatal brucellosis are included in
this book.
This book is the result of several months of outstanding efforts by authors and 
revision of the content by experts in the field of brucellosis. This book is a valid 
resource and is intended for everyone interested in infectious disease to learn the
most important aspects of brucellosis.
Please do not hesitate to share with us your invaluable comments to improve the
next editions. We are deeply appreciative of our colleagues as this work would not
have been possible without their contribution.
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Evaluation of Therapeutic Trials in
Bovines
Aneela Zameer Durrani, Muhammad Usman, Zain Kazmi 
and Muhammad Husnain 
Abstract
Brucellosis is one of the most common and economically important zoonotic
diseases globally. Office International des Epizooties (OIE) listed it as the second 
most important zoonotic disease. The disease affects almost all animals but impor-
tantly buffalo. The disease manifests itself in the form of abortion, still births, 
weak calves, infertility, and specific lesions on reproductive organs. It is prevalent
worldwide but still a neglected disease. As a zoonotic disease its importance is
multifarious for animals as well as public health. Taking into account poor health
facilities and unawareness, its control becomes very significant. The difficulty to
treat this disease and its zoonotic potential compel slaughtering as a best strategy
to get rid of this disease. There are not too many therapeutic trials conducted to
control bovine brucellosis. Instead many therapeutic trials have been conducted for
treating human brucellosis. The therapeutic trial requires long term administration
of drugs (almost 6 weeks) without any surety of complete recovery so it is a pre-
ferred practice to eradicate the animal or sell it out instead of treating.
Keywords: Brucella, bovines, therapeutic trial, slaughtering, zoonotic
1. Introduction
Brucellosis is one of the most common and economically important zoonotic
diseases globally [1]. It was first discovered by Bruce in 1887. It is also known as
undulant fever, Mediterranean fever, Epizootic abortion, Enzootic abortion, Malta
fever, and Bang’s disease [2, 3]. It is considered as the most rapidly spreading disease
by the World Health Organization (WHO), Food and Agriculture Organization
(FAO), and Office International des Epizooties (OIE) [4]. Significant economic
losses due to brucellosis are abortion, low milk yield, low conception rate and cull-
ing of animal [5]. Central Asia, the Middle East and adjacent subtropical geogra-
phies are among those with the highest incidence of brucellosis among humans
and livestock worldwide [6]. There is a reason to believe that the burden caused 
by brucellosis in low-income countries in Asia and Africa is large [1]. Important
animal species that can get this disease include cattle, buffalo, swine, sheep, goats, 
camels, dogs and being zoonotic can also infect humans [7]. Prevalence of brucel-
losis in Buffalo is 5.05% in Pakistan [8]. This is suggested by quite an old study and 
conduction of a new research is required to study the current trends of brucellosis
in Pakistan. It is for sure that its prevalence has increased to threatening level.
Brucella is Gram-negative, nonmotile, coccobacilli or small rods intracellular
pathogen that are taxonomically categorized in the in the class α-proteobacteria, order
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Rhizobiales, family Brucellaceae. It is caused by ingestion of unpasteurized milk or 
undercooked meat from infected animals, or close contact with their secretions [3]. 
It is caused by different bacteria of the genus Brucella characterized by abortion epi-
didymis and orchitus. Brucellosis causes abortions in the third trimester of pregnancy 
when unvaccinated cattle are exposed to the infectious organism. Brucellosis has been 
reported since long in Pakistan and due to its increasing prevalence emphasis has been 
put on regular screening of livestock herds and of animals brought at abattoirs and at 
livestock markets [9]. The overall prevalence of brucellosis in Punjab is found to be 2.5%.
2. Diagnosis of brucellosis
Brucella spp. is considered as the most common laboratory-acquired pathogens. 
Several serological tests have been widely used for diagnosis of Brucella such are 
Rose Bengal plate test (RBPT), standard tube agglutination test (STAT), comple-
ment fixation test (CFT), enzyme linked immunosorbant assay (ELISA). Besides 
these, polymerase chain reaction (PCR)-based identification and typing and fluo-
rescence polarization assays (FPA) are also important diagnostic tools [10]. These 
all diagnostic tools have been employed by various researchers to find out brucel-
losis. Shafee and other in 2011 used MRT and i-ELISA to find out overall prevalence 
of brucellosis in Quetta, capital of Baluchistan province of Pakistan [11].
ELISA and PCR are more specific tests to diagnose brucellosis but there are 
various limitations to these tests. Both of these tests are expansive and need sophis-
ticated equipment to perform. Both cannot be performed in field conditions.
2.1 Therapeutic trial of brucellosis
The bovine brucellosis is very prevalent but a neglected disease on the whole. The 
countries which are declared as Brucella free countries managed to attain this status 
through slaughtering and destroying the Brucella positive animals along with effective 
vaccination. The literature confirmed that no country overcome it through treating 
the Brucella positive animals. The main reason behind this practice is the long dura-
tion of therapeutic trial, i.e., almost 6 weeks without any surety of complete recovery. 
In most of the cases, animals relapse the disease or act as a carrier for rest of their life.
Alavi and Ali Reza treated Brucella positive patients with doxycycline-rifampin 
and doxycycline-cortimoxazol and compared their efficacy. They concluded that 
the later combination has a better efficacy than former [12]. In another study the 
therapeutic efficacy of doxycycline and rifampicin (DR) with a doxycycline plus 
streptomycin (DS) were compared. It was concluded that doxycycline-aminoglyco-
side combination has a better efficacy and doxycycline-rifampin and doxycycline-
cotrimoxazole should be the alternative regimens [10].
Hari and Sughanda conducted a different type of research and checked immuno-
therapeutic response in cattle using a specific biomarker. They are against brucellosis. The 
SL induced strong antibody response and RL reported successful use of phage lysates of 
RB51 (RL) and S19 (SL) against brucellosis. The SL induced strong antibody response and 
RL stimulated cell mediated immunity (CMI). Other than these, no therapeutic trial are 
available in literature for evaluation. The reasons of which have already been discussed.
3. Conclusions
Although bovine brucellosis is very prevalent and now reemerging still no 
therapeutic trial has been conducted since now. The main reasons behind include 
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the complex nature of Brucella infection, long duration of therapy, and relapse of 
disease after treatment.
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the pastoralists and small-scale livestock farmers. The humans can be infected by 
ingestion of food products such as unpasteurized milk and their derivative products 
contaminated with the pathogen or by direct interaction with an infected animal or 
by aerosol inhalation [1, 3].
In small ruminants, the brucellosis is caused by B. melitensis [4, 5], the most 
important agent that induces the disease in humans [6, 7]. The disease often occurs 
in cattle, sheep, and goat production units; the latter is the most important given its 
potential role in conveying disease to human. Because brucellosis is a public health 
problem, its presence and disease control strategies implemented in domestic 
ruminants affect the occurrence of disease in humans [8, 9]. In small ruminants, the 
disease is clinically characterized by a decrease in milk production, abortion, loss of 
weight, fetal death, placental retention, weak offspring, and acute orchitis. In dairy 
animals, Brucella spp. replicates in the mammary gland and supra-mammary lymph 
nodes, and infected animals continually excrete the pathogen into milk throughout 
their lives [10, 11].
In underdeveloped countries, vaccination is the main tool used in the control of 
this disease [12, 13], in particular as a preventive measure in small ruminants, and 
is considered necessary given the economic and medical consequences of having 
brucellosis in animals and people infected [14]. The main indicator of brucel-
losis reduction in animals is a concomitant reduction of human cases [13, 15]. In 
endemic areas, intensive vaccination with B. melitensis Rev. 1 strain in adult and 
young females has been developed, being the most popular vaccine for the control 
of brucellosis in small ruminants. The use of a reduced dose rate decreases the 
presence of vaccine-associated undesirable events, such as postvaccine reactors to 
conventional tests, abortion, and milk shedding [16]. The vaccination is recom-
mended prior to the first gestation between 3 and 7 months of age to avoid abortion 
in pregnant animals [17]. When used at a reduced dose, Rev. 1 has shown to protect 
goats for at least 5 years after vaccination [13, 15]. El Idrissi et al. show that after 
vaccination, the animals vaccinated with Rev. 1 became positive to rose bengal plate 
test (RBPT) and complement fixation test (CFT) at 2 weeks, reaching the highest 
number of seroconverted animals’ highest level between 2 and 6 weeks. Thereafter, 
the percentage of seropositive ewes declined to zero at 14 weeks after challenge. 
More than 75% of animals were seroconverted 15 days after challenge inoculation 
[18]. The seroconversion of vaccine is the persistent serological reaction, especially 
when animals are vaccinated as adults. These persistent serological reactions are 
mainly against the antigenic O-chain of the lipopolysaccharide present in smooth 
Brucella [19]. Some strains may generate diagnostic interferences in serological 
test [19, 20], like vaccines containing Brucella LPS O antigens that are detected by 
traditional serodiagnostic tests for brucellosis [21]. It has been reported that the 
average time from inoculation to seroconversion may range from 2 to 3 weeks in 
B. melitensis-infected goats, from 2 to 4 weeks in B. abortus-infected goats, and 
3 weeks for the majority of tests evaluated with goats infected with either Brucella 
species [5, 19].
In Mexico, the vaccine RB51 was approved since 1998 as the official one for 
use in cattle females. The strain has been evaluated in both goat and sheep under 
controlled conditions with good protection against the experimental challenge with 
B. melitensis, even though protection is lower than that obtained with the Rev. 1 vac-
cine. Under experimental conditions no abortion occurs. Also, no postvaccination 
antibodies can be detected by conventional serology. The same findings have been 
reported after mass goat vaccination with RB51 in Veracruz, Mexico [13, 15].
Nowadays, the homologous overexpression to induce a greater and more effec-
tive immune response for the improvement of protective immunity of the vaccines 
has been developed. This can be achieved by introducing a plasmid within the RB51 
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strain with the gene that encodes the antigen expressed, along with appropriate 
promoters. In mouse (Balb/c) it has been shown that the overexpression of Cu/Zn 
superoxide dismutase (SOD) induces the best protection facing the experimental 
infection by B. abortus indicating that the homologous overexpression can produce 
a better vaccine RB51 (RB51-SOD) with an equal or better protection than that 
induced by Rev. 1, against the infection with B. melitensis [14, 19, 20]. However, 
there are no reports in domestic animals on the seroconversion and the vaccine effi-
cacy. Therefore, the aim of this study was to determine the prevalence of Brucella 
melitensis in a goat flock and the seroconversion in animals vaccinated with Rev. 
1 Brucella melitensis, RB51, and RB51-SOD Brucella abortus strains to estimate the 
level of protection conferred on susceptible females.
2. Material and methods
2.1 Study design
A phase III field trial was performed from September to December 2016 in 
order to determine the seroprevalence and seroconversion of goat flocks positive to 
brucellosis in the Xaltepec community municipality of Perote, Veracruz, Mexico, 
and to evaluate the protection conferred by vaccines with Rev. 1 Brucella melitensis, 
RB51, and RB51-SOD Brucella abortus strains.
2.2 Experimental design
The experiment was performed in two stages. In the first one, 546 animals from 
14 herds with similar management, grazing, feeding, and confinement conditions 
were used to determine the prevalence of goat brucellosis in Xaltepec. In the second 
stage, groups required for vaccine evaluation were integrated by randomly selecting 
animals negative to serological tests meeting the inclusion criteria. Positive animals 
remained in the herds under field conditions in order to function as a challenge for 
healthy and vaccinated animals.
Sample size was calculated using Win Episcope Version 2.0 for simple random 
sampling, considering the 0.52% prevalence in goats reported in Veracruz by 
Román-Ramírez et al. of [12], a confidence interval of 95%, and an error margin 
of 5%. Since each animal had an identification number on its metallic earring, 
females were randomly assigned to each group and subgroup. For each group, 
the minimal calculated sample was 72 animals; each group was integrated by a 
vaccinated subgroup (36) and a not vaccinated or control subgroup (36). Studied 
groups were integrated by goats older than 3 months, seronegative to brucellosis, 
and not vaccinated previously and kept within positive flocks. Animals were ran-
domly split into three groups and kept together 8 months in the flock to maintain 
exposure to Brucella spp.
2.3 Vaccination of animals
Animals in each vaccinated group received 2 mL of vaccine subcutaneously 
applied in the neck region. The first group was injected with Rev. 1 (Brucella meli-
tensis) strain with a concentration of 1–2 × 109 CFU/mL, the second received RB51 
strain (Brucella abortus) 3 × 108 to 3 × 109 CFU/mL, and the third one was injected 
with RB51-SOD (Brucella abortus) with a concentration of 3 × 108 to 3 × 109 CFU/
mL. Each group had a control subgroup of unvaccinated animals which received 
2 mL of PSS by subcutaneous injection in the neck region.
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2.4 Sample collection
Follow-up sampling was performed at 30, 60, 90, and 365 days post vaccination 
by blood sampling collected from the jugular vein in vacutainer tubes without anti-
coagulant (BD Vacutate, Oxford, UK). Each tube was identified with the number 
in the animal earring. Tubes containing blood samples were placed in a tilt position 
about 2 hours at room temperature allowing the separation of serum from the blood 
package. Later, tubes were placed into coolers at 4°C and transported to the labora-
tory and then were centrifuged at 1000 × g 10 minutes at room temperature. Finally, 
the serum was stored in sterile vials at −20°C until analysis.
2.5 Serological testing
Serum samples were analyzed by series using the following tests: 3% RBPT as 
screening and simple radial immunodifusion test (SRD) as confirmatory [5, 22].
RBPT was used as a screening test on the serum samples collected for the pres-
ence of Brucella agglutinins. Equal volumes of test serum and B. abortus antigen 
strain 1119-3 at 3% and pH of 3.6 (Aba Test Tarjeta 3%) (National Producer of 
Veterinary Biologics PRONABIVE) were added and mixed. This test has shown 98% 
sensitivity and 100% specificity. This test gives presumptive results.
SRD was used as a confirmatory test, and the antigen was used at a concentra-
tion of 1 mg/mL on agarose gel prepared with a glycine buffer solution and native 
hapten obtained from B. melitensis 16 M strain (produced at CENID Microbiology 
Animal, INIFAP). The test has shown 96% sensitivity and 80–100% specificity 
for the differential diagnosis between goats infected with Brucella spp. and those 
vaccinated with the Rev. 1 strain.
2.6 Analyses of data
Seroconversion produced during the observation period was calculated. 
Differences between groups and the significance of association were calculated by 
chi square (Xi2), and the degree of association was estimated using relative risk 
(RR) [23]. In those cases that frequency of positive animals to tests was 0.0%, 
confidence interval was calculated according to Campbell et al. [24].
3. Results
The results of initial seroprevalence of brucellosis in goat flocks at Xaltepec are 
shown in Tables 1 and 2. The seroprevalence in the three groups determined by the 
3% RBPT as presumptive test resulted in 22.1, 26.1, and 16.0% (95%CI: 16.5–28.9, 
19.9–33.2, and 11.1–22.3, respectively).
The serum positive goats were confirmed with SRD, and the prevalence reduced 
to 0.5, 1.1, and 2.2% (95%CI: 0.3–3.4, 0.1–4.3, and 0.7–5.9, respectively). Thus, a 
general prevalence of 1.2% (95%CI: 0.5–2.7) was observed.
Tables 3–6 show the seroconversion rate in goats vaccinated with Brucella strain 
determined by RBPT at 30, 60, 90, and 365 days after vaccination. At 30 days 
after vaccination, the 77.7% (95%CI: 61.9–88.2) of goats vaccinated with Rev. 1 
strain became positive to RBPT. Thereafter, 60 and 90 days post vaccination the 
percentage of seropositive goats declined to 72.2% (95%CI: 56.0–84.1) and 63.8% 
(95%CI: 47.5–77.5), respectively. At 365 days, 13.8% of vaccinated animals remained 
as seropositive to RBPT. Only two animals vaccinated with RB51 and RB5-SOD, 
respectively, were positive to RBPT at 30, 60, and 90 days after vaccination with 
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a prevalence of 2.7% and 5.5% (95%CI: 0.4–14.1 and 1.5–18.1, respectively). At 
365 days post vaccination, only 11.1% of vaccinated animals with RB51 remained 
reacting; there were no seroreactors to RB51-SOD strain by RBPT. Meanwhile, 
animals vaccinated with RB51 and RB51-SOD did not produce anti-O side-chain 
antibodies as measured by RBPT. Non-vaccinated control goats were seronegative. 
The seroconversion of a vaccine is the persistent serological reaction, especially 
when animals are vaccinated as adults; these persistent serological reactions are 
mainly against the antigenic O-chain of the lipopolysaccharide present in smooth 
Brucella strains [20].
Tables 7–10 show positive animals to RBPT that were confirmed with the SRD 
at 30, 60, 90, and 365 days after vaccination. Only 2.7% (95%CI: 0.4–14.1) of goats 
Strain Sample size RBPT
Positive Seroprevalence (%) 95%CI
Rev. 1 185 41 22.1 16.5–28.9
RB51 180 47 26.1 19.9–33.2
RB51-SOD 181 29 16.0 11.1–22.3
Total 546 117 21.4 18.1–25.1
Table 1. 
Seroprevalence of brucellosis rate by RBPT in goat flocks of Xaltepec municipality Perote, Veracruz, Mexico.
Strain Sample size SRD
Positive Seroprevalence (%) 95%CI
Rev. 1 41 1 0.5 0.3–3.4
RB51 47 2 1.1 0.1–4.3
RB51-SOD 29 4 2.2 0.7–5.9
Total 117 7 1.2 0.5–2.7
Table 2. 
Seroprevalence of brucellosis rate by SRD in goat flocks of Xaltepec municipality Perote, Veracruz, Mexico.
Group/subgroup N Time after vaccination (days)
30
Positive Seroconversion rate (%) 95%CI
Rev 1 Vaccinated 36 28 a 77.7 61.9–88.2
Control 36 4 b 11.1 4.4–25.3
RB51 Vaccinated 36 1 a 2.7 0.4–14.1
Control 36 0 a 0.0 0.0–0.09
RB51-SOD Vaccinated 36 2 a 5.5 1.5–18.1
Control 36 0 a 0.0 0.0–0.09
Different superscripts indicate statistical difference by column (P< 0.01).
Table 3. 
Seroconvertion rates determined by RBPT at 30 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
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a prevalence of 2.7% and 5.5% (95%CI: 0.4–14.1 and 1.5–18.1, respectively). At 
365 days post vaccination, only 11.1% of vaccinated animals with RB51 remained 
reacting; there were no seroreactors to RB51-SOD strain by RBPT. Meanwhile, 
animals vaccinated with RB51 and RB51-SOD did not produce anti-O side-chain 
antibodies as measured by RBPT. Non-vaccinated control goats were seronegative. 
The seroconversion of a vaccine is the persistent serological reaction, especially 
when animals are vaccinated as adults; these persistent serological reactions are 
mainly against the antigenic O-chain of the lipopolysaccharide present in smooth 
Brucella strains [20].
Tables 7–10 show positive animals to RBPT that were confirmed with the SRD 
at 30, 60, 90, and 365 days after vaccination. Only 2.7% (95%CI: 0.4–14.1) of goats 
Strain Sample size RBPT
Positive Seroprevalence (%) 95%CI
Rev. 1 185 41 22.1 16.5–28.9
RB51 180 47 26.1 19.9–33.2
RB51-SOD 181 29 16.0 11.1–22.3
Total 546 117 21.4 18.1–25.1
Table 1. 
Seroprevalence of brucellosis rate by RBPT in goat flocks of Xaltepec municipality Perote, Veracruz, Mexico.
Strain Sample size SRD
Positive Seroprevalence (%) 95%CI
Rev. 1 41 1 0.5 0.3–3.4
RB51 47 2 1.1 0.1–4.3
RB51-SOD 29 4 2.2 0.7–5.9
Total 117 7 1.2 0.5–2.7
Table 2. 
Seroprevalence of brucellosis rate by SRD in goat flocks of Xaltepec municipality Perote, Veracruz, Mexico.
Group/subgroup N Time after vaccination (days)
30
Positive Seroconversion rate (%) 95%CI
Rev 1 Vaccinated 36 28 a 77.7 61.9–88.2
Control 36 4 b 11.1 4.4–25.3
RB51 Vaccinated 36 1 a 2.7 0.4–14.1
Control 36 0 a 0.0 0.0–0.09
RB51-SOD Vaccinated 36 2 a 5.5 1.5–18.1
Control 36 0 a 0.0 0.0–0.09
Different superscripts indicate statistical difference by column (P< 0.01).
Table 3. 
Seroconvertion rates determined by RBPT at 30 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
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vaccinated with Rev. 1 became positive during the first three samplings, but this situ-
ation did not persist until at 365 days post vaccination as expected. Also, goats vac-
cinated with RB51 and RB51-SOD during the first 90 days post vaccination expressed 
Group/subgroup N Time after vaccination (days)
60
Positive Seroconversion rate (%) 95%CI
Rev 1 Vaccinated 36 27 a 72.2 56.0–84.1
Control 36 4 b 11.1 4.4–25.3
RB51 Vaccinated 36 1 a 2.7 0.4–14.1
Control 36 0 a 0.0 0.0–0.09
RB51-SOD Vaccinated 36 2 a 5.5 1.5–18.1
Control 36 0 a 0.0 0.0–0.09
Different superscripts indicate statistical difference by column (P< 0.01).
Table 4. 
Seroconvertion rates determined by RBPT at 60 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
Group/subgroup N Time after vaccination (days)
365
Positive Seroconversion rate (%) 95%CI
Rev 1 Vaccinated 36 5 a 13.8 6.0–28.6
Control 36 9 a 25.0 13.7–41.0
RB51 Vaccinated 36 4 a 11.1 4.4–25.3
Control 36 9 a 25.0 13.7–41.0
RB51-SOD Vaccinated 36 0 a 0.0 0.0–0.09
Control 36 7 a 19.4 9.7–35.0
Different superscripts indicate statistical difference by column (P< 0.01).
Table 6. 
Seroconvertion rates determined by RBPT at 365 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
Group/subgroup N Time after vaccination (days)
90
Positive Seroconversion rate (%) 95%CI
Rev 1 Vaccinated 36 23 a 63.8 47.5–77.5
Control 36 4 b 11.1 4.4–25.3
RB51 Vaccinated 36 1 a 2.7 0.4–14.1
Control 36 0 a 0.0 0.0–0.09
RB51-SOD Vaccinated 36 2 a 5.5 1.5–18.1
Control 36 0 a 0.0 0.0–0.09
Different superscripts indicate statistical difference by column (P< 0.01).
Table 5. 
Seroconvertion rates determined by RBPT at 90 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
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antibodies that were detected with the RBPT test but were negative to the SRD test; 
however, at 365 days, an animal in the RB51 strain group was identified as seropositive 
(2.7%, 95%CI: 0.4–14.1). It is noteworthy that serological samples that underwent 
Group/subgroup Time after vaccination (days)
60
Positive Prevalence rate (%) 95%CI
Rev 1 Vaccinated 1/27 2.7 0.49–14.1
Control 0/4 0.0 0.0–0.49
RB51 Vaccinated 0/1 0.0 0.0–0.79
Control 0/0 w.d.* w.d.*
RB51-SOD Vaccinated 0/2 0.0 0.0–0.66
Control 0/0 w.d.* w.d.*
*w.d.= without data
Table 8. 
Seroconversion rates determined by SRD at 60 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
Group/subgroup Time after vaccination (days)
90
Positive Prevalence rate (%) 95%CI
Rev 1 Vaccinated 1/23 2.7 0.49–14.1
Control 0/4 0.0 0.0–0.49
RB51 Vaccinated 0/1 0.0 0.0–0.79
Control 0/0 w.d.* w.d.*
RB51-SOD Vaccinated 0/2 0.0 0.0–0.66
Control 0/0 w.d.* w.d.*
*w.d.= without data
Table 9. 
Seroconversion rates determined by SRD at 90 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
Group/subgroup Time after vaccination (days)
30
Positive Prevalence rate (%) 95%CI
Rev 1 Vaccinated 1/28 2.7 0.49–14.1
Control 0/4 0.0 0.0–0.49
RB51 Vaccinated 0/1 0.0 0.0–0.79
Control 0/0 w.d.* w.d.*
RB51-SOD Vaccinated 0/2 0.0 0.0–0.66
Control 0/0 w.d.* w.d.*
*w.d.= without data
Table 7. 
Seroconversion rates determined by SRD at 30 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
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the confirmatory test (SRD) correspond to animals that had a positive result to the 
screening test (RBPT); hence, the original sample size was not decreased.
4. Discussion
Goat herds in the present study had similar conditions of feeding, handling, 
and confinement. Each group was exposed to animals infected with Brucella spp. 
Overall seroprevalence in the herds under study was 21.4% (95%CI: 18.1–25.1) with 
3% RBST as screening and 1.2% (95%CI: 0.5–2.7) by SRD as the confirmatory one. 
These seroprevalences are similar to those found by Román-Ramírez et al. in 14 
municipalities in the central area of the state of Veracruz, Mexico, that were 18.18% 
(95%CI: 15.15–21.64) by RBST and 0.52% (95%CI: 0.13–1.65) by SDR tests [12]. 
However, the seroprevalence is also greater than 9.8% reported by Solorio-Rivera 
et al. (95%CI: 8.8–10.7) [5] using RBST test in goat herds of the state of Michoacán, 
Mexico. This shows that the herds located in the community of Xaltepec, munici-
pality of Perote, Veracruz, Mexico, have animals that could be exposed to brucello-
sis and the conditions of management provide an opportunity for the perpetuating 
the infection.
The permanent vaccination program for goat herds has been operating in the 
area since 1994 achieving the requirements for the control phase according to the 
Official Mexican Standard (NOM-041-ZOO-1995) National Campaign against 
brucellosis in animals. These findings may suggest that the vaccine used is not 
protecting all animals, the vaccine is not properly managed or injected, or vaccina-
tion is not timely applied, resulting in the possibility of maintaining infection in the 
animals. Furthermore, the animal may not develop the infection, but the immune 
response capability is then detected by the diagnostic screening test without being 
a truly infected animal. As a result, the recognized agglutination serological tests 
(RSBT) leads to diagnostic confusion determining infected animals to remain in the 
herds. Hence, it is necessary to evaluate the vaccine strain to be used in the brucel-
losis control programs, since the results shown in Table 1 demonstrate that more 
than 50% of the animals reacted to the screening test, but are not infected as shown 
by the SRD test (Tables 7–9), which possess a greater sensitivity. This situation 
determines the need to invest in confirmatory tests [25–29].
When vaccinated groups of goats were evaluated by the RSBT, animals vac-
cinated with Rev. 1 strain had a seroconversion rate of 77.7% (95%CI: 61.9–88.2), 
Group/subgroup Time after vaccination (days)
365
Positive Prevalence rate (%) 95%CI
Rev 1 Vaccinated 0/5 0.0 0.0–0.43
Control 0/9 0.0 0.0–0.29
RB51 Vaccinated 1/4 2.7 0.49–14.1
Control 1/9 2.7 0.49–14.1
RB51-SOD Vaccinated 0/0 w.d.* w.d.*
Control 1/7 2.7 0.49–14.1
*w.d.= without data
Table 10. 
Seroconversion rates determined by SRD at 365 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
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72.2% (95%CI: 56.0–84.1), 63.8% (95%CI: 47.5–77.5), and 13.8% (95%CI: 6.0–
28.6) at 30, 60, 90, and 365 days post vaccination, respectively (Tables 3–6). This 
agrees with Blasco et al. [7] who pointed out that vaccination with a full dose (1 × 
109 CFU/mL) may cause diagnostic interference and inconvenience to rely on vac-
cination as the only alternative for brucellosis eradication programs in goat herds 
[7, 27]. RBST-positive animals were confirmed by the SRD test, and only one 
animal resulted positive, representing 2.7% (95%CI: 0.4–14.1) (Tables 7–9). This 
indicates that the vaccine did not protect or that the animal was infected prior to 
vaccination, despite being negative at initial screening. Vaccinated animals were 
not challenged at a controlled dose of Brucella melitensis, since the challenge was 
through a natural exposure to the infected animals, which were kept in confine-
ment with the vaccinated animals, to allow exposed vaccinated animals to become 
infected as occurring in the normal management situation in the regional produc-
tion systems in Mexico [14, 30].
As observed in Tables 3–5, animals vaccinated with the RB51 and RB51-SOD 
strains, 2.7% (95%CI: 0.4–14.1) and 5.5% (95%CI: 1.5–18.1), respectively, reacted 
to the RBST during the evaluation period. However, when analyzed by the SRD for 
confirmation, all animals were negative. RB51 strain is officially used for vaccina-
tion only in bovine females; it is a rough mutant strain derived from B. abortus 
2308 smooth strain, so it does not induce response of anti-LPS antibodies. It has 
the advantage of allowing conventional serological tests to be used for brucellosis 
diagnosis in animals, and its use is considered safe in small ruminants [31]. Fosgate 
et al. carried out a study in water buffalo males and females which were vaccinated 
subcutaneously with RB51 at a concentration of 1.0–3.4 × 1010 UFC/mL, to evaluate 
the serological performance by agglutination tests [31]. Animals were challenged 
in a herd with an initial Brucella spp. prevalence of 56%. Out of the vaccinated 
animals, 2/32 (6.2%) reacted in different samplings in at least one serological test 
(STAT, SPAT, and/or BPAT). Authors conclude that the proportion of vaccinated 
animals that became positive to brucellosis in this field trial was greater than the 
corresponding proportion in the control group emphasizing that vaccination does 
not stop the seroconversion effect on the herds challenged with a field strain. 
Furthermore, the RB51 vaccine did not prevent seroconversion of the animals. 
Therefore, infected animals were able to process the agent and maintain such a 
condition that it could react to the diagnostic test by IgM production by stimulation 
of the O-type side chains of the field strain, although the animal was not infected 
[28, 29, 32].
El Idrissi et al. compared the vaccine efficacy of Rev. 1 and RB51 strains in sheep. 
Considering seroconversion, they conclude that after vaccination, all sheep vac-
cinated with Rev. 1 were positive to RBPT and complement fixation test (CFT) at 2 
weeks, reaching their maximum between 2 and 6 weeks [7]. Then the percentage 
decreased and was zero 14 weeks after challenge. Animals vaccinated with RB51 
did not produce anti-O side-chain antibodies, as measured by RBPT and CFT. After 
exposure to challenge, anti-O side-chain antibodies, measured by RBPT, were 
detected in the serum of vaccinated animals and controls [19].
Out of the animals vaccinated with RB51-SOD strain, 2/36 were serocon-
verted, representing 5.5% (95%CI: 1.5–18.1) (Tables 3–5). The animals that 
underwent the confirmatory test (SRD) were negative as shown in Tables 7–9. 
The above indicates that animals established an immune memory response 
generating the production of immunoglobulins detectable by the screening test, 
but they were not infected [34]. Olsen et al. [32] evaluated the RB51-SOD strain 
in bisons, which was less effective than RB51 in protecting against abortion and 
uterine infection in this species [32–34]. In the present study, some animals of 
the goat groups of B. abortus strains RB51 and RB51-SOD were positive only to 
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the screening test, which could be discarded by SRD test that identified them as 
negative to brucellosis [28, 29, 31, 33, 34].
The RB51-SOD strain was obtained from B. abortus 2308 in order to generate 
the overexpression of a protective periplasmic antigen of the protective antigen 
known as Cu/Zn SOD, which causes the immune cell response by T-helper-type Th1 
lymphocytes, and protection against the strain of B. abortus 2308, which has been 
demonstrated in murine models [26, 29, 31–33]. Despite the favorable outcome in 
mice, Dorneles et al. [33] pointed out that the potential use of RB51-SOD under 
field conditions is very limited, although satisfactory results have been obtained. It 
is important to consider that the response observed in the mice might not reflect the 
protection achieved in the natural hosts after vaccination. Moreover, to generate a 
strong and protective immune response that mimic natural infection is a complex 
challenge. However, the current study in goats allowed to evaluate the RB51-SOD 
strain and to know part of its satisfactory performance in the field, since the newly 
developed vaccines have only evaluated in murine models [28–30]. Contrary to 
the Rev. 1 vaccine, current study demonstrates that the RB51-SOD strain does not 
induce seroconversion in goats.
5. Conclusion
When evaluating the Rev. 1, RB51, and RB51-SOD vaccine strains, seroconver-
sion in animals vaccinated with Rev. 1 strain was higher than that shown by the 
strains RB51 and RB51-SOD by conventional serological tests in infected herds 
during the evaluated period. Therefore, vaccination with Rev. 1 originates the need 
to perform confirmatory tests causing an increase in diagnosis costs. According to 
results of the present study, the RB51-SOD vaccine represents an alternative for 
controlling one of the most important worldwide zoonosis in goats. However, fur-
ther studies are required to evaluate the performance of immune response, vaccine 
safety, and efficacy at field level.
Acknowledgements
We thank the state committee for the promotion and protection of livestock 
of Veracruz and the product system goats of Veracruz. This work was supported 
by SEP-PRODEP research grant project [DSA/I103.5/I5/14220] “Support for the 
integration of thematic networks of academic collaboration.”
Conflict of interest
The authors have no conflict of interest to declare.
15
Comparative Field Trial Effect of Brucella spp. Vaccines on Seroconversion in Goats…
DOI: http://dx.doi.org/10.5772/intechopen.87065
Author details
Baldomero Molina-Sánchez1, David I. Martínez-Herrera1*, Violeta T. Pardío-Sedas1, 
Ricardo Flores-Castro2, José F. Morales-Álvarez2 and José A. Villagómez-Cortés1
1 Facultad de Medicina Veterinaria y Zootecnia, Universidad Veracruzana, Veracruz, 
Veracruz, México
2 Centro Nacional de Investigación Disciplinaria Microbiología  
(CENID-Microbiología), Instituto Nacional de Investigaciones Forestales, Agrícolas 
y Pecuarias, Santa Fé, Ciudad de México, México
*Address all correspondence to: dmartinez@uv.mx
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
New Insight into Brucella Infection and Foodborne Diseases
14
the screening test, which could be discarded by SRD test that identified them as 
negative to brucellosis [28, 29, 31, 33, 34].
The RB51-SOD strain was obtained from B. abortus 2308 in order to generate 
the overexpression of a protective periplasmic antigen of the protective antigen 
known as Cu/Zn SOD, which causes the immune cell response by T-helper-type Th1 
lymphocytes, and protection against the strain of B. abortus 2308, which has been 
demonstrated in murine models [26, 29, 31–33]. Despite the favorable outcome in 
mice, Dorneles et al. [33] pointed out that the potential use of RB51-SOD under 
field conditions is very limited, although satisfactory results have been obtained. It 
is important to consider that the response observed in the mice might not reflect the 
protection achieved in the natural hosts after vaccination. Moreover, to generate a 
strong and protective immune response that mimic natural infection is a complex 
challenge. However, the current study in goats allowed to evaluate the RB51-SOD 
strain and to know part of its satisfactory performance in the field, since the newly 
developed vaccines have only evaluated in murine models [28–30]. Contrary to 
the Rev. 1 vaccine, current study demonstrates that the RB51-SOD strain does not 
induce seroconversion in goats.
5. Conclusion
When evaluating the Rev. 1, RB51, and RB51-SOD vaccine strains, seroconver-
sion in animals vaccinated with Rev. 1 strain was higher than that shown by the 
strains RB51 and RB51-SOD by conventional serological tests in infected herds 
during the evaluated period. Therefore, vaccination with Rev. 1 originates the need 
to perform confirmatory tests causing an increase in diagnosis costs. According to 
results of the present study, the RB51-SOD vaccine represents an alternative for 
controlling one of the most important worldwide zoonosis in goats. However, fur-
ther studies are required to evaluate the performance of immune response, vaccine 
safety, and efficacy at field level.
Acknowledgements
We thank the state committee for the promotion and protection of livestock 
of Veracruz and the product system goats of Veracruz. This work was supported 
by SEP-PRODEP research grant project [DSA/I103.5/I5/14220] “Support for the 
integration of thematic networks of academic collaboration.”
Conflict of interest
The authors have no conflict of interest to declare.
15
Comparative Field Trial Effect of Brucella spp. Vaccines on Seroconversion in Goats…
DOI: http://dx.doi.org/10.5772/intechopen.87065
Author details
Baldomero Molina-Sánchez1, David I. Martínez-Herrera1*, Violeta T. Pardío-Sedas1, 
Ricardo Flores-Castro2, José F. Morales-Álvarez2 and José A. Villagómez-Cortés1
1 Facultad de Medicina Veterinaria y Zootecnia, Universidad Veracruzana, Veracruz, 
Veracruz, México
2 Centro Nacional de Investigación Disciplinaria Microbiología  
(CENID-Microbiología), Instituto Nacional de Investigaciones Forestales, Agrícolas 
y Pecuarias, Santa Fé, Ciudad de México, México
*Address all correspondence to: dmartinez@uv.mx
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
16
New Insight into Brucella Infection and Foodborne Diseases
References
[1] Gul ST, Khan A. Epidemiology 
and epizootology of brucellosis: A 
review. Pakistan Veterinary Journal. 
2007;27:145-151
[2] Arenas-Gamboa AM, Rossetti CA, 
Chaki SP, Garcia-Gonzalez DG, Adams 
LG, Ficht TA. Human brucellosis 
and adverse pregnancy outcomes. 
Current Tropical Medicine Reports. 
2016;3:164-172
[3] Kaltungo BY, Saidu SNA, Musa 
IW, Baba AY. Brucellosis: A neglected 
zoonosis. British Microbiology Research 
Journal. 2014;4:1551-1574
[4] Reviriego FJ, Moreno MA, 
Domınguez L. Risk factors for 
brucellosis seroprevalence of sheep 
and goat flocks in Spain. Preventive 
Veterinary Medicine. 2000;44:167-173
[5] Solorio-Rivera JL, Segura-Correa 
JC, Sánchez-Gil LG. Seroprevalence 
of and risk factors for brucellosis of 
goats in herds of Michoacan, Mexico. 
Preventive Veterinary Medicine. 
2007;82(3):282-290
[6] Lopez-Merino AH, Migrañas-
Ortiz R, Perez-Miravete A, Magos 
C, Izaba BS, Tapia-Coyner R, et al. 
Seroepidemiología de la brucelosis 
en México. Salud Pública de México. 
1992;34(2):230-240
[7] Blasco JM, Molina-Flores B. Control 
and eradication of Brucella melitensis 
infection in sheep and goats. Veterinary 
Clinics of North America: Food Animal 
Practice. 2011;27(1):95-104
[8] Montiel DO, Frankena K, Udo H, 
Baer NMK, Van der Zijpp A. Prevalence 
and risk factors for brucellosis in goats 
in areas of Mexico with and without 
brucellosis control campaign. Tropical 
Animal Health and Production. 
2013;45(6):1383-1389
[9] Mendez-Lozano M, Rodríguez-Reyes 
EJ, Sánchez-Zamorano LM. Brucelosis, 
una zoonosis presente en la población: 
estudio de series de tiempo en México. 
Salud Pública México. 2015;57:519-527
[10] Tsegay A, Tuli G, Kassa T, Kebede 
N. Seroprevalence and risk factors 
of Brucellosis in small ruminants 
slaughtered at Debre Ziet and Modjo 
export abattoirs, Ethiopia. Journal of 
Infection in Developing Countries. 
2015;9:373-380
[11] Wareth G, Melzer F, Elschner MC, 
Neubauer H, Roesler U. Detection 
of Brucella melitensis in bovine milk 
and milk products from apparently 
healthy animals in Egypt by real-time 
PCR. Journal of Infection in Developing 
Countries. 2014;8(10):1339-1343
[12] Román-Ramírez DL, Martínez-
Herrera DI, Villagómez-Cortés JAJ, 
Peniche-Cardeña ÁE, Morales-Álvarez 
JF, Flores-Castro R. Epidemiología de la 
brucelosis caprina en la Zona Centro del 
Estado de Veracruz. Gaceta Médica de 
México. 2017;153(1):26-30
[13] Villa R, Perea M, Aparicio ED, 
Mobarak AS, Andrade LH, Güemes FS.  
Abortions and stillbirths in goats 
immunized against brucellosis using 
RB51, rfbK and Rev 1 vaccines. Tecnica 
Pecuaria en Mexico. 2008;46(3):249-257
[14] Schurig GG, Sriranganathan N,  
Corbel MJ. Brucellosis vaccines: 
past, present and future. Veterinary 
Microbiology. 2002;90(1):479-496
[15] Luna-Martı́nez JE, Mejı́a-Terán C.  
Brucellosis in Mexico: Current status 
and trends. Veterinary Microbiology. 
2002;90(1):19-30
[16] El Idrissi AH, Benkirane A, El 
Maadoudi M, Bouslikhane M, Berrada J, 
Zerouali A. Comparison of the efficacy 
17
Comparative Field Trial Effect of Brucella spp. Vaccines on Seroconversion in Goats…
DOI: http://dx.doi.org/10.5772/intechopen.87065
of Brucella abortus strain RB51 and 
Brucella melitensis Rev. 1 live vaccines 
against experimental infection with 
Brucella melitensis in pregnant ewes. 
Revue Scientifique et Technique-
Office International des Épizooties. 
2001;20(3):741-744
[17] Poester FP, Ramos ET, Gomes MJP,  
Chiminazzo C, Schurig G. The 
serological response of adult cattle 
after vaccination with Brucella abortus 
strain 19 and RB51. Brazilian Journal 
of Veterinary Research and Animal 
Science. 2000;37(1)
[18] Garin-Bastuji B, Blasco JM, 
Marín C, Albert D. The diagnosis of 
brucellosis in sheep and goats, old and 
new tools. Small Ruminant Research. 
2006;62(1):63-70
[19] Rahman S, Baek BK. Diagnostic 
efficacy of Brucella abortus strain 
RB51 in experimentally inoculated 
Sprague-Dawley rats using western blot 
assay. Journal of Infection in Developing 
Countries. 2008;2(05):384-388
[20] Mikolon AB, Gardner IA, Hietala 
SK, de Anda JH, Pestaña EC, Hennager 
SG, et al. Evaluation of North American 
antibody detection tests for diagnosis of 
brucellosis in goats. Journal of Clinical 
Microbiology. 1998;36(6):1716-1722
[21] Garin – Bastuji B, Blasco JM, 
Marín C, Albert D. The diagnosis of 
brucellosis in sheep and goats, old and 
new tolos. Small Ruminant Research. 
2006;62:63-70
[22] Coelho AM, Díez JG, Coelho 
AC. Brucelosis en pequeños rumiantes: 
efecto de la aplicación de un programa 
especial de vacunación en masa 
con REV-1. Revista electrónica de 
Veterinaria. 2013;14(12):1-16
[23] Thrusfield M. Veterinary 
Epidemiology. 3rd ed. UK: Blackwell 
Science Oxford; 2005
[24] Campbell MJ, Machin D, Walters SJ.  
Medical Statistics: A Textbook for the 
Health Sciences. 4th ed. Chichester, 
West Sussex, England: John Wiley & 
Sons; 2010. pp. 89-93
[25] Ali S, Akhter S, Neubauer H,  
Melzer F, Khan I, Ali Q , et al. 
Serological, cultural, and molecular 
evidence of Brucella infection in small 
ruminants in Pakistan. Journal of 
Infection in Developing Countries. 
2015;9(05):470-475
[26] Blasco JM. Existing and future 
vaccines against brucellosis in small 
ruminants. Small Ruminant Research. 
2006;62(1):33-37
[27] Martínez Martínez OL, Pérez De 
la Rosa R, Díaz Aparicio E, Snyderlaar 
Hardwicke AC, Hernández Andrade 
L, Suárez Güemes F. Estudio de la 
eliminación en la leche de la cepa 
Rev 1 de Brucella melitensis en cabras 
vacunadas con dosis reducida. 
Tecnica Pecuaria en Mexico. 
2005;43(3):399-404
[28] Yang X, Skyberg JA, Cao L, Clapp B, 
Thornburg T, Pascual DW. Progress in 
Brucella vaccine development. Frontiers 
of Biology. 2013;8(1):60-77
[29] Fosgate GT, Adesiyun AA, Hird 
DW, Johnson WO, Hietala SK, Schurig 
GG, et al. Evaluation of brucellosis 
RB51 vaccine for domestic water 
buffalo (Bubalus bubalis) in Trinidad. 
Preventive Veterinary Medicine. 
2003;58(3):211-225
[30] Vemulapalli R, He Y, Cravero S, 
Sriranganathan N, Boyle SM, Schurig 
GG. Overexpression of protective 
antigen as a novel approach to enhance 
vaccine efficacy of Brucella abortus 
strain RB51. Infection and Immunity. 
2000;68(6):3286-3289
[31] Oñate AA, Céspedes S, Cabrera 
A, Rivers R, González A, Muñoz C, 
16
New Insight into Brucella Infection and Foodborne Diseases
References
[1] Gul ST, Khan A. Epidemiology 
and epizootology of brucellosis: A 
review. Pakistan Veterinary Journal. 
2007;27:145-151
[2] Arenas-Gamboa AM, Rossetti CA, 
Chaki SP, Garcia-Gonzalez DG, Adams 
LG, Ficht TA. Human brucellosis 
and adverse pregnancy outcomes. 
Current Tropical Medicine Reports. 
2016;3:164-172
[3] Kaltungo BY, Saidu SNA, Musa 
IW, Baba AY. Brucellosis: A neglected 
zoonosis. British Microbiology Research 
Journal. 2014;4:1551-1574
[4] Reviriego FJ, Moreno MA, 
Domınguez L. Risk factors for 
brucellosis seroprevalence of sheep 
and goat flocks in Spain. Preventive 
Veterinary Medicine. 2000;44:167-173
[5] Solorio-Rivera JL, Segura-Correa 
JC, Sánchez-Gil LG. Seroprevalence 
of and risk factors for brucellosis of 
goats in herds of Michoacan, Mexico. 
Preventive Veterinary Medicine. 
2007;82(3):282-290
[6] Lopez-Merino AH, Migrañas-
Ortiz R, Perez-Miravete A, Magos 
C, Izaba BS, Tapia-Coyner R, et al. 
Seroepidemiología de la brucelosis 
en México. Salud Pública de México. 
1992;34(2):230-240
[7] Blasco JM, Molina-Flores B. Control 
and eradication of Brucella melitensis 
infection in sheep and goats. Veterinary 
Clinics of North America: Food Animal 
Practice. 2011;27(1):95-104
[8] Montiel DO, Frankena K, Udo H, 
Baer NMK, Van der Zijpp A. Prevalence 
and risk factors for brucellosis in goats 
in areas of Mexico with and without 
brucellosis control campaign. Tropical 
Animal Health and Production. 
2013;45(6):1383-1389
[9] Mendez-Lozano M, Rodríguez-Reyes 
EJ, Sánchez-Zamorano LM. Brucelosis, 
una zoonosis presente en la población: 
estudio de series de tiempo en México. 
Salud Pública México. 2015;57:519-527
[10] Tsegay A, Tuli G, Kassa T, Kebede 
N. Seroprevalence and risk factors 
of Brucellosis in small ruminants 
slaughtered at Debre Ziet and Modjo 
export abattoirs, Ethiopia. Journal of 
Infection in Developing Countries. 
2015;9:373-380
[11] Wareth G, Melzer F, Elschner MC, 
Neubauer H, Roesler U. Detection 
of Brucella melitensis in bovine milk 
and milk products from apparently 
healthy animals in Egypt by real-time 
PCR. Journal of Infection in Developing 
Countries. 2014;8(10):1339-1343
[12] Román-Ramírez DL, Martínez-
Herrera DI, Villagómez-Cortés JAJ, 
Peniche-Cardeña ÁE, Morales-Álvarez 
JF, Flores-Castro R. Epidemiología de la 
brucelosis caprina en la Zona Centro del 
Estado de Veracruz. Gaceta Médica de 
México. 2017;153(1):26-30
[13] Villa R, Perea M, Aparicio ED, 
Mobarak AS, Andrade LH, Güemes FS.  
Abortions and stillbirths in goats 
immunized against brucellosis using 
RB51, rfbK and Rev 1 vaccines. Tecnica 
Pecuaria en Mexico. 2008;46(3):249-257
[14] Schurig GG, Sriranganathan N,  
Corbel MJ. Brucellosis vaccines: 
past, present and future. Veterinary 
Microbiology. 2002;90(1):479-496
[15] Luna-Martı́nez JE, Mejı́a-Terán C.  
Brucellosis in Mexico: Current status 
and trends. Veterinary Microbiology. 
2002;90(1):19-30
[16] El Idrissi AH, Benkirane A, El 
Maadoudi M, Bouslikhane M, Berrada J, 
Zerouali A. Comparison of the efficacy 
17
Comparative Field Trial Effect of Brucella spp. Vaccines on Seroconversion in Goats…
DOI: http://dx.doi.org/10.5772/intechopen.87065
of Brucella abortus strain RB51 and 
Brucella melitensis Rev. 1 live vaccines 
against experimental infection with 
Brucella melitensis in pregnant ewes. 
Revue Scientifique et Technique-
Office International des Épizooties. 
2001;20(3):741-744
[17] Poester FP, Ramos ET, Gomes MJP,  
Chiminazzo C, Schurig G. The 
serological response of adult cattle 
after vaccination with Brucella abortus 
strain 19 and RB51. Brazilian Journal 
of Veterinary Research and Animal 
Science. 2000;37(1)
[18] Garin-Bastuji B, Blasco JM, 
Marín C, Albert D. The diagnosis of 
brucellosis in sheep and goats, old and 
new tools. Small Ruminant Research. 
2006;62(1):63-70
[19] Rahman S, Baek BK. Diagnostic 
efficacy of Brucella abortus strain 
RB51 in experimentally inoculated 
Sprague-Dawley rats using western blot 
assay. Journal of Infection in Developing 
Countries. 2008;2(05):384-388
[20] Mikolon AB, Gardner IA, Hietala 
SK, de Anda JH, Pestaña EC, Hennager 
SG, et al. Evaluation of North American 
antibody detection tests for diagnosis of 
brucellosis in goats. Journal of Clinical 
Microbiology. 1998;36(6):1716-1722
[21] Garin – Bastuji B, Blasco JM, 
Marín C, Albert D. The diagnosis of 
brucellosis in sheep and goats, old and 
new tolos. Small Ruminant Research. 
2006;62:63-70
[22] Coelho AM, Díez JG, Coelho 
AC. Brucelosis en pequeños rumiantes: 
efecto de la aplicación de un programa 
especial de vacunación en masa 
con REV-1. Revista electrónica de 
Veterinaria. 2013;14(12):1-16
[23] Thrusfield M. Veterinary 
Epidemiology. 3rd ed. UK: Blackwell 
Science Oxford; 2005
[24] Campbell MJ, Machin D, Walters SJ.  
Medical Statistics: A Textbook for the 
Health Sciences. 4th ed. Chichester, 
West Sussex, England: John Wiley & 
Sons; 2010. pp. 89-93
[25] Ali S, Akhter S, Neubauer H,  
Melzer F, Khan I, Ali Q , et al. 
Serological, cultural, and molecular 
evidence of Brucella infection in small 
ruminants in Pakistan. Journal of 
Infection in Developing Countries. 
2015;9(05):470-475
[26] Blasco JM. Existing and future 
vaccines against brucellosis in small 
ruminants. Small Ruminant Research. 
2006;62(1):33-37
[27] Martínez Martínez OL, Pérez De 
la Rosa R, Díaz Aparicio E, Snyderlaar 
Hardwicke AC, Hernández Andrade 
L, Suárez Güemes F. Estudio de la 
eliminación en la leche de la cepa 
Rev 1 de Brucella melitensis en cabras 
vacunadas con dosis reducida. 
Tecnica Pecuaria en Mexico. 
2005;43(3):399-404
[28] Yang X, Skyberg JA, Cao L, Clapp B, 
Thornburg T, Pascual DW. Progress in 
Brucella vaccine development. Frontiers 
of Biology. 2013;8(1):60-77
[29] Fosgate GT, Adesiyun AA, Hird 
DW, Johnson WO, Hietala SK, Schurig 
GG, et al. Evaluation of brucellosis 
RB51 vaccine for domestic water 
buffalo (Bubalus bubalis) in Trinidad. 
Preventive Veterinary Medicine. 
2003;58(3):211-225
[30] Vemulapalli R, He Y, Cravero S, 
Sriranganathan N, Boyle SM, Schurig 
GG. Overexpression of protective 
antigen as a novel approach to enhance 
vaccine efficacy of Brucella abortus 
strain RB51. Infection and Immunity. 
2000;68(6):3286-3289
[31] Oñate AA, Céspedes S, Cabrera 
A, Rivers R, González A, Muñoz C, 
New Insight into Brucella Infection and Foodborne Diseases
18
et al. A DNA vaccine encoding Cu, 
Zn superoxide dismutase of Brucella 
abortus induces protective immunity in 
BALB/c mice. Infection and Immunity. 
2003;71(9):4857-4861
[32] Olsen SC, Boyle SM, Schurig GG, 
Sriranganathan NN. Immune responses 
and protection against experimental 
challenge after vaccination of bison with 
Brucella abortus strain RB51 or RB51 
overexpressing superoxide dismutase 
and glycosyltransferase genes. 
Clinical and Vaccine Immunology. 
2009;16(4):535-540
[33] Dorneles EM, Sriranganathan N, 
Lage AP. Recent advances in Brucella 
abortus vaccines. Veterinary Research. 
2015;46(1):76
[34] Goodwin ZI, Pascual DW.  
Brucellosis vaccines for livestock. 




Kidney Disease in Brucellosis
Shokoufeh Savaj
Abstract
Brucellosis, a prevalent zoonosis disease in different countries, can involve the 
kidney during infection and also present in the complicated form in hemodialysis 
(HD), peritoneal dialysis (PD), and kidney transplant (Tx) patient. In spite of few 
reports of kidney involvements in the literature, this infection can imitate a wide 
range of glomerular disease from minimal change, membranous glomeropathy, 
focal and diffuse proliferative glomerular disease to rapidly progressive glomerulo-
nephritis. Cryoglobulinemia, thrombotic microangiopathy, and ANCA-associated 
glomerular disease are vasculitis form of the disease. Tubulointerstitial involve-
ment, electrolyte disorder, renal abscess, and pyelonephritis can present the same 
as other Gram-negative infections. Moreover, peritonitis in PD patient, spondylo-
arthropathy in HD, and severe infection in kidney Tx patients have been reported. 
Infection recurrence and infection from kidney donors are another dilemma in 
renal recipients. Brucellosis as a multifaced disease can mimic a wide range of 
presentations in nephrology. Clinicians should keep in mind the diverse pictures of 
the disease, especially when they practice in the endemic area.
Keywords: kidney, brucellosis, glomerular disease, dialysis, kidney transplant
1. Introduction
Brucellosis, a prevalent zoonosis disease with a worldwide distribution, can involve 
the kidney during infection. In 1889, Bruce [1] firstly reported kidney disease in Malt 
fever. Since then, a wide range of kidney involvements from direct invasion of Brucella 
with abscess and tubulointerstitial nephritis, immune complex disease, vasculitis, and 
drug toxicity have been reported. Brucella infection in immunocompromised patient 
can induce a confusing picture with peritonitis in peritoneal dialysis (PD), spondy-
lodiscitis in hemodialysis, and complicated form of the disease in kidney transplant 
(TX) patients. Immunosuppressive monitoring, drug side effects, and donor to recipi-
ent transmission or recurrence are great challenges in the management of organ recipi-
ents with brucellosis. In this chapter, different presentations of brucellosis in kidney 
including glomeruli, tubulointerstitial, and vasculature involvement are discussed. 
Secondly, the Brucella infection in PD, HD, and Tx patients are reviewed, and finally, 
the chance of infection transmission of Brucellosis in the donor and recipients and the 
challenging point of pretransplant evaluation in donors and recipients are discussed.
2. Glomerular disease in brucellosis
Glomerular disease is an uncommon presentation in brucellosis. It can present 
with hematuria, pyuria, proteinuria, increased blood pressure, edema, and renal 
New Insight into Brucella Infection and Foodborne Diseases
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the kidney during infection. In 1889, Bruce [1] firstly reported kidney disease in Malt 
fever. Since then, a wide range of kidney involvements from direct invasion of Brucella 
with abscess and tubulointerstitial nephritis, immune complex disease, vasculitis, and 
drug toxicity have been reported. Brucella infection in immunocompromised patient 
can induce a confusing picture with peritonitis in peritoneal dialysis (PD), spondy-
lodiscitis in hemodialysis, and complicated form of the disease in kidney transplant 
(TX) patients. Immunosuppressive monitoring, drug side effects, and donor to recipi-
ent transmission or recurrence are great challenges in the management of organ recipi-
ents with brucellosis. In this chapter, different presentations of brucellosis in kidney 
including glomeruli, tubulointerstitial, and vasculature involvement are discussed. 
Secondly, the Brucella infection in PD, HD, and Tx patients are reviewed, and finally, 
the chance of infection transmission of Brucellosis in the donor and recipients and the 
challenging point of pretransplant evaluation in donors and recipients are discussed.
2. Glomerular disease in brucellosis
Glomerular disease is an uncommon presentation in brucellosis. It can present 
with hematuria, pyuria, proteinuria, increased blood pressure, edema, and renal 
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failure. Glomerular involvement from mild proteinuria, microscopic hematuria up to 
the severe presentations of glomerular disease including rapidly progressive glomeru-
litis resulted in end-stage kidney disease have been reported. Glomeruli affected by 
immune complexes or vasculitis during Brucella endocarditis. The usual glomeru-
lopathy in cases with endocarditis is focal and diffuse proliferative glomerulonephri-
tis which are presented in the literature as membranoproliferative [2] and rapidly 
progressive glomerulonephritis; IgA nephropathy reported in two patients [3, 4] 
with proteinuria and hematuria. Siegelmann et al. [4] reported a case with nephrotic 
range proteinuria (6.0–13.0 g/day) and focal and segmental glomerulonephritis with 
mesangial proliferation and heavy deposit of IgA. Proteinuria persisted 3 months 
after completion of therapy, which indicates a secondary form of IgA nephropathy. 
Minimal change disease is a rare presentation of brucellosis reported only in one case 
without endocarditis. The patient had massive proteinuria who received prednisolone 
and antimicrobial treatment with complete remission and no recurrence after 1 year 
[5]. Membranous nephropathy is also diagnosed in one case with proteinuria [6].
3. Vasculitis in brucellosis
Vasculitis is a lethal picture of brucellosis with systemic organ involvement. 
Turgay et al. [7] reported 52-year-old male with Brucella infection and ANCA-
associated vasculitis that induced rapidly progressive glomerulitis. The patient had 
endocarditis with vegetation on the aortic valve and leukocytoclastic vasculitis. 
Serology showed a high titer of serum agglutinin for Brucella and positive P-ANCA 
test. The patient recovered with combination therapy of plasmapheresis, meth-
ylprednisolone pulse, and antibiotic therapy. The other vasculitis form of kidney 
disease is cryoglobulinemia. This systemic disease can happen in malignancy, 
autoimmune, and infectious disease. Mixed cryoglobulinemia in brucellosis has 
been reported in five cases (four from Peru and one from Spain). They had a high 
polyclonal cryoglobulin level (IgG, IgA, and IgM) with a female preponderance 
(4:1). Four cases had positive bone marrow culture and one diagnosed based on 
serology [8]. Thrombotic microangiopathy that presents with microangiopathic 
hemolytic anemia, thrombocytopenia, and variable signs of organ impairment due 
to platelet aggregation in the microcirculation has been reported in patients with 
brucellosis. Erdem et al. [9] reported a 51-year-old man with thrombotic micro-
angiopathy, hematuria, diminished consciousness, and renal failure. The patient 
received combination therapy with antimicrobials and plasma exchange with a good 
response and no recurrence in 1.5 years follow-up.
4. Tubulointerstitial and parenchymal involvement in brucellosis
Direct invasion of parenchyma and abscess formation is a rare manifestation 
of Brucella, which has been reported in five cases in the literature. Li et al. [10] 
reported a 45-year-old man with fever and flank pain. CT scan showed a low-density 
lesion in the right kidney in CT scan and positive culture for Brucella. He received 
8 weeks course of treatment and relapse after discontinuation of treatment, which 
needed another 16 weeks course of rifampin and moxifloxacin for the eradication of 
bacteria. There are reports of acute interstitial nephritis [11] and pyelonephritis [12] 
after Brucella infection. A perplexing point is antimicrobial therapy with rifampin, 
which can induce interstitial nephritis. Salih et al. reported a 52-year-old man with a 
diagnosis of Brucella. Patient referred with acute renal failure 2 weeks after treat-
ment with rifampin. Renal failure recovered since the drug was discontinued [13].
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5. Electrolyte abnormality in Brucella infection
Syndrome of inappropriate secretion of ADH (SIADH), which presented with 
hyponatremia in a euvolemic patient without other electrolyte abnormality has 
been reported in patients with brucellosis. Bala et al. [14] in a study of 160 chil-
dren and adolescent with SIADH reported 21.9% prevalence of SIADH. Urinary 
sodium (>25 mmol/L) with normal dietary salt intake, low uric acid (<2 mg/dL), 
the absence of kidney, thyroid or adrenal disease, and history of diuretic use were 
the criteria for diagnosis. Hyponatremia had a correlation to the severity of disease 
and managed with fluid restriction. Renal tubular disorder presented in 31 patients 
with active brucellosis [15]. They had phosphorus, potassium, and sodium handling 
abnormality in 31 patients. These patients were not malnourished, received fluid 
therapy, or hospitalized. They proposed that besides glomerular damage, tubular 
dysfunction is another presentation of Brucella infection.
6. Brucellosis in hemodialysis patients
Musculoskeletal problem is a prevalent feature in hemodialysis (HD) patients, 
which presents due to renal osteodystrophy and amyloidosis resulted from beta 2 
microglobulin deposition in the joints. These symptoms can mislead the clinician to 
overlook Brucella diagnosis. Inversely, fever as a common presentation of the infectious 
disease is missing in those ill patients. Most of the reported cases of brucellosis in HD 
patients presented with musculoskeletal pain, arthralgia, low back pain, and malaise in 
the acute form of brucellosis. Paravertebral and epidural abscess with spondylodiscitis 
in thoracic and lumbar vertebra and neurobrucellosis with a headache, diplopia, and 
cranial nerve involvement were reported as the complicated chronic form brucellosis 
in HD patients [16]. There is also a report of fatal septicemia and endocarditis [17, 18] 
in HD patients. Blood cultures should be performed in HD patients when typical 
symptoms of brucellosis exist even when the patient has no fever. Drug toxicity and 
dose adjustment are the other obstacles in the treatment of these patients. Rifampin 
and doxycycline with a hepatic metabolism do not need any dose adjustment; however, 
aminoglycosides, cephalosporins, and fluoroquinolones should be prescribed based on 
patient’s eGFR and patient needs a supplement dose after dialysis course.
7. Brucellosis in peritoneal dialysis (PD) patients
Peritoneal dialysis patients are at risk of peritonitis. Gram-positive organisms 
are the common cause of infections in 80% of the episodes. There are few reports of 
peritonitis due to Brucella infection in the literature. All of the cases presented with 
a typical peritoneal infection with neutrophil predominance with a positive culture 
in 5−21 days [19]. Organ involvement is hematogenous in most of the studies; 
however, Osizik et al. [20] showed a positive peritoneal fluid culture with a negative 
blood culture and serology. They proposed a direct inoculation of bacteria from the 
catheter to peritoneum based on the patient’s occupation. The other issue in Brucella 
peritonitis in PD patients is any need for catheter removal after Brucella infection. 
Taskapan et al. [21] and Alothman et al. [22] reported two cases with a recurrence 
of infection in 6−8 weeks after treatment that resulted in catheter removal for 
complete eradication of bacteria. On the other hand, Unal et al. [23] and Solak et al. 
[19] in two different reports showed the complete cure of infection despite keeping 
peritoneal catheter. Drug regimen in these studies was 6 weeks course of rifampin 
and doxycycline.
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8. Brucellosis in renal transplant recipients
However, the prevalence of brucellosis is around 1 in 500,000 population, and 
there are few reports in renal transplant recipients. In another view, these patients 
are at risk of different opportunistic infections. Most of the time, diagnosis of 
brucellosis was lately with the complicated form of the disease. There were two 
reports of neurobrucellosis in renal Tx patients in the literature, one with loss 
of consciousness and encephalitis [24] and the other one with a seizure and 
headache [25]. Endocarditis [26], pulmonary involvement [27], hepatobiliary 
and hematologic [28], pyelonephritis and dysuria [29], and arthritis [30] were 
other presentations of the disease. They were diagnosed based on serology or 
fluid culture that finally guided to the diagnosis of brucellosis. In addition to the 
complicated form of the disease and late diagnosis, drug interferences, especially 
calcineurin inhibitors, are another challenging point in the treatment of disease. 
Rifampin decreases drug level and inversely clarithromycin increases drug level 
that induces calcineurin toxicity. Hence, streptomycin with nephrotoxic nature 
cannot be the first choice in renal Tx patient. Ting et al. suggested tigecycline as 
an alternative drug in renal Tx patient. Triple antibacterial treatment has expe-
rienced in these immunocompromised patients with a complicated form of the 
disease [26, 30]. In these six reports, all of the patients completed the 6−12 weeks 
course of treatment with a good outcome and no recurrence; however, they 
experienced a serum creatinine rise.
9. Kidney donor evaluation before transplant
Evaluation for Brucella infection is suggested before organ transplantation 
in donors and recipients, especially in endemic areas. There are some reports of 
Brucella transmission and recurrence after liver [31], bone marrow transplantation 
[32, 33]. Serologic tests including serum agglutination and ELISA should be per-
formed before organ transplant. Positive titers consisted of 1:80 in the non-endemic 
area and 1:160 in the endemic area are suspicious and needs further evaluation. 
Serologic tests are not enough to distinguish active and past infection, which needs 
more evaluation by infectious disease specialist.
10. Conclusion
In this chapter, a wide range of Brucella presentations was discussed. 
Brucellosis as a multifaced disease can imitate a large group of non-infectious 
causes of kidney disease. Hence, the misdiagnosis could be hazardous and end to 
the patient’s morbidity and mortality. Clinicians should keep in mind the diverse 
pictures of the disease, especially when they practice in the endemic area.
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Brucellosis is a zoonotic infectious disease caused by the Brucella bacteria. 
Neonatal brucellosis is very rare and preventable and is an example of intrauterine 
infection, but clinical manifestations as well as transmission route are not well 
defined but presumed transplacental transmission. The neonate can be either 
infected transplacentally, or by ingestion of mother’s secretions and blood during 
delivery, or by ingestion of breast milk. Presentation of the neonatal brucellosis 
including fever, arthralgia, weakness, malaise, respiratory distress, pneumonia, 
enlargement of liver and spleen, fever, thrombocytopenia, late neonatal hyperbili-
rubinemia, and septicoemia. The diagnosis of brucellosis was based on a positive 
blood culture (isolation Brucella of blood culture from both the mother and the 
neonate or only neonate) and on a high or rising titer of antibodies to the Brucella 
organism (positive serology only in the mother or both). The neonates with 
negative Brucella serology may also have Brucella infection. The mortality rate is 
very high, and infected neonates need early detection and timely treatment. Early 
detection and treatment reduce the incidence of complications. The treatment of 
rifampicin and trimethoprim/sulfamethoxazole is useful for neonatal brucellosis. 
More patients with neonatal brucellosis well respond to antibiotic therapy and 
must monitor by a Brucella titer of <1:40.
Keywords: neonate, brucellosis, congenital
1. Introduction
Brucellosis is one of the most widespread zoonoses world [1, 2]. It is an acute or 
chronic zoonotic infection usually transmitted to humans through direct contact 
with infected animals or by eating contaminated food from infected animals (cat-
tle, sheep, goats, pigs, or another animals) or food products such as unpasteurized 
milk, cheese or inhalation of contaminated air or dust particles and exposure is fre-
quently occupational [1–4]. The prevalence of brucellosis has been increasing due 
to growing international tourism and migration of peoples [5, 6]. It is an important 
cause of economic loss and public health problems and is one of the important 
human infections in many developing countries or parts of the world. Brucellosis 
affects humans in all age groups and both genders with variable incidence accord-
ing to the geographic location and the strain [1–43]. Although this disease is now 
uncommon in the United States and Britain but common in the Latin America, 
Africa, Mediterranean and Persian Gulf regions and parts of Asia specially in Iran 
[1–8, 32, 39]. Brucellosis has high morbidity both for animals or humans and one of 
the causes of abortion in animals but in humans it causes multisystem disease [1–8, 
44]. Brucellosis is not uncommon in many parts of the world but human-to-human 






Brucellosis is a zoonotic infectious disease caused by the Brucella bacteria. 
Neonatal brucellosis is very rare and preventable and is an example of intrauterine 
infection, but clinical manifestations as well as transmission route are not well 
defined but presumed transplacental transmission. The neonate can be either 
infected transplacentally, or by ingestion of mother’s secretions and blood during 
delivery, or by ingestion of breast milk. Presentation of the neonatal brucellosis 
including fever, arthralgia, weakness, malaise, respiratory distress, pneumonia, 
enlargement of liver and spleen, fever, thrombocytopenia, late neonatal hyperbili-
rubinemia, and septicoemia. The diagnosis of brucellosis was based on a positive 
blood culture (isolation Brucella of blood culture from both the mother and the 
neonate or only neonate) and on a high or rising titer of antibodies to the Brucella 
organism (positive serology only in the mother or both). The neonates with 
negative Brucella serology may also have Brucella infection. The mortality rate is 
very high, and infected neonates need early detection and timely treatment. Early 
detection and treatment reduce the incidence of complications. The treatment of 
rifampicin and trimethoprim/sulfamethoxazole is useful for neonatal brucellosis. 
More patients with neonatal brucellosis well respond to antibiotic therapy and 
must monitor by a Brucella titer of <1:40.
Keywords: neonate, brucellosis, congenital
1. Introduction
Brucellosis is one of the most widespread zoonoses world [1, 2]. It is an acute or 
chronic zoonotic infection usually transmitted to humans through direct contact 
with infected animals or by eating contaminated food from infected animals (cat-
tle, sheep, goats, pigs, or another animals) or food products such as unpasteurized 
milk, cheese or inhalation of contaminated air or dust particles and exposure is fre-
quently occupational [1–4]. The prevalence of brucellosis has been increasing due 
to growing international tourism and migration of peoples [5, 6]. It is an important 
cause of economic loss and public health problems and is one of the important 
human infections in many developing countries or parts of the world. Brucellosis 
affects humans in all age groups and both genders with variable incidence accord-
ing to the geographic location and the strain [1–43]. Although this disease is now 
uncommon in the United States and Britain but common in the Latin America, 
Africa, Mediterranean and Persian Gulf regions and parts of Asia specially in Iran 
[1–8, 32, 39]. Brucellosis has high morbidity both for animals or humans and one of 
the causes of abortion in animals but in humans it causes multisystem disease [1–8, 
44]. Brucellosis is not uncommon in many parts of the world but human-to-human 
transmission, for example, through sexual intercourse, mother to newborn is rare, 
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but possible and has been reported [9–11]. Vertical transmission from mother to 
fetus during pregnancy (transplacental) or perinatal exposure has been reported 
[7, 8, 12, 13, 16–18, 25, 44]. Other modes of human-to-human transmission of bru-
cellosis include blood transfusion, bone marrow transplantation and breastfeeding 
[20–25]. Although few cases of perinatal brucellosis have been reported but the 
mode of transmission of Brucella from the mother to the baby remains uncertain.
2. Neonatal brucellosis
Brucellosis is a primarily zoonotic infection, public health problem and seri-
ous threat for people living in endemic areas of world which is caused by Gram-
negative, intracellular, non-spore-forming, non-capsulated, aerobic, nonmotile 
Coccobacilli [1, 26–41]. Brucella melitensis is the most important species for human 
brucellosis, but other species, including B. abortus, B. suis, B. canis, and B. novel 
marine have also been associated with human cases [1–3, 26, 29, 32, 43]. Brucellosis 
can be transmitted to humans from direct contact by infected animals, products 
of conception, or animal discharge, and by consumption of infected milk, milk 
products or meat [2, 3, 5, 26, 32, 43]. Human-to-human transmission is rare, but has 
been reported in association with blood transfusions, bone marrow transplanta-
tion, trans placental or perinatal exposure and possibly postnatally by consumption 
breast feeding [7, 8, 12, 13, 16–18, 20–25, 44].
Neonatal brucellosis is rare and there are only a few reports of congenital 
brucellosis [7, 8, 12–14, 17, 43, 44]. There are few data supporting transmission from 
mother to fetus or transmission via breast milk [7, 8, 12, 13, 16–18, 23, 25]. It seems 
that in most cases Brucella passes through the placenta. Transplacental and con-
sumption breast milk are the main routes of Brucella transmission in mammalian 
reservoirs [7, 8, 12, 13, 23–25]. Ingestion of maternal blood, urine or feces during 
delivery might be another rout of Brucella transmission [10, 14, 19].
Although infected pregnant animals transfer Brucella to their offspring transpla-
centally with resultant massive wastage of conception, this mode of transmission 
and resultant interference with the normal course of pregnancy has been disputed 
in humans [2, 32, 43].
Neonatal brucellosis is a very rare cause of early onset neonatal sepsis but 
should be considered in neonates born from mothers at risk for brucellosis [7–10]. 
Physicians dealing with mothers who lived in endemic areas during pregnancy 
should maintain a large index of suspicion when these mothers present with unex-
plained symptoms, especially for those with social and occupational risk for brucel-
losis because as soon as diagnosis and therapy can lead to good and better outcome. 
Education for pregnant women living in endemic areas for avoidance of exposure 
to sheep, goat, camels and do not consumption of unpasteurized products is most 
important and highly recommended. Family history of brucellosis or exposure must 
be obtained during prenatal care in endemic areas [1, 38, 39]. Sometimes maternal 
brucellosis lead to preterm delivery and with adverse long-term outcomes [16]. 
Transplacental transmissions from an infected mother, exposure to maternal blood, 
urine, or genital secretions during delivery are the main routes of transmission of 
neonatal brucellosis [10, 14, 19].
Pregnancy caused to impaired immunological status, and infection with 
Brucella can deformation obstetric outcomes, including congenital infection [44, 
45]. At one point it was believed that adverse pregnancy outcomes associated with 
human brucellosis should be uncommon due to the absence of erythritol in the 
human placenta [46, 47]. Another theory was that amniotic fluid contains anti-




spontaneous abortion, intrauterine fetal death, and preterm birth in mothers with 
brucellosis during pregnancy [49]. Recognition and suitable treatment of infection 
in early course of pregnancy lead to decrease of incidence of spontaneous abortion, 
intrauterine fetal death, and congenital infection [44, 46–49]. The clinical manifes-
tations of brucellosis in pregnancy are similar to other infected people and include 
arthralgia, arthritis, fever, chills, sweating, headache, malaise, nausea, vomiting, 
lymphadenopathy, hepatosplenomegaly, anorexia and weight loss [1–3, 45–47]. 
Positive blood or bone marrow culture are definite diagnosis but serologic tests 
(Wright and 2-mercapto ethanol, 2ME) are the commonest diagnostic methods 
[1, 3, 45–47].
The choice treatment for brucellosis in infected mother during pregnancy is a 
combination of rifampin and trimethoprim-sulfamethoxazole but trimethoprim-
sulfamethoxazole is contraindicated in first trimester and the last 2–4 weeks of 
pregnancy. During the third generation and first trimester of pregnancy, cephalo-
sporins have been used and in the last month of pregnancy, combination of amino-
glycosides (gentamycin) with rifampin is an alternative regimen [33, 39, 45–49].
3. Clinical manifestations
Newborns with symptom onset in the first week of life have presumably con-
genital brucellosis, although the incubation period of Brucella in newborn period 
can vary from less 1 week to 1 months (typically 2–4 weeks) [50]. Delayed diag-
nosis of congenital brucellosis in preterm infants can overlap with other diseases 
of prematurity. Term infants with onset of symptoms beyond 1 week of age may 
have acquired Brucella through breastfeeding or ingestion of nonhuman milk but 
congenital infection can also have a delayed presentation [9]. The neonatal immune 
system is immature, the response to well-characterized infective processes var-
ies from that described in older children and hence clinical manifestations may 
differ. Differential diagnosis between other bacterial infections in the newborn 
and brucellosis is difficult and presentations of brucellosis in the neonate are 
nonspecific and it is very difficult to distinguish brucellosis clinically from other 
bacterial infections. Fever, arthralgia, night sweating, anemia, bone marrow failure, 
jaundice, respiratory distress, vomiting, irritability, seizure, hepatosplenomegaly, 
dearie, skin rash, nausea, vomiting, malaise, poor feeding, failure to thrive (FTT) 
and distended abdomen are probable signs and symptoms in neonatal brucellosis 
[48]. The role of Brucella in myocarditis and hydrocephalus is difficult to determine 
both reported from neonates who acquired Brucella from breast milk [51, 52]. In 
summary, brucellosis should be considered as a possible cause of early or late onset 
sepsis in newborns presenting with fever, respiratory distress and hepatospleno-
megaly in endemic regions [53].
4. Diagnosis
Hematological and biochemical tests used in neonatal sepsis are of limited value 
for the diagnosis of brucellosis [17, 18]. In brucellosis, the white blood cell count is 
often normal or low. In neonates suspect to brucellosis, the diagnosis was made by 
the unexpected isolation of Brucella from blood culture obtained from a sick neo-
nate with suspected sepsis. Serologic tests are also important methods for clinical 
diagnosis but should be interpreted judiciously because of transplacental passage 
of maternal IgG antibodies [54]. A negative serologic test should never exclude the 
diagnosis, particularly in preterm neonates who may not have mounted their own 
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antibody response nor received transplacental antibodies. For further evaluation, 
blood should be sent for nested PCR and DNA sequencing. Definite diagnosis in 
neonates could be verified based on separating etiologic agent since maternal IgG 
exists in infant serum till 6 months after delivery [7–9, 17, 18, 54].
5. Treatment
Tetracycline or doxycycline with streptomycin or gentamicin are recommended 
therapies in older children or adults [39, 55]. Quinolones and doxycycline are some-
times used for treatment of brucellosis in adolescents but their safety in infants 
and newborns has not been established [32, 33]. Because of the side effects of 
tetracycline and doxycycline in children younger than 10 years of age, a variety of 
drugs can be used safely, for example a combination of rifampin and trimethoprim-
sulfamethoxazole [32, 33, 43, 55].
The combination of intravenous aminoglycosides for 5–7 days plus with rifampicin 
and trimethoprim-sulfamethoxazole orally 6–8 weeks is a commonly regimen and has 
been suggested as the treatment of choice for neonatal brucellosis [7, 8, 12, 13, 56].
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antibody response nor received transplacental antibodies. For further evaluation, 
blood should be sent for nested PCR and DNA sequencing. Definite diagnosis in 
neonates could be verified based on separating etiologic agent since maternal IgG 
exists in infant serum till 6 months after delivery [7–9, 17, 18, 54].
5. Treatment
Tetracycline or doxycycline with streptomycin or gentamicin are recommended 
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been suggested as the treatment of choice for neonatal brucellosis [7, 8, 12, 13, 56].
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Brucellosis
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Abstract
Currently, the only option for treating brucellosis is antibiotics especially to 
prevent complications. In this chapter, we want to talk about the drug therapy in 
brucellosis and the update of these therapies in the last years. Also, we will expose 
the principal antibiotics in brucellosis such as doxycycline, rifampin, streptomycin, 
cotrimoxazole (TMP/SMX), and gentamicin by talking about each one of their 
mechanism of action, pharmacokinetics, administration, risk assessment, adverse 
effects, and principal drug interactions. Furthermore, we will add the evidence of 
efficacy therapy in monotherapy or combinate therapy based on the evidence.
Keywords: brucellosis, aminoglycoside, doxycycline, rifampin, treatment
1. Introduction
Brucellosis is a zoonotic disease that can affect humans around the world, and it 
can affect any organ system. About the treatment, it is characterized to be prolonged 
therapy with a concomitant use of at least two or three antibiotics at different admin-
istration routes. The antibiotics have some special indications for administration, 
interactions, and risk assessment to prevent adverse reactions. That is why we will 
expose the principal antibiotics in brucellosis treatment based on the last evidence.
2. Antibiotic treatment
The principal objective of the treatment in brucellosis is to control the disease, 
prevent complications, relapse, and unfavorable outcomes. In the context of a zoonotic 
infection, the goal of its management is an appropriate antibiotic therapy with a pro-
longed duration of treatment, nevertheless the most effective antibiotic and treatment 
durations are unclear. Also, there are some limitations to choose the best treatment 
because of the need to choose antibiotics that act intracellularly and to prevent relapses 
with a prolonged therapy that can lead to increase the adverse effects of the drugs [1].
Furthermore, the monotherapy for brucellosis has been considered inadequate due 
to unacceptably high relapse rates, now we present possible treatment schemes [2, 3].
Uncomplicated brucellosis: (defined by not having focal disease like spondylitis, 
neurobrucellosis or endocarditis, and adults or > 30 kg):
• Doxycycline 100 mg orally twice daily for 6 weeks, plus streptomycin 1 g intra-
muscularly one daily for the first 14–21 days (or gentamicin 5 mg/kg for 5–14 days) 
[1, 2, 4].
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can affect any organ system. About the treatment, it is characterized to be prolonged 
therapy with a concomitant use of at least two or three antibiotics at different admin-
istration routes. The antibiotics have some special indications for administration, 
interactions, and risk assessment to prevent adverse reactions. That is why we will 
expose the principal antibiotics in brucellosis treatment based on the last evidence.
2. Antibiotic treatment
The principal objective of the treatment in brucellosis is to control the disease, 
prevent complications, relapse, and unfavorable outcomes. In the context of a zoonotic 
infection, the goal of its management is an appropriate antibiotic therapy with a pro-
longed duration of treatment, nevertheless the most effective antibiotic and treatment 
durations are unclear. Also, there are some limitations to choose the best treatment 
because of the need to choose antibiotics that act intracellularly and to prevent relapses 
with a prolonged therapy that can lead to increase the adverse effects of the drugs [1].
Furthermore, the monotherapy for brucellosis has been considered inadequate due 
to unacceptably high relapse rates, now we present possible treatment schemes [2, 3].
Uncomplicated brucellosis: (defined by not having focal disease like spondylitis, 
neurobrucellosis or endocarditis, and adults or > 30 kg):
• Doxycycline 100 mg orally twice daily for 6 weeks, plus streptomycin 1 g intra-
muscularly one daily for the first 14–21 days (or gentamicin 5 mg/kg for 5–14 days) 
[1, 2, 4].
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• Doxycycline 100 mg orally twice daily plus rifampin 600–900 mg (15 mg/kg) 
orally one daily for 6 weeks [1, 3].
• Consider triple therapy with addition of amikacin (intramuscularly twice a day 
for 7 days) to relief symptoms more rapid.
Alternative agents: (they may be useful in the setting of drug resistance, allergy, 
antimicrobial toxicity or relapse in combination with doxycycline or rifampin)
• Ciprofloxacin 500 mg twice daily or ofloxacin 200 mg twice daily [5, 6].
• Trimethoprim-sulfamethoxazole (TMP-SMX) one double-strength tablet 
twice a day.
Focal disease: spondylitis, neurobrucellosis, endocarditis, or localized suppura-
tive lesions (it requires longer courses of therapy at least 12 weeks):
• Spondylitis
 ○ Doxycycline 100 mg orally twice daily for 12 weeks plus streptomycin 1 g intra-
muscularly once daily for the first 14–21 days [7].
 ○ Alternative: doxycycline 100 mg orally twice daily plus rifampin 600–900 mg 
(15 mg/kg) once daily for 12 weeks.
 ○ Surgery in the context of spinal instability, persistence or progression of neuro-
logical deficit or localizes abscess epidural or paravertebral [8].
• Neurobrucellosis
 ○ Doxycycline, rifampin, and ceftriaxone or TMP-SMX.
 ○ Corticosteroids may be appropriate in the setting of neurobrucellosis complicated 
by iritis, papilledema, myelopathy, polyneuropathy, or cranial nerve palsies.
• Endocarditis
 ○ Doxycycline plus rifampin 300 mg every 12 h and gentamycin 5 mg/kg  
each day, the duration of therapy is uncertain usually for 6 weeks to 
6 months [9].
 ○ Surgery: valve replacement.
Pregnant women: [2, 10].
• Limited data.
• Rifampin 900 mg once daily, with or without TMP-SMV (one double-strength 
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 ○ (<8 years of age): oral TMP-SMX [10 mg/kg per day TMP (maximum 
480 mg/day) and 50 mg/kg per day SMX (maximum 2.4 g/day) by mouth 
divided into two doses] daily plus rifampin [15–20 mg/kg per day by mouth 
(maximum 900 mg/day) divided in one or two doses] (or gentamycin 5 mg/
kg IV daily for 7 days) for 6 weeks [10–12].
 ○ (>8 years of age): oral doxycycline [2–4 mg/kg per day by mouth (maximum 
200 mg/day) divided into two doses] or tetracycline [30–40 mg/kg per day 
by mouth (maximum 2 g/day) divided into four doses] plus rifampin for 
6 weeks [11].
• Osteoarticular disease, neurobrucellosis, or endocarditis
 ○ <8 years of age: oral TMP-SMX for at least 6 weeks plus parenteral aminogly-
coside [gentamicin (5 mg/kg per day parenterally divided into one to three 
doses) or streptomycin (20–40 mg/kg per day (maximum dose 1 g/day) 
parenterally divided in two doses)] for the first 14 days of therapy.
 ○ >8 years of age: oral doxycycline or tetracycline for at least 6 weeks, plus 
parenteral aminoglycoside (gentamicin or streptomycin) for the first 14 days 
of therapy.
2.1 Doxycycline
2.1.1 Mechanism of action
It belongs to the group of tetracyclines that are a series of derivatives of basic 
four-ring structure. Doxycycline inhibits bacterial protein synthesis by binding to 
the 30S bacterial ribosome and blocking the access of aminoacyl tRNA to  
the A (acceptor) site on the mRNA-ribosome complex and inhibits protein  
synthesis [13].
2.1.2 Antimicrobial activity
Doxycycline is a bacteriostatic antibiotic with activity against Streptococcus 
pneumoniae and H. influenzae and excellent activity against atypical pathogens such 
as Mycoplasma and Chlamydophila pneumoniae, methicillin-resistant Staphylococcus 
aureus and methicillin-susceptible Staphylococcus aureus, Bacillus anthracis, and 
Listeria monocytogenes and most strains of Brucella are susceptible. Some species 




• Oral: administer with meals to decrease gastrointestinal (GI) discomfort. 
Administer capsules and tablets with a considerable amount of water and have 
patient sit up for at least 30 minutes to reduce esophageal irritation. Oral admin-
istration is preferable unless patient has significant nausea and vomiting [13].
• IV: infuse prolonged over 1–4 hours to prevent thrombophlebitis.
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• Oral: administer with meals to decrease gastrointestinal (GI) discomfort. 
Administer capsules and tablets with a considerable amount of water and have 
patient sit up for at least 30 minutes to reduce esophageal irritation. Oral admin-
istration is preferable unless patient has significant nausea and vomiting [13].
• IV: infuse prolonged over 1–4 hours to prevent thrombophlebitis.
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2.1.5 Risk assessment
When therapy of doxycycline needs to be used in prolonged therapy, some 
parameters need to be taken to prevent some of the adverse effects: complete 
blood count (CBC), renal and liver function tests periodically, during  
therapy [13].
2.1.6 Adverse effects
• Gastrointestinal: it can produce GI irritation especially after oral admin-
istration (epigastric burning, abdominal discomfort, nausea, vomiting 
and diarrhea). To prevent this, the patient should take oral formulations with 
a glass full of water, administration on an empty stomach is generally not 
recommended [14].
• Photosensitivity: it may produce photosensitivity reactions in treated individu-
als exposed to sunlight. The patient needs to use skin protection and avoid 
prolonged exposure to sunlight and ultraviolet light [14].
• Hepatotoxicity: rarely occurs during the treatment. If patient became symptomatic, 
assess liver function tests, and discontinue drug [14].
• Hypersensitivity syndromes: severe skin reactions have been reported. Discontinue 
therapy for serious hypersensitivity reactions.
• Superinfection: prolonged use may result in fungal or bacterial superinfection 
like pseudomembranous colitis.
• Tissue hyperpigmentation: may induce hyperpigmentation in many organs: 
nails, bone, skin, eyes, thyroid, oral cavity (permanent brown discoloration 
of the teeth in children <8 years or in children from pregnant women in 
their last half of pregnancy), and sclerae, most dependently of time and 
chronic use [15].
2.1.7 Principal drug interactions
See Table 2.
Absorption Oral: almost completely absorbed from the gastrointestinal tract (GI) (90–100%), plasma 
concentration may be reduced 20% by high-fat meal or milk
Time to peak serum: oral: 2–4 hours
Distribution Widely distributed into tissues and fluids including synovial, pleural, prostatic, seminal 
fluids and bronchial secretions, saliva, aqueous humor
Poor cerebrospinal fluid penetration
Protein binding: >90%
Distribution volume
Bioavailability: reduced at high pH
Metabolism Not hepatic, partially inactivated in GI tract by chelate formation
Elimination Half-time elimination: 18–22 hours, end-stage renal disease: 18–25 hours
Excretion: feces (30%); urine (23–40%)
Table 1. 
Pharmacokinetics parameters of doxycycline [13].
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2.1.8 Important
• Tetracyclines are inexpensive, widely available, and poor associated with side 
effects, and also it have proven safe in all age groups [21].
• The doxycycline-streptomycin regimen is considered the first line and has been 
proven to be more effective than doxycycline-rifampin in some studies [4, 22].
• Do not administer to children <8 years of age due to permanent discoloration 
of teeth, retardation of skeletal development, and bone growth; more common 
with long-term use, but may be observed with repeated, short courses [12, 23].
2.2 Streptomycin
2.2.1 Mechanism of action
It is an aminoglycoside antibiotic bactericidal. Aminoglycosides diffuse through 
aqueous channels formed by porin proteins in the outer membrane of Gram-
negative bacteria to enter to the periplasmic space, and its transport across the cyto-
plasmic membrane depends on an electrical gradient coupled to electron transport 
to drive permeation of these antibiotics. That is why they are not used in anaerobic 
environments of abscess. Once streptomycin is inside the cell, it binds to the 30S 
ribosomal subunit and interferes with protein synthesis by causing misreading and 
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2.1.8 Important
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premature termination of mRNA translation, and the resulting aberrant proteins 
may be inserted into the cell membrane altering permeability [24–26].
2.2.2 Antimicrobial activity
It is less active than other members of the class against aerobic Gram-negative, 
and it is used for the treatment of unusual infections and in combination with 
other antimicrobial agents. The inhibitory activity of aminoglycosides persists after 
the serum concentration has fallen below de minimum inhibitory concentration 
(MIC), and it is known as the post antibiotic effect and it improves the efficacy of 
high-dose extended-interval dosing regimens for aminoglycoside. It is used for the 
treatment of tuberculosis, tularemia, severe M. avium complex, brucellosis, and 




Streptomycin may be administered by deep intramuscular injection into large 
muscle mass, rotate injection sites (it may be painful with a hot tender mass develop-
ing at the site injection) or intravenously (after dilution in admixture, infuse over 
30–60 minutes). High-dose, extended-interval administration is the preferred admin-
istration of aminoglycosides because of less toxic effect than divided doses [24, 27].
2.2.5 Risk assessment
It is important to monitor hearing tests (baseline and periodic audiograms), 
BUN, creatinine, and serum drug concentrations should be monitored in all patients:
• Therapeutic peak: 20–30 mcg/mL [25].
2.2.6 Adverse effects
• Ototoxicity: aminoglycoside induces ototoxicity irreversible, bilateral, high- 
frequency hearing loss or vestibular hypofunction. It has been seen degeneration 
of hair cells and neurons in the cochlea and accumulation in the perilymph and 
endolymph at high antibiotic concentration in plasma. The initial symptoms such 
Absorption Oral: poorly absorbed, IM: well absorbed
Time to peak IM: 1–2 hours
Distribution Into most body tissues and fluids except the brain and adipose tissue (because of their polar 
nature)
Protein binding: 34%
Volume of distribution (Vd): 260 mL/kg
Metabolism None known
Excretion Half-time elimination: adults: 2–4, 7 hours, prolonged with renal impairment
Urine: 29–89% as unchanged drug
Bile, saliva, sweat and tears: (1%)
Table 3. 
Pharmacokinetic parameters of streptomycin [24, 28].
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as high-pitched tinnitus, nausea, vomiting, and difficulty in equilibrium may be 
reversible, so it should be monitored carefully for ototoxicity [24].
• Nephrotoxicity: it is because the accumulation and retention of aminoglycoside 
in the proximal tubular cells and the initial manifestations of damage at this 
site are mild proteinuria and hyaline and granular casts, and also the glomeru-
lar filtration rate is reduced after several additional days [24].
2.2.7 Principal drug interactions
See Table 4.
2.2.8 Important
• Streptomycin is not available always in some regions and it is administered only 
intramuscularly or intravenously, so it is a disadvantage [2].
• Gentamicin has replaced streptomycin for some indications because the toxicity of 
gentamicin is renal and mostly reversible although streptomycin is most vestibular 
compromise and irreversible [24].
2.3 Gentamicin
2.3.1 Mechanism of action
Gentamicin is a bactericidal aminoglycoside. It binds to the 30S ribosomal 
subunit and interferes with initiation of protein synthesis causing misreading of 
mRNA, premature termination of translation, and incomplete synthesized protein, 
creating nonfunctional proteins [24, 33].
2.3.2 Antimicrobial activity
Gram-negative bacteria such as Pseudomonas aeruginosa, Proteus species, Escherichia 
coli, Klebsiella species, Enterobacter species, Serratia, Citrobacter, and Staphylococcus 
species [24].
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as high-pitched tinnitus, nausea, vomiting, and difficulty in equilibrium may be 
reversible, so it should be monitored carefully for ototoxicity [24].
• Nephrotoxicity: it is because the accumulation and retention of aminoglycoside 
in the proximal tubular cells and the initial manifestations of damage at this 
site are mild proteinuria and hyaline and granular casts, and also the glomeru-
lar filtration rate is reduced after several additional days [24].
2.2.7 Principal drug interactions
See Table 4.
2.2.8 Important
• Streptomycin is not available always in some regions and it is administered only 
intramuscularly or intravenously, so it is a disadvantage [2].
• Gentamicin has replaced streptomycin for some indications because the toxicity of 
gentamicin is renal and mostly reversible although streptomycin is most vestibular 
compromise and irreversible [24].
2.3 Gentamicin
2.3.1 Mechanism of action
Gentamicin is a bactericidal aminoglycoside. It binds to the 30S ribosomal 
subunit and interferes with initiation of protein synthesis causing misreading of 
mRNA, premature termination of translation, and incomplete synthesized protein, 
creating nonfunctional proteins [24, 33].
2.3.2 Antimicrobial activity
Gram-negative bacteria such as Pseudomonas aeruginosa, Proteus species, Escherichia 
coli, Klebsiella species, Enterobacter species, Serratia, Citrobacter, and Staphylococcus 
species [24].
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• IM: it should be administered by deep IM route.
• IV: infuse over 30–120 minutes [27].
2.3.5 Risk assessment
During therapy with gentamicin, you should monitor parameters like: urinaly-
sis, urine output, BUN, serum creatinine, plasma gentamicin levels (before and 
after the third dose), hearing tests before, during and after treatment especially in 
prolonged therapy [36, 37].
• Therapeutic peak: 5 and 12 μg/mL [36, 37].
2.3.6 Adverse effects
• Nephrotoxicity: usual risk factors include preexisting renal impairment, 
concomitant nephrotoxicity drugs, advanced age, and dehydration. If nephro-
toxicity occurs, it is better to discontinue therapy because the renal damage is 
usually reversible [24, 38].
• Ototoxicity: use with caution in patients with preexisting vertigo, tinnitus or 
hearing loss [24, 38].
• Neuromuscular blockade: aminoglycosides may inhibit prejunctional release of 
acetylcholine reducing postsynaptic sensitivity to the transmitter, and this reaction 
can follow intravenous, intramuscular or even oral administration of this antibiot-
ics, especially with concomitant use of anesthesia and other neuromuscular block-
ing agents. It can be reversed by intravenous administration of calcium salt [24].
2.3.7 Principal drug interactions
See Table 6.
Absorption Intramuscular: rapid and complete
Oral: poorly absorbed
Time to peak: IM 30–90 minutes; IV: 30 minutes after 30-minute infusion
Distribution Primarily into extracellular fluid, renal cortex. Poor penetration in cerebrospinal fluid 
(CSF) and ocular tissues
Vd: children: 0.35 L/kg; adults: 0.2–0.3 L/kg
Protein binding: <30%
Metabolism Minimal metabolism
Excretion Half-life elimination: adults 2 hours, renal failure: 41–24 hours
Urine: >70% as unchanged drug
Clearance is decreased in renal impairment
Table 5. 
Pharmacokinetic parameters of gentamicin [24, 34, 35].
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2.4 Rifampin
2.4.1 Mechanism of action
Rifampin is a bactericidal drug that kills cell growing and it binds to the beta 
subunit of DNA-dependent RNA polymerase (rpoB) to form a drug-enzyme 
complex blocking the chain formation in RNA transcription [44].
2.4.2 Antimicrobial activity
It inhibits most Gram-positive bacteria and Gram-negative microorganisms 
such as Escherichia coli, Pseudomonas, Proteus, and Klebsiella, and also it is  
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Principal drug interactions of gentamicin.
Absorption Oral: well absorbed (bioavailability 68%). Food may delay or reduce peak by one-third. It 
should be taken on an empty stomach
Time to peak serum: oral: 2–4 hours
Distribution Good penetration into many tissues and crosses CSF
Vd: 53 L/kg
Protein binding: 80%
Metabolism Microsomal B-esterases and cholinesterases. Also, 85% liver metabolism (potently 
induction CYP 1A2, 2C9, 2C19 and 3A4) and enterohepatic recirculation
Excretion Half-life elimination: 3–4 hours, prolonged with hepatic impairment feces (60%) and urine 
(30%) as unchanged drug
Table 7. 
Pharmacokinetic parameters of rifampin [34, 44–46].





• IM: it should be administered by deep IM route.
• IV: infuse over 30–120 minutes [27].
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sis, urine output, BUN, serum creatinine, plasma gentamicin levels (before and 
after the third dose), hearing tests before, during and after treatment especially in 
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Table 5. 
Pharmacokinetic parameters of gentamicin [24, 34, 35].
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2.4 Rifampin
2.4.1 Mechanism of action
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subunit of DNA-dependent RNA polymerase (rpoB) to form a drug-enzyme 
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Principal drug interactions of gentamicin.
Absorption Oral: well absorbed (bioavailability 68%). Food may delay or reduce peak by one-third. It 
should be taken on an empty stomach
Time to peak serum: oral: 2–4 hours
Distribution Good penetration into many tissues and crosses CSF
Vd: 53 L/kg
Protein binding: 80%
Metabolism Microsomal B-esterases and cholinesterases. Also, 85% liver metabolism (potently 
induction CYP 1A2, 2C9, 2C19 and 3A4) and enterohepatic recirculation
Excretion Half-life elimination: 3–4 hours, prolonged with hepatic impairment feces (60%) and urine 
(30%) as unchanged drug
Table 7. 
Pharmacokinetic parameters of rifampin [34, 44–46].
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2.4.4 Administration
• IV: administer IV preparation by slow infusion rate IV over 30 minutes to 3 hours, 
monitor administration to prevent extravasation.
• Do not administer IM or SC.
• Oral: administer on an empty stomach with a glass of water to increase 
absorption [44].
2.4.5 Risk assessment
During the therapy with rifampin, it should be monitored with periodical liver 
function test, CBC, and therapeutic drug monitoring of rifampin [47].
2.4.6 Adverse effects
• Hypersensitivity reactions: cases of severe cutaneous adverse reactions like 
Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with 
eosinophilia. It is mediated by hypersensitivity type I (IgE). It requires discon-
tinue of therapy and management of the symptoms [48].
• Flu-like syndrome: symptoms of fever, chills, headache related with the use of 
oral rifampin. It is related with regimens of >600 mg once or twice 
 weekly, and it resolves spontaneously. Flu-like syndrome is mediated by 
hypersensitivity type III (antibodies against rifampicin IgM that produce 
immunocomplex) [48, 49].
• Hematologic effects: it may cause thrombocytopenia, leukopenia, or anemia. 
The platelets are damaged by complement activation following the formation 
of drug-antibody complex [48, 50].
• Hepatotoxicity: it may cause hepatic dysfunction especially if it is used with 
other hepatotoxic agents [44].
2.4.7 Principal drug interactions
Most of the interactions of rifampin are because it is a strong inducer of CYP3A4 
and CYP2C19, moderate inducer of CYP2C8 and CYP2C9, and P-glycoprotein 
inducer (Table 8) [51].
2.4.8 Important
• In children, pregnant or lactating women rifampin should not be used 
except where tetracyclines are contraindicated or when there are limitations 
on the use of streptomycin or gentamicin and it should not be used  
alone [1, 6, 9].
• It can be an alternative treatment for doxycycline or aminoglycosides, but 
the use of rifampin should be restricted in endemic areas of tuberculosis 
because monotherapy with rifampin can lead to the selection of resistant 
Mycobacterium tuberculosis strains [1, 3, 6, 9].
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2.5 Ciprofloxacin
2.5.1 Mechanism of action
The fluoroquinolones inhibit two bacterial enzymes: DNA gyrase (in many 
Gram-negative bacteria) and topoisomerase IV (in many Gram-positive bacteria) 
blocking the DNA bacterial replication. This action results in damage of bacterial 
DNA and cell death being bactericidal agents [56, 57].
2.5.2 Antimicrobial activity
It is a bactericidal agent against Proteus, E. coli, Klebsiella, Salmonella, Shigella, 
Enterobacter, and Campylobacter [56].
2.5.3 Pharmacokinetics
See Table 9.
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Table 8. 
Principal drug interactions of rifampin [55].
Absorption Oral: well absorbed
Bioavailability: 70%. Avoid taking with most antacids and milk




Metabolism Poor hepatic metabolism and forms 4 metabolites, inhibitor of CYP1A2
Excretion Half-life elimination: children: 4–5 hours and adults: 3–5 hours, prolonged in older adults 
and in renal impairment
Urine 50% as unchanged drug), feces (15%)
Table 9. 
Pharmacokinetic parameters of ciprofloxacin [55, 56].
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2.5.4 Administration
• Oral: administer with food to minimize GI symptoms, avoid antacid use, milk, 
yogurt or calcium-fortified juices alone.
• IV: administer by slow IV infusion over 60 minutes [56].
2.5.5 Risk assessment
During the treatment with ciprofloxacin parameters like: CBC, renal and hepatic 
function, signs and symptoms of tendonitis should be monitored [56].
2.5.6 Adverse effects
• Gastrointestinal: nausea, vomiting, and abdominal discomfort [56].
• Neurologic: headache and dizziness, peripheral neuropathy, it can occur at 
any time during treatment and can last for months to years after finishing the 
treatment [58].
• Musculoskeletal: tendon rupture or tendinitis usually of the Achilles tendon, 
arthralgias, and join pain are reported, especially in ancient people and 
patients taking corticosteroids [59, 60].
• QT interval prolongation and arrhythmia: it may be produced by inhibition of 
potassium channels encoded by the KCNH2 gene (HERG gene). Ciprofloxacin 
use should be avoided in patients with a history of QT prolongation, torsade de 
pointes, uncorrected hypokalemia, cardiac disease or concomitant use of other 
medications that prolong the QT interval [56, 61].
2.5.7 Principal drug interactions
See Table 10.
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Principal drug interactions of ciprofloxacin.
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2.5.8 Important
• It may be useful in the setting of drug resistance, antimicrobial toxicity, and 
some cases of relapse.
2.6 Trimethoprim-sulfamethoxazole (TMP/SMX)
2.6.1 Mechanism of action
The combination of trimethoprim with sulfamethoxazole enhances the 
effectivity and synergist antimicrobial activity. TMP inhibits bacterial dihydro-
folate reductase preventing the formation of tetrahydrofolic acid, and SMX is 
a structural analog of the para-aminobenzoic acid (PABA), and it binds to the 
dihydropteroate synthetase and competes with PABA to inhibit the synthesis of 
dihydrofolic acid [56, 66].
2.6.2 Antimicrobial activity
The antibacterial spectrum is most S. pneumoniae, S. aureus, and Staphylococcus 
epidermidis, some E. coli according to the geographic region, Proteus mirabilis, 




• Oral: administer without regard to meals and a lot of water.
• IV: infuse over 60–90 minutes, and it is not administered by IM injection [56].
2.6.5 Risk assessment
Some monitoring parameters during the treatment are CBC, serum potassium, 
creatinine, and BUN [56].
Absorption Oral: rapid 90–100%, TMP is absorbed more rapidly than sulfamethoxazole, 
bioavailability of 85%
Distribution Good penetration in middle ear fluid, sputum, vaginal fluid, and bronchial 
secretions
Vd: adults: 1.3 L/kg
Protein binding: SMX 70%, TMP 44%
Metabolism Hepatic, SMX via CYP2C9 and also conjugated with glucuronide; TMP to oxide 
and hydroxy derivatives
Excretion Half time elimination: TMP: children 3.7–5.5 hours and adults: 6–11 hours. SMX 
9–12 hours
Both excreted in urine as metabolites and unchanged drug
Table 11. 
Pharmacokinetic parameters of TMP/SMX [56].
New Insight into Brucella Infection and Foodborne Diseases
46
2.5.4 Administration
• Oral: administer with food to minimize GI symptoms, avoid antacid use, milk, 
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function, signs and symptoms of tendonitis should be monitored [56].
2.5.6 Adverse effects
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• Neurologic: headache and dizziness, peripheral neuropathy, it can occur at 
any time during treatment and can last for months to years after finishing the 
treatment [58].
• Musculoskeletal: tendon rupture or tendinitis usually of the Achilles tendon, 
arthralgias, and join pain are reported, especially in ancient people and 
patients taking corticosteroids [59, 60].
• QT interval prolongation and arrhythmia: it may be produced by inhibition of 
potassium channels encoded by the KCNH2 gene (HERG gene). Ciprofloxacin 
use should be avoided in patients with a history of QT prolongation, torsade de 
pointes, uncorrected hypokalemia, cardiac disease or concomitant use of other 
medications that prolong the QT interval [56, 61].
2.5.7 Principal drug interactions
See Table 10.
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2.6.1 Mechanism of action
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effectivity and synergist antimicrobial activity. TMP inhibits bacterial dihydro-
folate reductase preventing the formation of tetrahydrofolic acid, and SMX is 
a structural analog of the para-aminobenzoic acid (PABA), and it binds to the 
dihydropteroate synthetase and competes with PABA to inhibit the synthesis of 
dihydrofolic acid [56, 66].
2.6.2 Antimicrobial activity
The antibacterial spectrum is most S. pneumoniae, S. aureus, and Staphylococcus 
epidermidis, some E. coli according to the geographic region, Proteus mirabilis, 




• Oral: administer without regard to meals and a lot of water.
• IV: infuse over 60–90 minutes, and it is not administered by IM injection [56].
2.6.5 Risk assessment
Some monitoring parameters during the treatment are CBC, serum potassium, 
creatinine, and BUN [56].
Absorption Oral: rapid 90–100%, TMP is absorbed more rapidly than sulfamethoxazole, 
bioavailability of 85%
Distribution Good penetration in middle ear fluid, sputum, vaginal fluid, and bronchial 
secretions
Vd: adults: 1.3 L/kg
Protein binding: SMX 70%, TMP 44%
Metabolism Hepatic, SMX via CYP2C9 and also conjugated with glucuronide; TMP to oxide 
and hydroxy derivatives
Excretion Half time elimination: TMP: children 3.7–5.5 hours and adults: 6–11 hours. SMX 
9–12 hours
Both excreted in urine as metabolites and unchanged drug
Table 11. 
Pharmacokinetic parameters of TMP/SMX [56].
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2.6.6 Adverse effects
• Blood dyscrasias: agranulocytosis, aplastic anemia, leukopenia, or thrombo-
cytopenia because of the margin between toxicity for bacteria and humans 
related with folate deficient [67].
• Neurologic effects: it is associated with adverse neurologic events like aseptic men-
ingitis, tremor, delirium because TMP/SMX crosses the blood-brain barrier [67].
• Dermatologic reactions: severe reactions including Stevens-Johnson syndrome 
produced by immune-mediated idiosyncratic reactions associated with reac-
tive metabolite leading to drug-specific antibodies [67].
• Hyperkalemia: it is produced because of the TMP similar structure to potassium-
sparing diuretics. Potential risk factors include renal impairment, older age, and 
concomitant use of medications causing or exacerbating hyperkalemia [56].
2.6.7 Principal drug interactions
See Table 12.
2.6.8 Important
• TMP-SMX may be used as an additional agent in complex cases of focal brucel-
losis, relapse, or refractory disease [2].
• TMP-SMZ should not be used in pregnancy, either before 13 weeks because of the 
risk of teratogenic effects or after 36 weeks because of the risk of kernicterus [21].
• It has been a popular choice and it is included in combination regimens around 
the world, due to its lower cost compared to other antimicrobials being the 
most cost-effective drug against brucellosis in developing countries [2].
• No alternative anti-brucellosis therapy for children under 8 years old has been 
reported, but there is a case that had a 2.5 years old patient with brucellosis 





increase the serum 
concentration of 
phenytoin



















protein binding sites, 
reductions in GI 
flora responsible for 
production of vitamin 
K [69, 70]
Monitor toxic 










Principal drug interactions of TMP/SMX.
49
Update of Antibiotic Therapy of Brucellosis
DOI: http://dx.doi.org/10.5772/intechopen.86325
with TMP-SMX allergy, they use as an alternative for treatment ciprofloxacin 
having a good result of the treatment and continue follow up visits, but there 
are no evidence enough for this treatment, so it is necessary to search for 
alternative treatment for this patient population [12].
3. Other considerations about treatment
• Doxycycline is the drug of choice in the treatment of brucellosis, but antibi-
otic susceptibility patterns of Brucella appears to vary geographically, that is 
why tigecycline can be an option for treatment in brucellosis. Tigecycline is a 
glycylcycline derivate from tetracycline and minocycline. It has demonstrated 
activity against Enterobacteriaceae, Gram-positives, atypical, and anaerobes. It 
has the lowest minimal inhibitory concentration on in vitro efficacy models, 
and also it provided the better synergistic activity compared to doxycy-
cline. Tigecycline can be a therapeutic alternative for brucellosis especially 
in patients in whom conventional antibiotics is contraindicated or limited 
because of the presence of severe comorbidities or drug-drug interactions, but 
it should be supported with more clinical studies [72].
• There are some regional experience and some different treatments that differs 
according the regional experiences but here are some considerations:
 ○ The World Health Organization (WHO) recommends the use of doxycycline 
for 6 weeks combined with rifampicin for 6 weeks, or streptomycin for 
2–3 weeks, but this regimen has not been universally used in clinical prac-
tice. Even this fact it remains unclear what is the best regimen to be used and 
more clinical studies are needed in this regard [2].
 ○ From the comparison of regimens that can be established in random-
ized clinical trials are: doxycycline and streptomycin vs. doxycycline and 
rifampicin that favors the first combination in terms of relapse (OR 3.52; CI 
95% = 2.14–5.81; p < 0.001); doxycycline and streptomycin vs. doxycycline 
and gentamicin is not statistically significant as regards either relapses 
(OR = 1.65; CI 95% = 0.53–5.15; p = 0.386); doxycycline and rifampicin vs. 
doxycycline and quinolone favors the first one (OR 3.92; CI 95% = 1.35–
11.42; p = 0.01) [73].
 ○ The most effective regimen is combined doxycycline for 45 days with strep-
tomycin for 14 days, in endemic areas where many patients have a mild form 
of the disease and diagnosis and prescription can be made in the urgency 
room the used to use gentamycin for the first 5–7 days [4, 73].
 ○ About the comparison of the efficacy of gentamicin for 5 days plus 
 doxycycline for 8 weeks vs. streptomycin for 2 weeks plus doxycycline 
for 45 days in human brucellosis, there is a clinical trial that compare the 
efficacy  showing that this treatment is not superior to the standard treat-
ment  regimen [74].
 ○ There are a few studies using doxycycline, rifampicin, and aminoglycosides vs. 
other regimens in uncomplicated brucellosis with no conclusions on the value 
of this triple therapy, also some studies were performed only in patients with 
osteoarticular complications. Another option for triple therapy is doxycycline, 
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rifampin, and amikacin (intramuscularly twice a day for 7 days) that have 
higher efficacy and more rapid action in terms of relief of symptoms, but it has 
no significant difference in drug side-effects and disease relapse, thus adding 
amikacin to the standard treatment regimen seems beneficial [6, 75].
4. Conclusion
In conclusion, there are some antibiotic therapies that are approved for the treat-
ment of brucellosis, and some of them are in prolonged therapy that could affect 
the adherence of the patient and some of the antibiotics have important recommen-
dations and need to be used in some conditions. Also, they have some parameters 
that may be monitorable to prevent adverse effects and to improve the outcome of 
the treatment in all the patients.
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the treatment in all the patients.
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Abstract
Salmonella is an intracellular pathogenic, gram-negative, facultative anaerobe 
and non-spore-forming and usually a motile bacillus that leads to salmonellosis in 
the host. It is a common food-borne disease that ranges from local gastrointestinal 
inflammation and diarrhoea to life-threatening typhoid fever and presents usually 
a serious threat to public health due to its socio-economic value. Inadequate sanita-
tion and impure water help in the propagation of this disease. Despite advance-
ment in the sanitation standards, Salmonella enters the food chain and affects 
communities globally. There is an immediate need to develop improved vaccines 
to minimise Salmonella-related illnesses. Some Salmonella serovars infect a wide 
range of hosts, while others are known to be host restricted. Many different factors 
determine the adaptability and host specificity of Salmonella. The host-pathogen 
interactions play a unique role in Salmonella invasion and progression which needs 
to be studied in detail. This chapter shall focus on our current understanding of 
Salmonella invasion, pathogenesis and interactions with the host, host specificity 
and adaptability.
Keywords: Salmonella, serovars, adaptability, specificity, invasion,  
non-typhoidal Salmonella, typhoidal Salmonella, immune response
1. Introduction
Salmonellae are facultative anaerobes and gram-negative, non-spore-forming 
and usually motile bacilli. Two species, namely, Salmonella enterica and Salmonella 
bongori, belong to genus Salmonella. Salmonella enterica is further subdivided into 
six subspecies that are distinguished by variations in O (somatic) and H (flagellar) 
antigens with at least 2500 serotypes. S. enterica subsp. enterica comprises of more 
than half of the known serotypes [1]. New serotypes are being discovered increas-
ing the serotype complexity. Approximately 99% of the Salmonella serotypes that 
infect humans and other mammals belong to S. enterica subspecies. These serovars 
are mostly the inhabitants of intestinal tract of humans and other organisms that 
include reptiles, birds and insects. At farm level, sources of bacterial contamination 
are faecal matter, litter, feed and soil [2]. Salmonella most commonly causes food-
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1. Introduction
Salmonellae are facultative anaerobes and gram-negative, non-spore-forming 
and usually motile bacilli. Two species, namely, Salmonella enterica and Salmonella 
bongori, belong to genus Salmonella. Salmonella enterica is further subdivided into 
six subspecies that are distinguished by variations in O (somatic) and H (flagellar) 
antigens with at least 2500 serotypes. S. enterica subsp. enterica comprises of more 
than half of the known serotypes [1]. New serotypes are being discovered increas-
ing the serotype complexity. Approximately 99% of the Salmonella serotypes that 
infect humans and other mammals belong to S. enterica subspecies. These serovars 
are mostly the inhabitants of intestinal tract of humans and other organisms that 
include reptiles, birds and insects. At farm level, sources of bacterial contamination 
are faecal matter, litter, feed and soil [2]. Salmonella most commonly causes food-
borne illnesses worldwide; the two commonly associated foods are eggs and poultry 
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meat [3]. Serovars S. Enteritidis, S. Typhimurium, S. Heidelberg and S. Newport 
are linked to such food-borne diseases, with farm animals being reservoirs for these 
serotypes [4, 5]. Salmonellosis is a big socio-economic threat worldwide that causes 
considerable mortality and morbidity in both humans and animals [6]. Most of the 
human-related diseases are food-borne, and exposure to these bacteria at different 
places has also been linked to human salmonellosis. The most orthodox mode of 
bacterial transmission is the faecal-oral route. Once the bacteria are transmitted, 
the initial site for bacterial infection is the small intestine. Following infection, 
different manifestations that arise range from gastroenteritis to enteric fever [7].
2. Epidemiology
The extensive investigation of the associated epidemiological risk factors that 
make an organism a persistent Salmonella carrier needs to be carried out. Non-
typhoidal Salmonella (NTS) infections that cause self-limiting manifestations are 
the most common to occur globally. In comparison, typhoidal Salmonella (TS) 
causing enteric fever leads to a high rate of mortality and morbidity that predomi-
nantly affects the underdeveloped countries [8]. Recent studies conclude that 
Salmonella Paratyphi A incidences have risen especially in South East Asia where 
approximately half of the TS-infected enteric fever patients are reported to be 
infected with S. Paratyphi A [9]. The food chain can get contaminated at any stage, 
and most of the transmission can occur by contaminated foods like poultry and 
dairy-related products. Apart from contaminated food products, NTS transmission 
can also result from person-to-person contact or from contact with other bacterial 
reservoirs. After gaining entry into the host, both TS and NTS serovars initially 
invade the intestinal epithelium of the small intestine.
3. Diseases caused by Salmonella infection
Salmonella species cause a varying number of clinical manifestations in the host 
that can range from self-limiting gastroenteritis typically associated with non-
typhoidal Salmonella (NTS) to typhoidal or paratyphoidal fevers, which can be 
life-threatening [6].
3.1 Typhoidal Salmonella (TS)
Humans are exclusive hosts for serovars such as S. Typhi, S. Sendai and  
S. Paratyphi A, B and C. These serovars are known as typhoidal serovars (TS) that 
can cause enteric fever/typhoidal/paratyphoidal fevers. Enteric fever is a systemic 
disease that is highly invasive and life threatening and is endemic in the developing 
world. Within an incubation period of around 2 weeks, bacteraemia occurs, which 
is marked by fever and malaise. The symptoms that start to appear after a week 
include fever, malaise, nausea, dry cough and abdominal discomfort. Common 
symptoms include tender abdomen, coated tongue, splenomegaly and hepato-
megaly [10]. As the lack of adequate water and sanitation facilities in the developing 
countries help in the spread of Salmonella through faecal-oral route [11], so to 
prevent typhoidal Salmonella transmission, societal standards need to be improved. 
The development of improved societal infrastructures is generally cost prohibitive 
in developing countries, hence, having little significance in reducing the disease 
frequency. In comparison, the development of effective and safe typhoidal vaccines 




3.2 Non-typhoidal Salmonella (NTS)
Many industrialised and underdeveloped countries across the globe face a 
significant threat of non-typhoidal Salmonella (NTS). Worldwide, about 93.8 
million gastroenteritis cases arise from Salmonella infections leading to 1.5 million 
deaths annually [7]. In infants, young, aged and immunologically compromised 
subjects NTS cause invasive bacterial infection [12, 13]. After post infection with 
NTS, symptoms that arise last for about 10 days that triggers a massive inflamma-
tory response involving the release of pro-inflammatory cytokines and chemokines. 
The human NTS patients have higher serum levels of different interleukins and 
cytokines like IL-18, IL-12, IL-10, IL-15, TNF- α and IFN γ [14]. Non-typhoidal 
Salmonella serovars can cause severe extra-intestinal disease in patients with 
deficiencies in type 1 cytokine pathways such as IFN-γ/IL-12/IL-23 especially IL-12 
abnormalities. Effective vaccination against NTS is lacking as there is a greater 
variance among different serovars. So, for generating effective vaccines against 
NTS, knowledge regarding different target antigens needs to be studied in detail. To 
disrupt the bacterial transmission and the incidence, effective preventive measures 
such as improving sanitation, hygiene and drinking clean water must be taken into 
consideration. Different host specificities and adaptability are shown by different 
Salmonella serovars that shall be discussed in detail.
4. Host specificity and adaptation
Salmonellosis susceptibly ranges from organism to organism and can occur in 
almost all animal species, but the clinical severity of this disease varies among the 
hosts. There are only specific serovars that cause severe clinical manifestations in 
their specific hosts [15]. Although most of the serovars of S. enterica subspecies 
cause infections which give rise to gastroenteritis that lasts for short durations, 
some serovars lead to severe systemic illness in humans and animals accompanied 
by septicaemia, fever and in some cases abortion. Based on the host specific-
ity, these serovars can be grouped into two categories: the first category consists 
of serovars that are single-host restricted and the second category infecting a 
broad range of hosts. Different factors can be considered for grouping different 
serovars under the above-mentioned categories. Also, serovar pathogenicity and 
host epidemiology define host specificity. Keeping the above factors into account, 
different serovars have been grouped into three major groups. The first group 
comprises of serovars that mainly infect cattle and pigs but can also infect other 
animals including humans in some accidental cases. In this group, S. choleraesuis 
and dublin have been included that cause systemic diseases in the above-mentioned 
hosts. In humans and other animals, clinical symptoms may not be visible, thus 
making them asymptomatic. Salmonella carriers that can shed the bacteria in the 
surroundings thus leading to increased risk for susceptible hosts are also known as 
host-adapted serovars (HA) [16]. The second group infects specific hosts and is col-
lectively known as host-restricted (HR) serovars. The HR serovars cause systemic 
diseases and can sometimes prove lethal in their hosts that include poultry, humans, 
sheep, equine and pigs. This group includes S. gallinarum, S. typhi, S. abortus and 
S. abortusequi. They interfere with the environment of their hosts in a way that 
paves their way for invading the host. This ability to cause mammalian abortions 
and loss in poultry egg production is due to their remarkable ability to multiply in 
the foetal tissues [16–18]. The serovars of the third group are known as unrestricted 
serovars that are of zoonotic, epidemiological importance and impose a great threat 
to many animals and humans. The serovars of this group that are of much clinical 
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importance are S. typhimurium and S. enteritidis [18]. These cause mild symptoms in 
the adult host, and sometimes the host does not show any visible clinical symptoms 
despite infection. They severely invade young hosts as compared to adult hosts 
because the adult hosts have a well-built immune system that hinders the invasion 
by these serovars [16]. The host specificity and adaptability of different serovars are 
a complex process and involve many molecular mechanisms. The exact mechanisms 
are poorly studied, but certain factors have been found to be responsible for deter-
mining host specificity and adaptability.
4.1 Factors determining Salmonella host specificity and adaptation
Although the exact mechanisms to host specificity have not been fully deci-
phered, the existing evidence shows that serovars act independently of each other at 
the various phases of infection. The expression of serovar’s pathogenicity is affected 
by the environmental and genetic factors influencing each host during adaptation 
[19]. Each HA/HR serovar must overcome the encountered specific and non-
specific immune mechanisms. Thus, pathogenicity of HA serovars results from the 
development of ways helping their survival in a host. Examples of this are serovars 
of S. enterica subsp. enterica, which have developed the ability to evade the immune 
mechanisms of warm-blooded animals. They have, during their evolution, acquired 
the ability to modify to their favour the physiological functions of their host, such 
as intracellular engulfment, apoptosis, transfer of antigens by M (microfold) cells, 
migration of macrophages and lymphocytes in the reticuloendothelial system and 
others [20]. A well-known serovar S. typhi has evolved to survive in human macro-
phages making it pathogenic to man, but not to mice [21]. Serovars such as the HR 
S. typhi, S. gallinarum and S. abortusovis show high tropism for the lymphatic organs 
of their hosts, thereby regulating their natural host’s biological environment in their 
favour [19]. By anchoring to the cells of the bone marrow, PPs and bursa of 
Fabricius in the development of B cells, thus immune response is affected. The 
result of such interactions, particularly in adult animals, helps in the establishment 
of chronic or subclinical infection and thus prolonged subclinical excretion, but 
they do not help in the development of severe gastroenteritis [22]. Serovars not fully 
adapted to evade the mature immune system lack specificity, causing deadly 
systemic disease in adult animals by invading their defence mechanisms compared 
to HR serovars [20]. HR serovars are mildly enteropathogenic compared to the 
unrestricted serovars; thus, they do not cause intestinal inflammation [23]. It has 
also been shown that the ability of a serovar to metabolise a wide range of amino 
acids adds to its virulence and is thought to be closely related [24, 25]; however, HR 
or HA serovars have most likely evolved independently. On the other hand, the 
heterogenicity of serovars in relation to different metabolic profiles facilitates either 
the completion of the pathway to infection [26] or, when lacking specificity, it is 
favouring host adaptation [19]. The process of Salmonella host adaptation is 
believed to be involving either the loss of genes or the acquisition of novel genetic 
elements that encode specific virulence factors, and thus an inconvenience is 
observed frequently in the pathogenic strains. Best examples of host specificity 
dependent on gene deletions are, perhaps, of S. enteritidis, Typhimurium, 
Choleraesuis, Gallinarum, Abortusovis, Pullorum and Paratyphi C [27]. Genome 
sequencing of HA/HR serovars, such as Typhi, Gallinarum, Choleraesuis and the 
newly emerging in sub-Saharan Africa invasive strains of S. Typhi, has divulged 
that these have encountered extensive gene deletions and truncation [28, 29]. In 
systemically noninvasive Salmonella, the majority of lost genes have functional 
orthologues, which play a key role in intestinal colonisation, thus resulting in the 




followed by a concurrent acquisition of mechanisms helping the microorganism to 
survive in a systemic niche [30]. Point mutations, horizontal gene transfer, positive 
selection and genome degradation could be responsible for a differential pathoad-
aptive evolution of some Salmonella serovars [31]. It appears from the analysis of 
the mannose-sensitive fimbrial adhesin FimH that even single amino acid replace-
ment, resulting in specific structural mutations in FimH variants of HA serovars, 
plays an important role in the differential adaptive evolution of Salmonella spp. 
Thus, activation or inactivation of mannose-specific adhesive properties in differ-
ent systemically invasive serovars reflects the dynamic trajectories of adaptation to 
the biological environment of a specific host. Furthermore, phylogenetic analysis 
has indicated that these mutations are, most likely, of a convergent nature (common 
pathogenic traits incorporated into different genetic backgrounds) and occur under 
strong positive selection, illustrative of the role of point amino acid changes for HA 
Salmonella. Certainly, deep study for the molecular composition of flagella, chemo-
taxis genes [32], fimbriae and bacteriophages and the presence of virulence plas-
mids and subtypes of each specific serovar is needed, to understand mechanisms of 
pathogenicity and host specificity [19]. Correlation between some phage types of  
S. Typhi with their hosts has shown considerable host specificity [33]. However, the 
majority of phage types studied had a broad host range, perhaps, suggesting a phage 
transfer of virulent genes between hosts, leading eventually to host specificity. The 
unrestricted serovar Typhimurium may comprise a spectrum of variants differing 
in regard to virulence, reflecting a summation of the spatial and/or temporal 
selective pressures within a particular host [34]. Salmonella Typhimurium strains 
derived from animal cases were also virulent in mice, whereas many strains derived 
from a clinically ill man lacked this ability. Of interest was that many derived from 
human gastroenteritis lacked the Salmonella virulence plasmid, present in all 
animal strains and strains isolated from human bacteraemia. Furthermore, some 
strains harbouring the virulence plasmid isolated from the man were avirulent in 
mice, and the opposite was observed with those derived from animals. Altogether, 
isolates of a specific bacterial serovar obtained from human salmonellosis are 
different from those isolated from animals. This means that selective pressure 
within a specific host gives rise to bacterial strain variants that exhibit different 
pathogenicity determinants, thus varying degree of pathogenicity. Similarly, 
serovars of S. enterica subsp. enterica, associated with disease in mammals and 
birds, show different degrees of adaptability. Pathogenicity determinants, such as 
the FimH adhesins, play an important role. Type 1 FimH adhesins are expressed by 
serovars of S. enterica isolated from mammalian and avian hosts, while type 2 FimH 
is expressed exclusively by the avian-adapted serovar Gallinarum. Allelic variation 
of the S. enterica FimH adhesin directs host-cell-specific recognition, thus selec-
tively binding to mammalian or avian receptors [35]. The distribution of SPIs, 
fimbriae operons and virulence plasmids has shown that various combinations of 
virulent determinants formed during the evolution of the microorganism are 
needed for a variant to become pathogenic in a particular range of host species. 
Mutations horizontally transmitted could have helped the development of host 
specificity by helping Salmonella serovars to harbour unique virulence factors [36]. 
Molecular and phylogenetic analyses of the SPI genes showed that these encode for 
translocon proteins (SipD, SseC and SseD) present on both Salmonella pathogenic-
ity islands SPI-1 and SPI-2 and also encode an effector protein that inhibits the 
MAPK pathway of the host cells [37]. In addition, they encode effector proteins 
(SseF and SifA) important in placing the Salmonella-containing vacuole (SCV) in a 
juxtanuclear position. The products of SPI genes interact directly with the host and 
modulate its functions, thus favouring host specificity. Another study of the SPI 
genes has shown the close evolutionary relatedness between serovars Gallinarum 
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and Enteritidis [38], although the former is highly adapted (restricted) to poultry 
and is the only known non-motile serovar, while serovar Enteritidis is unrestricted. 
Analysis of the functions of genes associated to SPI-1 showed that virulence genes 
might have evolved under positive selection imposed by a serovar’s respective 
host(s) contributing to the different host specificity observed between different 
serovars. This has displayed that a close similarity of core regions exists within as 
well as among different serovar genomes [39]. In particular, genomic comparisons 
of HR and HA serovars show that genomic degradation is a common evolutionary 
mechanism for host adaptation and increased pathogenicity [39, 40]. Others have 
shown that host restriction and change of ecological niche are associated with the 
accumulation of pseudogenes and an overall reduction in genome size [28]. For 
example, S. Typhi and Paratyphi A are restricted to the man and cause a similar 
systemic disease. Genome sequence similarity between Typhi and Paratyphi A 
serovars and their different pathogenicity when compared to the unrestricted 
serovars of S. enterica have been attributed to a relatively recent recombination of a 
quarter of their genomes, making the aggregation of pseudogenes a key feature of 
convergent evolution for these and other HA pathogens [31]. Another example 
supporting the role of convergent evolution is serovar Paratyphi C, which has 
diverged from the same ancestor as serovar Choleraesuis, by accumulating genomic 
novelty during its adaptation process to man. The genomic analysis of these two 
Salmonella serovars has revealed a highly similar genomic construction between the 
two and their distinct pathogenic features, making them excellent models for 
studying Salmonella’s host adaptation and pathogenic divergence [39]. Hence, 
Salmonella adaptation to a particular host species is a complex phenomenon, which 
depends, apparently, on a large number of gene products. The prowess of under-
standing host-pathogen interactions requires analysis of the physiological associa-
tions between various animal species and genetic composition.
5. Salmonella invasion
After ingestion of Salmonella by the host organism, it travels from the stomach 
and invades intestinal epithelial cells. Bacterial recognition generates an inflam-
matory response following the recruitment of a variety of bone-marrow-derived 
phagocytes [41]. The ability of Salmonella to access intestinal epithelium (M cells) is 
due to the presence of virulence genes encoded by Salmonella pathogenicity island 
1 (SPI-1). Proteins that are encoded by SPI-1 form a needle-like Type III secretion 
system which allows the transport of several bacterial proteins into the host cell 
cytosol. These proteins induce changes in the host cells such as the rearrangement of 
the cytoskeleton and cell membrane and disconnection of epithelial cell junctions, 
facilitating bacterial invasion [42]. The primary site of Salmonella infection occurs 
at specialised microfold, or M cells, that are dispersed among the enterocytes, 
covering the follicle-associated epithelium (FAE) of the Peyer’s patch (PP) [43] 
(Figure 1). Salmonella is considered to preferentially invade PPs in the distal ileum, 
but in practice, all intestinal PPs will harbour bacteria after moderate-to-high-dose 
infection. Once Salmonella is penetrated, it initiates destruction of M cell which 
disrupts the mucosal barrier and allows additional entry of bacteria through neigh-
bouring enterocytes [43]. This process is extremely efficient, with M-cell penetra-
tion followed by M-cell destruction. Once access to PP via FAE is gained, invading 
bacteria enter the lymphatic system where they interact with professional killing 
cells (phagocytes) that ultimately determine the fate of the infection. Phagocytes 
are involved in both oxygen-dependent and oxygen-independent killing of the 




and nitrogen species creates a highly oxidative environment which is not permissive 
for the growth of bacteria. The subepithelial dome also contains dendritic cell (DC) 
subsets apart from macrophage populations, each of which can phagocytise the 
bacteria and then undergo apoptosis through a caspase-1-dependent mechanism 
[44]. Consequently, during Salmonella infection, the number of obligate anaerobes 
decline in the gut. Also, host-signalling environment is highly crucial for the disease 
development initiated by contact between microbe and host cells in various tissues, 
largely mediated by cytokine signalling. These cytokines aid in initiating and regu-
lating the innate and adaptive branches of the immune response against Salmonella. 
In order to avoid damage to the host, the release of pro- and anti-inflammatory 
cytokines must be balanced [45]. M cells are not only abundant in PPs; they also 
predominate in other intestinal locations and so can, therefore, mediate infection of 
non-PP intestinal tissues (Figure 1). The most likely non-PP entry route is through 
the bacterial invasion of solitary intestinal lymphoid tissues (SILTs), which are het-
erogeneous intestinal lymphoid aggregates found in mice and humans that contain 
Figure 1. 
Salmonella entry in intestinal epithelial cells. SPI-1 facilitates uptake and destruction of M cells, SILTs. After 
invasion of under tissues, Salmonella is taken by phagocytes and transported to mesenteric lymph nodes.
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certain features of PPs, including the presence of FAE-containing M cells [46, 47]. 
These SILTs are invaded by bacteria in a much similar manner as described above 
for PPs [48]. SILTs can be important in humans since in a study of typhoid patients, 
both PPs and SILTs showed inflammation. It has also been reported that intravillous 
M cells, which are sparsely located along the intestinal tract, may serve as a portal 
of entry for invasive Salmonella bacteria [49, 50] (Figure 1).
5.1 Alternative route for invasion
The main entry route described above involve, bacterial interactions with M 
cells, the possibility is that it can invade the host by an alternative route that does not 
involve M cells. A population of phagocytes in the lamina propria capture bacteria 
directly from luminal contents which also allow bacterial entry [51, 52]. This is for 
those bacteria that lack SPI-1 genes as this route does not involve M cell-mediated 
uptake. These cells might have been referred to as DCs, but as this is not clear [53, 54], 
they will be referred to as lamina propria phagocytes in this chapter. Although this 
pathway has now become an alternative to our general understanding of bacterial 
entry through M cells, the physiological importance of this route to systemic salmo-
nellosis is poorly defined. The compelling evidence for a non-M-cell pathway is largely 
derived from microbiological and immunological investigations. Recent interest was 
stimulated by demonstrating that strains lacking SPI-1 and the fimbrial lpfC gene that 
did not normally infect mice retained the ability to infect mice in a CD18-dependent 
manner and were rapidly detected in the blood after oral inoculation [55, 56]. This 
extremely rapid dissemination to the blood and lack of serovar specificity might be 
due to bacterial entry in the bloodstream of the host through abrasions caused during 
gavage. Many cervical lymph node infection cases that attributed to the entry through 
mucosal abrasions during gavage were revealed through bacterial imaging system 
[57]. Expression of the SPI-2 type-III secretion system effector protein (SrfH) of 
bacteria was required for very early dissemination of bacteria to the blood and spleen 
[58]. This finding supports the idea that rapid entry through an alternative pathway 
involves active processes, so, therefore, it is important to examine this route from a 
microbiological perspective. In vitro studies demonstrated that DCs could capture 
bacteria by extending processes between the tight junctions of a monolayer and the 
apical surface of epithelial cells [59]. Subsequently, a similar process was directly visu-
alised in vivo when CX3CR1-expressing phagocytes were detected extending tran-
sepithelial dendrites in the lamina propria, and the number of dendrites increased 
in the terminal ileum after infection [60]. So, these studies suggested an alternative 
entry model, whereby Salmonella might commonly access the intestinal lamina pro-
pria by cell sampling, as large numbers of bacteria were detected within the lamina 
propria [60]. However, Salmonella is not normally recoverable in large numbers 
from the lamina propria unless the bacterial flora is first depleted before infection 
[48]. Also, the formation of transepithelial dendrites is dispensable for the uptake of 
other pathogenic microorganisms [61]. More importantly, it has been demonstrated 
that CX3CR1+ lamina propria cells are unlikely to migrate to the mesenteric lymph 
nodes (MLN) and have poor immunostimulatory capacity [53]. Thus, CX3CR1+ cells 
most likely represent a population of non-migrating phagocytes that provide innate 
immune defence against infection within the lamina propria. Surprisingly, the role 
of cell-mediated uptake has not been examined carefully in PPs or in SILTs, but still, 
phagocytic cells are often found in association with the epithelium of tissues [48, 62]. 
In summary, a prominent role for M cell-mediated intestinal entry by Salmonella is 
played both in the PPs and SILTs, whereas Salmonella entry of the lamina propria and 
the mechanisms like immune activation and bacterial dissemination associated with 




6.  Salmonella infection of mesenteric lymph nodes (MLNs) and systemic 
tissues
After initial invasion through PPs, the ultimate fate of infection is decided in 
the lymphatic system. The indication for the bacterial migration is based on our 
understanding of the lymph and the conjectural finding that bacteria are detected 
initially in PPs, followed by the MLN and finally the liver and spleen [63, 64]. 
Salmonella after getting access to efferent lymphatics reaches the systemic tissues 
via the thoracic duct and blood after reaching the MLN [65, 66]. The immune cell 
population that aids in the transport of bacteria to the blood and other tissues is 
not well known; however, intestinal DCs are usually considered as a possibility. 
The majority of bacteria were found free in the lymph or were associated with 
non-DC phagocytes [67], but it is not clear whether this also occurs during exit 
from the MLN. Disseminated bacteria show a tropism of tissues that contain a high 
number of phagocytic cells, and in most circumstances, this involves the spleen, 
liver, and bone marrow [65, 68]. Disruption of erythropoiesis and splenomegaly by 
Salmonella can be explained majorly by the expansion of immature erythrocytes 
in the spleen in an erythropoietin-dependent manner. Cancer studies have demon-
strated that bacteria preferentially accumulate in primary and metastatic tumours 
[69, 70], suggesting that it does not have a precise organ tropism but finds tissues 
that contain a sufficient number of cells that support bacterial replication. The 
large size of the spleen, liver, and bone marrow means that these tissues gradually 
comprise the major sites of bacterial replication [71, 72]. Thus, Salmonella causes 
systemic infection that uses intestinal lymphoid tissues as a portal of entry. Also 
that bacteria clearance from the host and resistance to secondary infection requires 
the coordinated action of both systemic and mucosal immunity.
7. Host innate immune response to Salmonella
After phagocytosis by macrophages, Salmonella can survive and replicate within 
modified intracellular vesicles, termed as Salmonella-containing vacuoles (SCV) 
[73, 74]. The ability of Salmonella to survive within the phagosome is mediated by 
SPI-2, which prevents movement of RNS and ROS into the phagosome where the 
bacteria reside [75, 76]. In addition, Salmonella phoP/phoQ regulon inhibits fusion 
of the SCV with toxic lysosomes and endosomes [77]. The natural resistance-
associated macrophage protein encoding gene, which enables macrophages to 
transport ions into the SCV, provides resistance/susceptibility to infection [78]. 
Survival of bacteria intracellularly within tissue phagocytes is a prerequisite to 
the bacterial virulence, and bacterial mutants that cannot survive and replicate 
within macrophages are attenuated for virulence [79]. The initial invasion induces 
a massive inflammatory response, characterised by recruitment of neutrophils, 
DCs, inflammatory monocytes and macrophages [48, 80]. Neutrophils follow the 
chemokine gradient to the gut and extravagate into the mucosa. As they encounter 
and eliminate the bacteria by mechanisms that are not yet fully elucidated [81], 
neutrophils are believed to be important in preventing dissemination of the bacteria 
from the intestine to systemic tissues, so the patients with low neutrophil levels 
have a high risk of bacteraemia during infection with NTS strains [82]. Also, that 
depletion of neutrophils allows extracellular growth of bacteria, suggesting that 
neutrophils confine and reduce bacterial replication immediately after entry. 
Inflammatory monocytes are an important source of antimicrobial factors, such as 
TNFs and inducible NO synthase, during the initial stages of infection [80]. Myd88-
dependent chemokine production within the PPs drives the recruitment of these 
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in the terminal ileum after infection [60]. So, these studies suggested an alternative 
entry model, whereby Salmonella might commonly access the intestinal lamina pro-
pria by cell sampling, as large numbers of bacteria were detected within the lamina 
propria [60]. However, Salmonella is not normally recoverable in large numbers 
from the lamina propria unless the bacterial flora is first depleted before infection 
[48]. Also, the formation of transepithelial dendrites is dispensable for the uptake of 
other pathogenic microorganisms [61]. More importantly, it has been demonstrated 
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inflammatory cells [81]. Indeed, Salmonella expresses several pathogen-associated 
molecular patterns (PAMPs), including lipopolysaccharide (LPS) and flagellin, 
which can be detected by Toll-like receptors (TLRs) expressed by enterocytes 
and phagocytes [83]. Also, macrophages after sensing cytosolic flagellin through 
NLRC4 (also known as Ipaf) activate caspase-1 and induce the production of IL-18 
(pro-inflammatory) [84, 85]. Dendritic cells are professional antigen-presenting 
cells and increase the expression of MHC class II and the co-stimulatory molecules 
CD86, CD80 and CD40 by responding to the recognition of Salmonella LPS or 
flagellin [86, 87]. DCs present antigen to naive CD4+ T cells, thus providing a vital 
link between innate immune responses and the induction of adaptive immunity. In 
the PPs, flagellin also induces the secretion of the inflammatory chemokine CCL20, 
which is an important ligand for CCR6 [88]. This response activates an early process 
whereby CCR6-expressing DCs are recruited to the FAE, for efficient activation of 
CD4+ T cells [89].
8. Host-adaptive immune response to Salmonella
Adaptive immune response to Salmonella can be mediated via early CD4+ T-cell 
activation. Due to the small size of intestinal lymphoid tissues and low frequency 
of naive CD4+ T cells specific for any given antigen [90], detecting initial bacte-
rial specific T-cell activation in these tissues is challenging. However, studies 
with T-cell receptor transgenic mice visualised the processes of bacterial specific 
CD4+ T cells responding to oral infection [64, 91]. An artificially elevated naive 
precursor frequency of CD4+ T cells at a high dose of infection provides the most 
accurate assessment of Salmonella-specific CD4+ T-cell activation [92]. The earliest 
Salmonella-specific CD4+ T-cell activation occurs within the MLN after oral infec-
tion but usually peaks few hours after that in the PPs [91]. At very early time points, 
CD4+ T cells were not found to be activated in any other secondary lymphoid tissues 
[89], suggesting that whatever the explanation for early bacterial dissemination to 
blood as discussed above, no early adaptive immune response is initiated outside 
the gut-associated lymphoid tissue. Interestingly, the T-cell receptor transgenic 
model used recognises a bacterial peptide from the carboxy-terminal region of 
flagellin [93] which is also a ligand for TLR5 [94]. Generally, the early activation 
of flagellin-specific CD4+ T cells in the PPs is representative of the naive CD4+ 
response to other bacterial antigens [95, 96]. However, this is difficult to demon-
strate conclusively as very few, naturally occurring bacterial specific MHC class-II 
peptides are known [97]. Interestingly, activation of CD4+ T cells in the MLN is also 
dependent on CD11c+ DCs and CCR6, indicating that T-cell activation in the MLN 
and PP has similar requirements. The evidence clearly suggests that the MLNs are 
an important site for immune protection during the course of Salmonella infection. 
Indeed, after MLNs were surgically removed, there was an elevated bacterial load 
and severe immunopathology in the liver [98]. The importance was also highlighted 
using a relapsing model of murine typhoid in which primary infection returns after 
apparent antibiotic clearance [57]. Although MLN is often considered a potential 
site of bacterial accumulation [99, 100], it acts as a protective firewall, preventing 
bacterial dissemination and relapsing Salmonella infection.
9. Host effector responses against Salmonella
The development of robust protective immunity against Salmonella infec-




cells have a critical role in clearing the primary infection and are also required for 
acquired resistance to secondary infection [100]. In contrast, B cells are dispensable 
for resolving primary infection but are required for protection against secondary 
challenge [101]. There is a massive expansion of Salmonella-specific CD4+ T cells 
and rapid acquisition of Th1 effector functions, i.e. the enhanced ability to secrete 
INF-γ, TNF α and IL-2 upon restimulation [102] (Figure 2). These activated Th1 
cells can be clearly detected a week after infection, which is consistent with the rapid 
tempo of CD4+ T-cell activation. Optimal expansion of Th1 cells have been shown to 
require expression of both programmed death ligand-1 (PD-L1) and the TNF recep-
tor family members, OX40 and CD30. Appropriately, expansion of activated Th1 
cells eventually comprises ~50% of all CD4+ T cells few weeks after infection [103]. 
Furthermore, Th1 cells are capable of responding to innate signals such as Salmonella 
LPS by secreting cytokines [104]. This innate response is unexpected as effector Th1 
cells are normally stimulated only after recognition of cognate peptide and MHCs 
[105]. This innate immune responsiveness suggests a means by which the host can 
rapidly produce INF-γ to activate macrophages within an infected tissue, even if 
bacteria are capable of inhibiting antigen presentation by infected phagocytes [106]. 
Despite the rapid and efficient development of Th1 effector cells, there is actually 
little evidence that suggests their contribution to bacterial clearance during primary 
infection. Thus, it was found that when CD4+ or CD4+ Th1 cells were completely 
absent, bacterial growth enhanced a few weeks after infection which indicates that 
Th1 cells contribute little to regulate bacterial growth before this point [107]. Many 
in vitro studies point to an inhibitory effect of Salmonella on antigen presentation to 
naive T cells in vitro [108], but in vivo, there is no effect on Salmonella-specific CD4+ 
expansion [109]. In contrast, the gradual loss of effector CD4+ T cells detected in the 
process of Salmonella infection that required the presence of live bacteria and the 
expression of SPI-2 genes indicated that the effector function of cells is specifically 
Figure 2. 
Induction of IFN γ production by Salmonella-specific CD4+T cells. Expansion of activated CD4+T cells in 
secondary lymphoid tissues which in turn produces IFNγ at infection sites. Production of IFNγ finally activates 
macrophages.
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inhibited by actively replicating bacteria [110]. Effector Th1 cells are effective in 
providing immunity to salmonellosis [111]; however, effector CD4+ subsets includ-
ing regulatory T cells (Tregs) and Th17 cells are also known to contribute. Tregs arise 
from the thymus or develop after naive T-cell activation in the presence of TNF β 
which suppresses effector T-cell responses [112]. In contrast, Th17 cells arise from 
naive CD4+ T-cell stimulation in the presence of IL-6 and TNF-β and are important 
in mediating immunity against extracellular bacterial infections [113, 114]. During 
the development of Th1 cells and Tregs after infection, it was found that changes in 
the cogency of Tregs reduced the efficacy of Th1 responses and increased bacterial 
growth [102]. After oral infection with Salmonella, cytokines associated with Th17 
cells, IL-17 and IL-22 are rapidly produced within the intestinal mucosa [115], and 
the production is induced by innate responses to infection rather than Th17 cells, 
however, still indicating the potential for Th17 cytokines to participate in intestinal 
defence against bacteria. In vivo, production of IL-22 dependent on IL12B, rather 
than IL-17, contributed to bacterial clearance [116]. Taken together, it is suggested 
that Th17 cells contribute additionally to protection against Salmonella infection by 
not only initiating or enhancing neutrophil infiltration to intestinal tissues but by 
the production of antimicrobial peptides by the epithelium which is effective against 
luminal bacteria as well [117]. In summary, it has been suggested that Th17 cells have 
an additional role in defence against Salmonella in the intestine and a role for Tregs in 
modulating the potency of Salmonella-specific Th1 cells in vivo.
10. Host antibody (Ab) response against Salmonella
Salmonella-specific B-cell responses contribute to bacterial clearance in the hosts 
[39, 120, 121]. Although the bacteria are generally found within SCV in phagocytic 
cells, there is a short period during the infection cycle when bacteria are expected to 
be extracellular. Salmonella is not only tightly associated with mononuclear phago-
cytes in vivo [118] but also induces these infected cells to undergo apoptosis [44]. 
After cell death, bacteria are presumably found in the extracellular compartment 
before infecting a neighbouring phagocyte. Thus, antibody might have direct access to 
the bacteria during this short period of time and prevent cell-to-cell transmission [92]. 
Bacterial colonisation obstructs the bacterial opsonization with Salmonella-specific 
Ab [119]. The Ab also plays a role in amplifying the processing and presentation of 
antigens to CD4+ T cells, thus affecting the Th1 response [120]. B-cell innate immune 
response to TLR-specific ligands is necessary for the development of Th1 responses 
in vivo [121]. New findings also suggest the suppression of protective immunity 
through B-cell MyD88 pathway during infection [122]. Therefore, innate immune sig-
nalling in B cells contributes to an important regulatory function but requires further 
analysis. The presence of Salmonella-specific Ab IgA in the intestinal mucosa may also 
prevent or reduce bacterial penetration of the intestinal barrier [123]. However, which 
of these mechanisms makes the greatest contribution to protective immunity is yet 
to be deciphered, but an important role for Ab is also suggested from human studies 
[124]. Although the specificity of Ab responses is undefined, Abs specific for the LPS 
O-antigen, flagellin, Vi capsular polysaccharide (ViCPS) antigen and outer membrane 
porin protein (OmpD) are all believed to be protective [125].
11. Conclusion
Members belonging to genus Salmonella are the major intestinal pathogens of 




populations have led to the increase in dissemination potential of these ubiquitous 
microorganisms. Due to the systemic nature of some infections, where many tis-
sues get involved to display immunity to specific infection, salmonellosis and the 
immune response that results are pliable. Deciphering the pathogenesis of invasive 
salmonellosis may hopefully lead to potential therapeutic treatment strategies 
that are urgently required in light of propagating antimicrobial resistance. Future 
studies must focus on the identification of molecular targets of Salmonella virulence 
factors during intracellular life in immune cells and designate the molecular mecha-
nisms of interference. This would impart a novel perception into the cell biology 
of DCs and other immune cells. Furthermore, understanding the intracellular life 
of Salmonella may lead to new advancement in generating reliable vaccines against 
infections, to wield Salmonella strains as live carriers for recombinant vaccines and 
to evolve novel forms of treatment that target the function of specific virulence 
factors. Further explorations to clarify the contribution of genes differently repre-
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[39, 120, 121]. Although the bacteria are generally found within SCV in phagocytic 
cells, there is a short period during the infection cycle when bacteria are expected to 
be extracellular. Salmonella is not only tightly associated with mononuclear phago-
cytes in vivo [118] but also induces these infected cells to undergo apoptosis [44]. 
After cell death, bacteria are presumably found in the extracellular compartment 
before infecting a neighbouring phagocyte. Thus, antibody might have direct access to 
the bacteria during this short period of time and prevent cell-to-cell transmission [92]. 
Bacterial colonisation obstructs the bacterial opsonization with Salmonella-specific 
Ab [119]. The Ab also plays a role in amplifying the processing and presentation of 
antigens to CD4+ T cells, thus affecting the Th1 response [120]. B-cell innate immune 
response to TLR-specific ligands is necessary for the development of Th1 responses 
in vivo [121]. New findings also suggest the suppression of protective immunity 
through B-cell MyD88 pathway during infection [122]. Therefore, innate immune sig-
nalling in B cells contributes to an important regulatory function but requires further 
analysis. The presence of Salmonella-specific Ab IgA in the intestinal mucosa may also 
prevent or reduce bacterial penetration of the intestinal barrier [123]. However, which 
of these mechanisms makes the greatest contribution to protective immunity is yet 
to be deciphered, but an important role for Ab is also suggested from human studies 
[124]. Although the specificity of Ab responses is undefined, Abs specific for the LPS 
O-antigen, flagellin, Vi capsular polysaccharide (ViCPS) antigen and outer membrane 
porin protein (OmpD) are all believed to be protective [125].
11. Conclusion
Members belonging to genus Salmonella are the major intestinal pathogens of 




populations have led to the increase in dissemination potential of these ubiquitous 
microorganisms. Due to the systemic nature of some infections, where many tis-
sues get involved to display immunity to specific infection, salmonellosis and the 
immune response that results are pliable. Deciphering the pathogenesis of invasive 
salmonellosis may hopefully lead to potential therapeutic treatment strategies 
that are urgently required in light of propagating antimicrobial resistance. Future 
studies must focus on the identification of molecular targets of Salmonella virulence 
factors during intracellular life in immune cells and designate the molecular mecha-
nisms of interference. This would impart a novel perception into the cell biology 
of DCs and other immune cells. Furthermore, understanding the intracellular life 
of Salmonella may lead to new advancement in generating reliable vaccines against 
infections, to wield Salmonella strains as live carriers for recombinant vaccines and 
to evolve novel forms of treatment that target the function of specific virulence 
factors. Further explorations to clarify the contribution of genes differently repre-










MHC major histocompatibility complex
SPI Salmonella pathogenicity island
SCV Salmonella-containing vacuoles
MLN mesenteric lymph nodes
PAMPs pathogen-associated molecular patterns
LPS lipopolysaccharide
Tregs regulatory T cells




Myd myeloid differentiation primary response
Fim fimbrin
TNF tumour necrosis factor
CD cluster of differentiation
MAPK mitogen-activated protein kinase
SILTs solitary intestinal lymphoid tissues
ViCPS Vi capsular polysaccharide
TLRs Toll-like receptors
OmpD outer membrane porin protein
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Application of Artificial Barrier 
as Mitigation of E. coli Which Pass 
through Riverbank Filtration
Nur Aziemah Abd Rashid and Ismail Abustan
Abstract
Water security in the water treatment plant has been doubted, and the treatment 
process may have given unreliable and unsafe water to the public. A newspaper 
reported on November 19, 2011, that laboratory tests on water samples in Kelantan 
for each year by the Ministry of Health have found harmful bacteria including 
Escherichia coli (E. coli) in the water samples. More worryingly, it was stated in a 
study that chlorine in water treated with high chlorine can be harmful to human 
health. In 2010, Malaysia has begun to approach a natural treatment technique, 
namely, riverbank filtration (RBF), and firstly used it at the Water Treatment 
Plant in Jeli, Kelantan, and Kuala Kangsar, Perak. RBF limitation is the invisible 
groundwater flow that makes it difficult to predict the transport of contaminants. 
Managing groundwater is important to ensure that water is aligned in compliance 
with government legislation and environmental protection. Due to that, this study 
suggests an implementation of an artificial barrier for microorganism in RBF to sus-
tain the good water quality abstracted from the abstraction well. This pretreatment 
or purifying method is to improve the effectiveness of RBF in removing pollutants 
during shock loads and reduce the load placed in the water treatment process.
Keywords: artificial barrier, riverbank filtration, E. coli, groundwater, water security
1. Introduction
Potable water access globally is now under crisis, which leads to poor human 
health issue, affecting Malaysia as one of the countries facing this problem. The 
main reasons why this happens are due to climate change, deterioration of river 
water quality, unreliable water treatment system, and increase of population, 
which, at the same time, causes water shortage to occur. During dry weather condi-
tions, further depletion of water occurs. Pertinently, climate changes make the 
drought season becomes longer and hotter than usual. The dam water becomes low 
and the river water dries up. The deterioration of river water quality in Malaysia has 
brought an impact to the water treatment plant due to the increase of treatment cost 
and maintenance. Chemicals such as PACI, alum, and others will also be increased 
to treat the polluted river. In the year of 2011, it was stated in a study that chlorine 
in water treated with high chlorine can be harmful to human health [1]. Thus, water 
security in the water treatment plant has been doubted, and the treatment process 
may have given unreliable and unsafe water to the public. Recently, Utusan Malaysia 
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newspaper reported on November 19, 2011, that laboratory tests on water samples 
in Kelantan for each year by the Ministry of Health have found heavy metals and 
harmful bacteria including Escherichia coli (E. coli) in the water samples. More 
worryingly, E. coli was also found in water supplied to homes by Air Kelantan Sdn. 
Bhd. (AKSB). The discovery of E. coli in water samples in Kelantan detected by the 
ministry was then carried out from 2008 to 2010.
Providing reliable and safe potable water has become a human right for us. 
Therefore, finding a solution to these issues is highly desirable to improve the safety 
and reliability of potable water. In 2010, Malaysia has begun to approach a new 
treatment technique, namely, riverbank filtration (RBF). RBF is a method using 
groundwater that is expected to provide a new way to increase water intake and 
untapped resources in Malaysia, firstly used at the Water Treatment Plant in Jeli, 
Kelantan, and Kuala Kangsar, Perak. RBF is a natural system in which it involves the 
entry of river water into underground aquifers and is caused by hydraulic gradi-
ents, whereby water retrieval is from collector wells located at banks, at a certain 
distance from the river [2]. Although it is still less than 10 years in Malaysia, RBF 
method shows good results to reduce the use of chemicals and produces biologically 
stable water; the system also improves water quality by removing particles (turbid-
ity and suspended solids), organic pollutants, microorganisms, heavy metals, and 
nitrogen. One previous experience in Germany shows that RBF provides a strong 
barrier for various pollutants and can help to ease the temperature fluctuations and 
concentration peaks when it is associated with spills into rivers. It also replaces and 
supports other treatment processes and reduces the overall costs of water treat-
ment plant [3]. The removal of sediment, organic and inorganic compounds, and 
pathogens takes place during the first meters from the river in what is known as the 
hyporheic zone, which usually presents reducing conditions, due to high microbial 
activity that consumes oxygen in the water. Within this zone, there are important 
biochemical processes and redox reactions that affect groundwater quality [4]. In 
general, every stage of RBF has an environmental influence that is from the river 
until abstraction well.
Safe potable water is one of the implicit requisites for a healthy human popula-
tion. In the existence of RBF, artificial barrier is a new efficient purifying method 
to maintain safer water abstraction. This study demonstrates the potential of a 
new application of artificial barrier to filtrate E. coli in water in RBF system. The 
artificial barrier efficiency was examined for different media ratio. Artificial 
barrier is a man-made vertical barrier to pretreat water abstraction intake. It is 
a mixture of sand (local soil), granular activated carbon (GAC), and zeolite. 
Generally, the individual application of coconut shell GAC and zeolite has shown 
great advantages in terms of characteristics, adsorption capacities, as well as their 
physicochemical versatility. For that reason, the idea of combining the precursors 
in order to make an effective filter-based adsorbent for RBF purifying process 
is highly recommended. Besides that, the inherited limitation of an individual 
precursor in water treatment process could be minimized by combining them 
in layered filter adsorbent as first and second barriers in RBF aquifer due to low 
turbidity. GAC and zeolite have high permeability which make them suitable 
to be applied in RBF aquifer, which requires high permeability condition as for 
the RBF site. However, studies on the removal of E. coli from actual river water 
using artificial barrier (GAC and zeolite) in RBF as the pretreatment or purifying 
process are still limited until now. Similarly, studies concerning the optimization 
of adsorption treatment for the studied parameter removal from river water are 
inadequate. Due to that, this research study is mainly focused on the treatment of 
actual river water from Sungai Kerian, Lubok Buntar, Kedah, via artificial barrier 
fixed-bed flow studies.
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2. Riverbank filtration
2.1 Principle and treatment
RBF has begun to be widely used in Malaysia as to optimize the water supply. 
The introduction of RBF in Malaysia is started in 2010 at Jeli, Kelantan. The plants’ 
operation has demonstrated the success of the combination of RBF (as pretreat-
ment) and water treatment plant (as posttreatment). Most RBF in Malaysia have 
been applied in Kelantan areas. After calculating all the costs (not including the 
cost of pumps, pipes, valves, etc.), 1 m3 of drinking water costs approximately USD 
0.04, which is considered to be a competitive price for the Malaysian. The combined 
method has therefore proved to be both technologically and financially viable. 
These findings should pave the way for other municipal authorities to follow suit by 
introducing their own combined RBF with ultrafiltration.
RBF post water treatment has been employed dating back to the nineteenth cen-
tury. During RBF, river or lake water is extracted indirectly by drawing it through 
the subsurface prior to use as in Figure 1. The extraction is accomplished by an infil-
tration line of well either vertical or horizontal. The well is located at a short (below 
30 m) to intermediate (up to 60 m) distance from the riverbank or lake. During 
extraction of water, the groundwater that discharges into the river decreases, and 
the groundwater table near the waterline may decrease below the river water level. 
To ensure a satisfactory purification, the distance between the river and the extrac-
tion well should such that the travel time exceeds 30–60 days [5].
During infiltration and travel through the soil and aquifer sediments, surface 
water is subjected to a combination of physical and chemical and biological pro-
cesses of filtration. The top few centimeters of the riverbank materials formed are 
a screen or filter medium that removes the suspended solids present in the water. 
Heavy metal, phosphorous, and hydrophobic organic compounds present in the 
water are removed by adsorption onto certain aquifer materials. In the presence of 
biomass, the organic matter is further biodegraded (initially under oxic conditions 
and later under anoxic conditions). The water quality in most cases is improved by 
dilution of the surface water source with native groundwater [6]. When a particle 
becomes attached to the biofilm on the sand grain, microorganism may degrade that 
particle. There is an interception when particles are carried by one of the stream-
lines closest to the sand grain and a brushing effect occurs. There is general agree-
ment that straining, adhesion, attachment, chemical adsorption, sedimentation, 
and biological growth all operate to some extent.
Figure 1. 
Riverbank filtration system.
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The conventional treatment commonly involves screening, aeration, coagulation, 
flocculation, sedimentation, slow sand filtration, and chlorination. The chemical 
treatment and waste product will increase if the pollutants in surface water increased. 
The RBF reduces the posttreatment step from six to only two steps which is removal 
of heavy metals (usually iron and manganese) by either aeration, activated carbon 
filter, or ultrafiltration and chlorination for taste and odor. This RBF system as a 
pretreatment technique applied in countries like the Netherlands, Germany, China, 
Korea, India, Egypt, and others has already succeeded in optimizing the potable 
water supply. The underground passage ensures the high quality of drinking water, 
which does not need any further treatment or disinfection before supply [7].
The posttreatment after RBF depends on the water abstraction water quality. 
Each RBF site has a different technique step for posttreatment. Previous study 
shows the most common pollutants that occur in RBF sites are iron and manganese. 
The treatments used to remove these contaminants in water are aeration, activated 
carbon filter, and ultrafiltration method. The second contaminant that occurs is 
taste and odor which are usually removed using chlorination. The third contami-
nant was microbiology which is solved by using ozonation and UV disinfection. 
This all posttreatment technique is commonly used at RBF site and summarized 
in Table 1. Meanwhile, there are RBF sites which are not using a posttreatment as 
a means for direct usage such as in China. However, in several years there will be 
oocyst problems.
2.2 Benefits and limitation
The RBF is a sustainable natural treatment process which avoids or reduces the 
use of chemicals and produces biologically stable water. The system improves water 
quality by removing particles (turbidity and suspended solid), organic pollutants, 
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microorganism, heavy metals, and nitrogen. The RBF also helps to dampen the tem-
perature fluctuations and concentration peaks when it is associated with spills into a 
river or lake. This treatment process also replaces and supports the other treatment 
processes by providing a robust barrier for multiple contaminants and reduces the 
overall cost of water treatment [3].
RBF limitation is the invisible groundwater flow that makes it difficult to predict 
the transport of contaminants. A specific concern of the RBF limitation is due to 
hydrology and dynamics of the river and groundwater, which have different climate 
variations (drought and rainy seasons), and thus, the groundwater level patterns 
result in significant fluctuation of contaminants in well stream loads. In rainy 
season, the rate of groundwater flow increases to a maximum level and causes small 
particles and pollutants to absorb into the soil where it encloses the flow along the 
groundwater flow, which initiates pollutants to enter the borehole. On the other 
hand, in dry season, minimum and ideal flow rates for pollutants are attached to 
the local soil. Moreover, since maximum groundwater flow rate occurs frequently 
in Malaysia, this incident is predicted to often result in significant fluctuations of 
underground hydraulic conductivity of groundwater and shock load of pollutants. 
Significant amount of pollutants may exist in borehole water due to high hydraulic 
conductivity and soil feature, which concludes that RBF is a natural treatment 
method that depends on natural behavior. In general, the quality of RBF water 
is influenced by the environmental conditions, where managing groundwater is 
important to ensure that water is aligned in compliance with government legislation 
and environmental protection.
The posttreatment step in most RBF sites is usually focused on iron and man-
ganese treatment which result in the usage of aeration, activated carbon filter, and 
ultrafiltration treatment process. The weakness of this treatment which cannot be 
ignored has been discussed in the above section. The occurrence of the pollutants 
can be worse during shock load and clogging. Due to that, artificial barrier seems 
important which can increase the hydraulic conductivity of the underground water 
flow, reduce the pressure load to the aquifer during clogging, and enhance the pol-
lutants adsorption during shock load. This can reduce the consumption of chemical 
treatment and strengthen the RBF barrier.
2.3 Factors influencing optimization of RBF
There are four basic important criteria affecting the performance of RBF which 
are hydrogeological conditions, source water quality and mixing with native 
groundwater, distance of the well from riverbank and spacing of wells and pumping 
rates, and sediment permeability. The effectiveness of RBF for removing surface 
water contaminants depends largely on hydrogeological conditions. It is about the 
soil microbiology, characteristic of the bank materials and streambed, and scour-
ing characteristic [13]. In many countries, the alluvial soil aquifers hydraulically 
connected to a water course would be preferred sites for drinking water production 
[14]. The actual biochemical interactions that sustain the quality of the pumped 
bank filtration depend on numerous factors, including aquifer mineralogy and the 
extent of the aquifer [15].
The RBF shows a decreasing RBF water level with an increasing distance of the 
well apart from the riverbank. In addition to the decreasing RBF water level due 
to increasing distance, there is no cross flow of natural groundwater that the well 
could abstract river water [12]. Pumping test result shows that the water in well 
(below 60 m) comes from river water. However, the low-lying coastal aquifer is gen-
erally fragile and easily depleted due to anthropogenic activities and overexploita-
tion of groundwater and agriculture. To manage and protect precious groundwater 
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microorganism, heavy metals, and nitrogen. The RBF also helps to dampen the tem-
perature fluctuations and concentration peaks when it is associated with spills into a 
river or lake. This treatment process also replaces and supports the other treatment 
processes by providing a robust barrier for multiple contaminants and reduces the 
overall cost of water treatment [3].
RBF limitation is the invisible groundwater flow that makes it difficult to predict 
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hydrology and dynamics of the river and groundwater, which have different climate 
variations (drought and rainy seasons), and thus, the groundwater level patterns 
result in significant fluctuation of contaminants in well stream loads. In rainy 
season, the rate of groundwater flow increases to a maximum level and causes small 
particles and pollutants to absorb into the soil where it encloses the flow along the 
groundwater flow, which initiates pollutants to enter the borehole. On the other 
hand, in dry season, minimum and ideal flow rates for pollutants are attached to 
the local soil. Moreover, since maximum groundwater flow rate occurs frequently 
in Malaysia, this incident is predicted to often result in significant fluctuations of 
underground hydraulic conductivity of groundwater and shock load of pollutants. 
Significant amount of pollutants may exist in borehole water due to high hydraulic 
conductivity and soil feature, which concludes that RBF is a natural treatment 
method that depends on natural behavior. In general, the quality of RBF water 
is influenced by the environmental conditions, where managing groundwater is 
important to ensure that water is aligned in compliance with government legislation 
and environmental protection.
The posttreatment step in most RBF sites is usually focused on iron and man-
ganese treatment which result in the usage of aeration, activated carbon filter, and 
ultrafiltration treatment process. The weakness of this treatment which cannot be 
ignored has been discussed in the above section. The occurrence of the pollutants 
can be worse during shock load and clogging. Due to that, artificial barrier seems 
important which can increase the hydraulic conductivity of the underground water 
flow, reduce the pressure load to the aquifer during clogging, and enhance the pol-
lutants adsorption during shock load. This can reduce the consumption of chemical 
treatment and strengthen the RBF barrier.
2.3 Factors influencing optimization of RBF
There are four basic important criteria affecting the performance of RBF which 
are hydrogeological conditions, source water quality and mixing with native 
groundwater, distance of the well from riverbank and spacing of wells and pumping 
rates, and sediment permeability. The effectiveness of RBF for removing surface 
water contaminants depends largely on hydrogeological conditions. It is about the 
soil microbiology, characteristic of the bank materials and streambed, and scour-
ing characteristic [13]. In many countries, the alluvial soil aquifers hydraulically 
connected to a water course would be preferred sites for drinking water production 
[14]. The actual biochemical interactions that sustain the quality of the pumped 
bank filtration depend on numerous factors, including aquifer mineralogy and the 
extent of the aquifer [15].
The RBF shows a decreasing RBF water level with an increasing distance of the 
well apart from the riverbank. In addition to the decreasing RBF water level due 
to increasing distance, there is no cross flow of natural groundwater that the well 
could abstract river water [12]. Pumping test result shows that the water in well 
(below 60 m) comes from river water. However, the low-lying coastal aquifer is gen-
erally fragile and easily depleted due to anthropogenic activities and overexploita-
tion of groundwater and agriculture. To manage and protect precious groundwater 
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resources in a sustainable manner, the characterization and understanding of the 
natural evolution of groundwater chemistry are crucial to elucidate their geochemi-
cal nature and its relation.
The collector well can be far from the river if the soil type is sand and gravel 
such as RBF at Yellow River, China. The combination of vertical and horizontal 
collector well can maximize the water capacity such as RBF at Elbe River, Germany. 
However, clayey alluvial soil will limit the water capacity as RBF site at Lek River, 
Netherlands, shows the water capacity is only 0.01 MLD, compared to clayey 
alluvial soil at Nakdong River, Korea, which can be abstracted to 10 MLD water 
capacity. This shows clayey alluvial soil type needs deeper built collector well near 
the riverbank. The nearer to riverbank, the more water capacity can be abstracted 
than collector well at Nakdong River, Korea, which is only 10 MLD with 150 m 
distance from river, and collector well at Nile River, Egypt, with 22 MLD. Some 
sites do not contain gravelly sand alluvial soil type but can apply RBF such as Kali 
River, India. The highly pollutant river demands to use RBF methods; however, it 
only can abstract 0.8 MLD water capacity because the transmissivity of brownish 
red silty loam alluvial soil is low. Sites with clayey alluvial soil can apply limestone 
to increase the transmissivity of water such RBF sites at Ohio River, Kentucky, and 
Great Miami River, USA. Malaysia RBF sites at Sungai Semerak contain gravelly 
sand and shallow vertical well collector type. The shallow collector well nearer to 
riverbank helps RBF to avoid problem with iron and manganese. Thus, the RBF site 
that can supply huge water capacity is 25 MLD.
3. Escherichia coli in riverbank filtration
The abstracted water from RBF is very clear which has less contaminants than 
river water. According to previous study from other RBF sites, the contaminants 
that are below drinking water standard are turbidity, color, pH, TDS, chloride, 
ammonia, COD, BOD5, sulfate, iron, manganese, total coliform, and E. coli. RBF 
sites show great anthropogenic activity with the absence of total coliform and E. 
coli because the schmutzdecke (biofilm) layer exists at the bottom of the streamline 
[16] which can reduce the disinfection treatment. According to data obtained from 
the monitoring wells, the shallow geology of the RBF area is related to the alluvial 
deposition at the bottom of the streamline by the river which usually consists of 
upper fine, medium, and lower fine sand layers [17]. The quality of the ambient 
groundwater of the previous RBF sites at Louisville also shows that distance and 
location of the RBF wells from river are the key parameters of the RBF performance. 
If the RBF wells are very close to the river, then the problems of E. coli will be 
detected [18]. The existence of these enteropathogenic bacteria in abstracted well 
can be high in the range of 1–140 MPN/100 mL, respectively, as in Table 2.
Several of E. coli infection issues related to groundwater as drinking water 
were detected [19, 20] which the source of the infection was positively identified 
Table 2. 
E. coli concentration during treated with RBF.
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as a contaminated well or runoff from cow manure after torrential rain was 
thought to have been responsible for contamination [21]. As a safety precaution 
against E. coli infection in the body, the WHO fixed a 0.0 MPN/100 ml of E. coli 
for drinking water standard.
This study is focusing mainly on E. coli removal from groundwater. Typically 
the amount of E. coli depends on the aquifer types, distance of abstracted well to 
river, and climates. The removal of these parameters is crucial to ensure the treated 
groundwater can safely deliver to water treatment plant or directly distribute to 
consumer. E. coli is a Gram-negative, facultative anaerobic bacterium that belongs 
to the family of Enterobacteriaceae. E. coli is recognized as the most important 
parameter of fecal contaminants by microbiology and public health experts [26]. 
Depending on environmental conditions, E. coli can survive for 4–12 weeks [27]. 
There are various factors affecting the survival of E. coli in environment such as 
protozoa, antagonists, temperature, light, soil, pH, toxic substances, and oxygen 
[28]. The survival periods of E. coli in various surroundings were reported: in the 
groundwater at 10°C, recharged well and river water at 9–16°C, E. coli survived for 
100 days, 63 days, and 55 days, respectively [29, 30]. Due to its strong relevance 
with the fecal contamination and relatively easy quantification methods, E. coli has 
been employed in a wide range of investigation including water treatment [31–33].
In natural conditions at RBF sites, water percolates through the organic soil 
where dissolved oxygen (DO) is consumed by the decomposition of organic matter 
and microbes in the soil. The decomposition process reduces the pH due to micro-
bial action. When groundwater is pumped up to the surface, it gets into contact with 
air (O2) which enters the solutions and starts the oxidation process that releases 
carbon dioxide (CO2) from the groundwater to the atmosphere.
The reason for choosing E. coli as the main parameter is because it is a model for 
waterborne bacteria and reduces chemical usage in posttreatment. The Escherichia 
coli which is easily called as E. coli is a group of bacteria that are commonly found 
in food and water. Most of the E. coli is harmless, but some can cause sickness to 
human. These bacteria will lead to stomach and intestinal problems such as diar-
rhea and vomiting. The disease-causing E. coli strains live in the intestinal tracts of 
animals that ruminate, such as cows, deer, and goats. Bacteria early pretreatment 
seems important since it avoids to stimulate the bacterial growth in distribution 
system pipeline.
4. The possibility of Escherichia coli infection in riverbank filtration
The site was located at coordinates 5° 07′38.61“ N and 100° 35’44.24”, Lubok 
Buntar, Kedah. The examined site was influenced by the water from the Kerian 
River which was also influenced by the discharge of the wastewater from palm oil, 
mining industry, and poultry farming area at Sungai Mahang (upstream). The river 
water and borehole water samples were taken for laboratory (characteristics) test. 
Figure 2 shows concentration plots of E. coli against height of water in tube well. It 
can be observed that the increase of height of water in tube well was caused by E. 
coli existence. The existing of E. coli was changed from absent to <200 MPN.
The depth of borehole was 30 m signifying that this borehole was under uncon-
fined aquifer. The unconfined aquifer is recharged more rapidly when raining 
and groundwater hydraulic conductivity at maximum due to infiltration and 
runoff [34]. The increase of solute concentration during rainy season due to the 
groundwater flow exceeded the permeability of alluvial soil. Groundwater flow was 
maximized when raining which creates pressure to the alluvial soil. This leads small 
particle to flow together into abstraction well which in turn increases contaminant 
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riverbank helps RBF to avoid problem with iron and manganese. Thus, the RBF site 
that can supply huge water capacity is 25 MLD.
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as a contaminated well or runoff from cow manure after torrential rain was 
thought to have been responsible for contamination [21]. As a safety precaution 
against E. coli infection in the body, the WHO fixed a 0.0 MPN/100 ml of E. coli 
for drinking water standard.
This study is focusing mainly on E. coli removal from groundwater. Typically 
the amount of E. coli depends on the aquifer types, distance of abstracted well to 
river, and climates. The removal of these parameters is crucial to ensure the treated 
groundwater can safely deliver to water treatment plant or directly distribute to 
consumer. E. coli is a Gram-negative, facultative anaerobic bacterium that belongs 
to the family of Enterobacteriaceae. E. coli is recognized as the most important 
parameter of fecal contaminants by microbiology and public health experts [26]. 
Depending on environmental conditions, E. coli can survive for 4–12 weeks [27]. 
There are various factors affecting the survival of E. coli in environment such as 
protozoa, antagonists, temperature, light, soil, pH, toxic substances, and oxygen 
[28]. The survival periods of E. coli in various surroundings were reported: in the 
groundwater at 10°C, recharged well and river water at 9–16°C, E. coli survived for 
100 days, 63 days, and 55 days, respectively [29, 30]. Due to its strong relevance 
with the fecal contamination and relatively easy quantification methods, E. coli has 
been employed in a wide range of investigation including water treatment [31–33].
In natural conditions at RBF sites, water percolates through the organic soil 
where dissolved oxygen (DO) is consumed by the decomposition of organic matter 
and microbes in the soil. The decomposition process reduces the pH due to micro-
bial action. When groundwater is pumped up to the surface, it gets into contact with 
air (O2) which enters the solutions and starts the oxidation process that releases 
carbon dioxide (CO2) from the groundwater to the atmosphere.
The reason for choosing E. coli as the main parameter is because it is a model for 
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coli which is easily called as E. coli is a group of bacteria that are commonly found 
in food and water. Most of the E. coli is harmless, but some can cause sickness to 
human. These bacteria will lead to stomach and intestinal problems such as diar-
rhea and vomiting. The disease-causing E. coli strains live in the intestinal tracts of 
animals that ruminate, such as cows, deer, and goats. Bacteria early pretreatment 
seems important since it avoids to stimulate the bacterial growth in distribution 
system pipeline.
4. The possibility of Escherichia coli infection in riverbank filtration
The site was located at coordinates 5° 07′38.61“ N and 100° 35’44.24”, Lubok 
Buntar, Kedah. The examined site was influenced by the water from the Kerian 
River which was also influenced by the discharge of the wastewater from palm oil, 
mining industry, and poultry farming area at Sungai Mahang (upstream). The river 
water and borehole water samples were taken for laboratory (characteristics) test. 
Figure 2 shows concentration plots of E. coli against height of water in tube well. It 
can be observed that the increase of height of water in tube well was caused by E. 
coli existence. The existing of E. coli was changed from absent to <200 MPN.
The depth of borehole was 30 m signifying that this borehole was under uncon-
fined aquifer. The unconfined aquifer is recharged more rapidly when raining 
and groundwater hydraulic conductivity at maximum due to infiltration and 
runoff [34]. The increase of solute concentration during rainy season due to the 
groundwater flow exceeded the permeability of alluvial soil. Groundwater flow was 
maximized when raining which creates pressure to the alluvial soil. This leads small 
particle to flow together into abstraction well which in turn increases contaminant 
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concentrations in abstraction water. For that reason, the application of artificial 
barrier seemed beneficial since it will increase the permeability of aquifer near 
the river avoiding small particles to flow together to abstraction well during rainy 
season. Besides raining, E. coli can penetrate into abstracted well due to pollution in 
streamline, abstracted well is near the riverbank, and sources of pollution such as 
poultry field and sanitary tank are close to abstracted well.
The experiment shows that the application of artificial barrier as RBF water 
purification method seems important to avoid the possibility of E. coli infection. 
Smith et al. [35] and Uhlmann et al. [36] previously identified exposure to drinking 
water from private underground water supply as a significant risk factor in human 
pathogen infections in the UK and Canada, respectively. In addition, O’Sullivan 
et al. [37] and Garvey et al. [38] have proposed that increases in E. coli infection in 
Ireland may be associated with water consumption from untreated water wells in 
rural areas, particularly following periods of excessive rainfall.
5. Artificial barrier for riverbank filtration
5.1 Methodology
The fixed-bed flow studies were carried out to evaluate their ability to remove 
E. coli during filtration process. The column was made from Perspex glass with 
inner diameter 8.5 cm. Figure 3 shows a schematic diagram of the column setup 
used in this study. The pretreated media were filled in the column. To avoid 
channeling, the river water was pumped upward through the column at flow rate 
50 mL/min. The flow rate was controlled by a peristaltic pump.
The water samples used in the column were taken from the Kerian River at 
coordinates 5° 07′38.61“ N and 100° 35’44.24” E. The sand, GAC, and zeolite were 
oven dried for 24 hours at 105°C. Before placing the sand, GAC, and zeolite in the 
column, the column was washed with a solution of 3% acid nitric. The removal of 
E. coli in column test was observed in close exposure to light. This is due to the real 
condition in the aquifer which is close to sunlight exposure.
The E. coli was measured according to Method 9223B. The sample was trans-
ferred into the sterile vessel, and the water sample bottle is vigorously shaked 
25 times within 7 seconds. The interval between shaking and measuring the test 
portion does not exceed 3 minutes. Aseptically the lid was removed, and the 
sample volume was adjusted to the calibrated 100 ml line of the sample container. 
Aseptically one packet of Colilert reagent was added to the 100 ml test bottle. 
Figure 2. 
The monitoring of E. coli concentration and height of borehole water for duration 2015–2017.
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Aseptic technique refers to a procedure that is performed under sterile condi-
tions. The bottle was recapped and shaked until reagent was mostly dissolved. 
One hand was used to hold open the Quanti-Tray 2000. Well side was facing the 
palm of the hand. The upper part of the tray was squeezed so it bent toward the 
palm and gently pulled the foil tab to open the tray. Avoid touching inside of 
the tray or foil tab. The 100-ml sample was poured into the tray, and small wells 
are tapped two to three times to release air bubbles. The tray was placed with 
the sample into rubber insert so that the wells sat within the cutouts and rubber 
insert slided with tray into the sealer. The Quanti-Tray once sealed was incubated 
for 24 hours at 35 +/− 0.5°C. After 24 hours, the fluorescence light under UV light 
was counted which indicated as positive E. coli.
The measured E. coli using IDEXX was also validated with modified mTEC agar 
plates. Modified mTEC agar plates are prepaid powder by Arachem, BCBS2082V 
number. The powder was suspended in 1000 mL of distilled water for 45.6 g. 
The suspended powder was autoclaved and sterilized at 15 lbs. pressure (121°C) 
for 15 minutes. After that, the suspended powder was cooled to 45–50°C and 
poured into sterile petri plates. The filtered sample is placed at the top of agar and 
incubated at 35°C for 2 hours followed by incubation at 44.5°C for 22 hours. The 
modified mTEC agar contains selective and differential agents. Sodium lauryl 
sulfate and sodium desoxycholate are selective agents that inhibit Gram + cocci and 
endospore-forming bacteria. The modified mTEC agar contains the differential 
agent, 5-bromo-6-chloro-3-indolyl-β-D-glucuronide, which is catabolized to gluc-
uronidase. Unlike the original mTEC method, the modified mTEC does not require 
the transfer of the membrane filter to another substrate. The positive colony was in 
magenta color. The analysis on surface morphology of the raw material was carried 
out using scanning electron microscope (Leo Supra 50 VP Field Emission, UK).
5.2 Result and discussion
In this study, 15 mixture components that are represented by soil, GAC, and 
zeolite bed height (in real site of RBF equal to distance of abstracted well water to 
river) were chosen for the optimization studies since they influenced the presence 
of E. coli in RBF abstracted water as well as volume of abstracted water. In addition, 
since the absence of E. coli and volume of abstracted water was concomitant, the 
experiments were done using high flow rate. This study determined the optimum 
Figure 3. 
Laboratory fixed bed column experimental setup.
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25 times within 7 seconds. The interval between shaking and measuring the test 
portion does not exceed 3 minutes. Aseptically the lid was removed, and the 
sample volume was adjusted to the calibrated 100 ml line of the sample container. 
Aseptically one packet of Colilert reagent was added to the 100 ml test bottle. 
Figure 2. 
The monitoring of E. coli concentration and height of borehole water for duration 2015–2017.
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Aseptic technique refers to a procedure that is performed under sterile condi-
tions. The bottle was recapped and shaked until reagent was mostly dissolved. 
One hand was used to hold open the Quanti-Tray 2000. Well side was facing the 
palm of the hand. The upper part of the tray was squeezed so it bent toward the 
palm and gently pulled the foil tab to open the tray. Avoid touching inside of 
the tray or foil tab. The 100-ml sample was poured into the tray, and small wells 
are tapped two to three times to release air bubbles. The tray was placed with 
the sample into rubber insert so that the wells sat within the cutouts and rubber 
insert slided with tray into the sealer. The Quanti-Tray once sealed was incubated 
for 24 hours at 35 +/− 0.5°C. After 24 hours, the fluorescence light under UV light 
was counted which indicated as positive E. coli.
The measured E. coli using IDEXX was also validated with modified mTEC agar 
plates. Modified mTEC agar plates are prepaid powder by Arachem, BCBS2082V 
number. The powder was suspended in 1000 mL of distilled water for 45.6 g. 
The suspended powder was autoclaved and sterilized at 15 lbs. pressure (121°C) 
for 15 minutes. After that, the suspended powder was cooled to 45–50°C and 
poured into sterile petri plates. The filtered sample is placed at the top of agar and 
incubated at 35°C for 2 hours followed by incubation at 44.5°C for 22 hours. The 
modified mTEC agar contains selective and differential agents. Sodium lauryl 
sulfate and sodium desoxycholate are selective agents that inhibit Gram + cocci and 
endospore-forming bacteria. The modified mTEC agar contains the differential 
agent, 5-bromo-6-chloro-3-indolyl-β-D-glucuronide, which is catabolized to gluc-
uronidase. Unlike the original mTEC method, the modified mTEC does not require 
the transfer of the membrane filter to another substrate. The positive colony was in 
magenta color. The analysis on surface morphology of the raw material was carried 
out using scanning electron microscope (Leo Supra 50 VP Field Emission, UK).
5.2 Result and discussion
In this study, 15 mixture components that are represented by soil, GAC, and 
zeolite bed height (in real site of RBF equal to distance of abstracted well water to 
river) were chosen for the optimization studies since they influenced the presence 
of E. coli in RBF abstracted water as well as volume of abstracted water. In addition, 
since the absence of E. coli and volume of abstracted water was concomitant, the 
experiments were done using high flow rate. This study determined the optimum 
Figure 3. 
Laboratory fixed bed column experimental setup.
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ratio for combination of soil with GAC and zeolite that would support and improve 
the capability of E. coli removal compared to alluvial soil in RBF with a constant 
50 mL/min flow rate. The removal of E. coli was less than 85% for soil with 81 and 
82% removal as in Figure 4. In comparison with 70% soil combined with 15% GAC 
and 15% zeolite, the removal of E. coli was increased to 89%. Meanwhile, with 50% 
soil combined with 15% zeolite, the removal of E. coli was increased higher up to 
90%. However, the combination of GAC and zeolite showed the lowest removal of 
E. coli compared to soil only by less than 50%. The honeycomb structure in GAC 
created the strongest biofilm layer which assisted the trap of microbe during high 
flow rate. Effective microbial adhesion and immobilization are essential for biofilm 
activities [39].
The GAC morphology (Figure 5(a)) showed that the surface structure and pore 
were well developed similar to honeycomb structure. The surface morphology of 
the GAC was also comparable to the analysis done by Hameed and Ahmad [40]. 
However, the adsorption of E. coli to GAC surfaces occurred on the outside of the 
Figure 5. 
The morphology of GAC for (a) before and (b) after adsorption with images of E. coli cells attach to surface.
Figure 4. 
Laboratory fixed bed column experimental setup.
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pore (honeycomb structure) as depicted in Figure 5(b). E. coli adhesion to media 
surface is the initial step to schmutzdecke (biofilm) layer formation which later 
will create sticky surface and help in more adsorption of E. coli. The honeycomb 
structure provides strong physical confinement for the bacterial cells’ adhesion and 
subsequently resists biofilm formation [41].
The enumeration of E. coli throughout optimization using Colilert. However, 
due to sensitivity and verification of the result, the mTEC agar enumeration 
method was used to increase the reliability of the result. Figure 6 shows that the 
E. coli enumeration can be trusted due to linear R2 of 0.92 which was acceptable 
(MPN acceptable values +20%). This means the results measured using mTEC agar 
are quite close to the mean value of MPN and in 95% of confidence limit for MPN 
measurement.
Until now, the health effects endemic to human for groundwater supply in 
Malaysia are not investigated. Casemore [42] notes that the occurrence of sporadic 
or pseudo-sporadic infection is particularly important in the context of groundwa-
ter-related infection. This is because the groundwater is often seen as pure quality 
and therefore not examined as potential sources of enteric infections that occur, 
thus leading to important effect.
6. Conclusion
The performance of RBF depended on alluvial soil particles’ size distribution, 
soil gradation, and soil structure. From the monitoring, results show that the 
possibility of E. coli infection may happen. Thus, the purification method using 
artificial recharge seems important. In this study, the adsorption of E. coli by 
soil becomes higher in combination with GAC and zeolite. It was the honeycomb 
morphology of GAC that assists the attachment of E. coli. The schmutzdecke 
(biofilm) layer formation helps to enhance the E. coli adhesion to media surface 
which later will create sticky surface and help more adsorption of E. coli. The 
zeolite has higher CaO than other adsorbents; the attachment of E. coli in zeolite is 
based on mineral content. The aquifer is advisable but should not have too high or 
too low permeability for RBF because majority of removal mechanism was assisted 
by medium filter media permeability. The chemical usage technique in controlling 
E. coli in water treatment may not be a suitable method, whereby in a certain time, 
E. coli may resist to that chemical. Thus, from that reasoning, it’s better to use the 
adsorption method.
Figure 6. 
Validation of measurement E. coli with using colilert and mTEC agar.
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The present book deals with the following microorganisms: E. coli, Salmonella, 
and Listeria. The first two are Gram-negative bacteria belonging to the group of 
Enterobacteriaceae with the characteristic of becoming resistant to the most com-
mon antibiotics; whereas, the last one is a Gram-positive bacterium belonging to 
Corynebacterium, Erysipelothrix, and other Gram-positive microorganisms showing 
an involvement in pathologies as newborn meningitis and gynecological infec-
tion which may interfere with the pregnancy outcome. The peculiarity of all these 










The bacteria, in fact, can be found in the gastrointestinal tract (GI) of humans 
and animals, but they are mainly considered as ubiquitous microorganisms.
This bacterium includes a single species (E. coli) and is divided into 171 sero-
types, aerobic-anaerobic Gram-negative rods with flagella fimbriae, and able to 
ferment glucose and lactose.
The most important serotype is Escherichia coli O157:H7 or enterohemorrhagic 
Escherichia coli (EHEC), which often leads to enterohemorrhagic diarrhea and is 
also able to induce hemolytic uremic syndrome (HUS) which is characterized by 
acute renal failure, hemolytic anemia, and thrombocytopenia that are more com-
mon in children and in elderly people [1].
Serotype O157-H7 causes numerous outbreaks and sporadic cases of bloody 
diarrhea. Foodborne pathogenic E. coli contamination, such as that with E. coli O157 
and O104, is very common even in developed countries. Bacterial contamination may 
occur from environmental, animal, or human sources and cause foodborne illness [2].
The three main diseases, depending on each particular serotype involved, are 
urinary tract infections, intestinal diseases, and neonatal meningitis [3].
Many different mechanisms of action are reported regarding the virulence of  
E. coli. Although most strains are saprophytic colonizing the large bowel, some 
types of them are involved in different pathologies such as traveler’s and childhood 
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diarrhea (ETEC and EPEC also in Mexico and North Africa EAEC), hemorrhagic 
colitis (EHEH), and a Shiga-like disease (EIEC). As far as this last point is concerned, 
it is reported that the differentiation between Shigella and E. coli is quite more com-
plicated when we consider enteroinvasive E. coli (EIEC). In fact, EIEC are strains that 
are similar to E. coli but are able to cause dysentery using the same method of inva-
sion as Shigella. In fact, in this specific situation, EIEC is more related to Shigella than 
to non-invasive E. coli [4]. This strain is among the most common cause of foodborne 
diseases other than of neurological and renal complications, especially in children.
Escherichia coli K1 strains are major causative agents of invasive disease of new-
born infants. Colonization of the small intestine following oral administration of K1 
bacteria leads rapidly to blood stream infections (BSI). Indeed, these microorgan-
isms are the cause of life-threatening infections that are acquired from the mother 
at birth thus colonizing the small intestine, from where they invade the blood and 
central nervous system.
E. coli is increasingly present as a MDR (multi-drug resistant) bacterium, in 
fact its genomic outfit has acquired various antibiotic resistances through the 
production of ESBL [5] and carbapenemases as well as metallo-beta lactamases 
(NDM = New Delhi metallo-beta lactamases) making the infections of this bacte-






Listeria monocytogenes is a Gram-positive, mobile, rod-shaped bacterium that is 
ubiquitous in the environment. It can be isolated in soil and wood and decays in the 
natural environment; however, the principal acquisition of Listeria is through the 
ingestion of contaminated food products. Listeria is a foodborne pathogen that con-
taminates food-processing environments and persists within biofilms in the surround-
ings. The peculiar characteristic of this microorganism is its ability to grow even in 
extreme situations, such as under high salt conditions and refrigeration temperatures, 
maintaining its vitality in various food products [7]. Even though the incidence of 
listeriosis is lower than other enteric illnesses, infections caused by  
L. monocytogenes are more serious and may lead to hospitalizations and fatali-
ties. These infections mainly affect women and children who acquire the disease 
Figure 1. 
Morphology of E. coli. http://www.lacolonscopia.it/colonscopia/escherichia-coli-come-prevenirlo-e-curarlo/
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through vertical transmission from mother to infant during pregnancy or childbirth. 
Nosocomial infections between children are rare but anyhow they were reported. The 
most important disease for the newborns is the neonatal meningitis, which shows a 
high degree of mortality (higher in the developing countries which can reach 40–58% 
of cases). Listeriosis requires rapid treatment with antibiotics and most drugs suit-
able for Gram-positive bacteria are effective against L. monocytogenes. Generally, 
the Listeria clinical strains are susceptible to the common antibiotics because only a 
minority results as being resistant to antimicrobial agents. In the same way, several 
Figure 2. 
Slide from “New Delhi metallo-beta-lactamase (NDM-1). Facts, controversies, solutions. An update” T.V. Rao 
(Powerpoint 2016). https://www.slideshare.net/doctorrao/new-delhi-metallobetalactamse
Figure 3. 
Phagocytosis of Listeria. Legenda: (internalins InlA and InlB), phagosome lysis (listeriolysin O (LLO)), 
phosphatidylinositol-specific phospholipase C (PI-PLC) and phosphatidylcholine ((PC)-PLC), cell-to-cell 
spread (actin assembly-inducing protein (ActA)), intracellular growth (hexose-6-phosphate transporter 
(Hpt)) [10].
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strains detected from food exhibited resistance to antimicrobials not suitable against 
listeriosis [8]. Pregnant women can carry Listeria asymptomatically in their gastro-
intestinal tract or vagina and the risk of transmitting this infection to their babies is 
high. The consequence of listeriosis to human health is a very important issue due to 
its virulence mainly in children with an underlying immunodeficiency. Symptoms 
include fever, headache, abdominal pain, diarrhea, vomiting, and convulsions. The 
complications can be appendicitis and Meckel’s diverticulitis [9].
Listeria which is saprophyte in the environments such as water, soil, and food, 
once internalizes into the mammalian host, shows its virulence through the expres-









Salmonella is the most commonly isolated bacterial agent of foodborne and 
epidemic infections. It was reported for the first time in 1886, in a case of swine 
fever by the American doctor Daniel Elmer Salmon.
The genus Salmonella is characterized by Gram-negative facultative anaerobic 
bacilli without spores. They are mobile through peritrichous flagella with the excep-
tion of S. gallinarum and S. pullorum. The serotypes are diversified according to 
the somatic antigen “O,” the flagellar antigen “H” and the surface antigen “Vi.” The 
Vi antigen is exclusively expressed by S. typhi and is able to circumvent the innate 
immune response by repressing flagellin and LPS expression [11]. The “O” antigens 
are distinguished in the serogroups A, B, C1, C2, D, and E.
Salmonella is present in the environment and can be either commensal or 
pathogen for men and various animals; some serotypes are exclusively pathogen 
for humans (i.e., S. typhi and S. paratyphi A and C), others infect both humans and 
animals such as S. typhimurium [12].
In humans, there are two kind of infectious diseases:
1. typhoid and paratyphoid fever [13]
2. minor salmonellosis [14]
Salmonella infection is transmitted through fecal route by the ingestion of 
contaminated food and drink. Salmonella typhi is responsible for typhoid fever, and 
its transmission can occur, especially in developing countries, by water and food 
infected or with direct contact among people, especially in poor hygienic condi-
tions. The minimum infectious dose can be less than 15–20 cells. Individual sensi-
tivity depends on the patients’ age and on the nature of Salmonella strains.
In most cases, Salmonella infection occurs in mild form and resolves on its own 
within a few days. In these situations, the advice is not to consider the diarrheal 
phenomenon, since it is the natural defense mechanism used by the organism to 
expel germs. Normally, for Salmonella, it should be enough to adopt a supportive 
therapy: administration of oral rehydration solutions (which are used to compensate 
for water and salts lost with vomiting and diarrhea), lactic ferments, and probiotics.
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Although salmonellosis is a bacterial infection, the use of antibiotics is not 
recommended as it could lengthen the persistence time of Salmonella in feces or 
induce antimicrobials resistance [15]. Hospitalization and the use of antibiotics are 
indicated only in severe cases (with extra-intestinal symptoms), in infants under 
3 months and in subjects with chronic-degenerative diseases.
In recent times, Salmonella has changed its characteristics worldwide, becoming 
the etiologic agent of many peculiar pathological processes such as cancer develop-
ment, inflammatory process, and immune-pathogenesis [16, 17] (Figure 4).
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Figure 4. 
Salmonella infection pathogenesis. The ingestion of contaminated food or water begins the infective processes 
(gastroenteritis or systemic infection) depending on the species of Salmonella involved (minor and major 
Salmonellae). The microorganisms reach the intestinal epithelial cells and migrate to the lamina propria 
invading the liver from where Salmonella reaches the gall bladder and can cause chronic carriage which gives 
rise to healthy carriers [18].
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Lateral Flow Assay for Salmonella 
Detection and Potential Reagents
Dilek ÇAM
Abstract
Salmonella is among the very important pathogens threating human and animal 
health. It is a common food pathogen transmitted from animals to humans via con-
taminated food, drinking water, and air. It invades the intestinal tract of hosts and 
causes salmonellosis leading to death. S. enteritidis was the most common species 
accounted for all salmonellosis cases. S. typhimurium is also another significant 
species causing the serious cases worldwide. To ensure public health, early detec-
tion of pathogens is crucial. Lateral flow assay (LFA), immunochromatographic 
assay, is a simple and rapid diagnostic test kits used in various fields and can be 
developed by, aptamers, antibodies (Abs), and nucleic acids. They are also being 
continued to develop different capture reagents coming from the recombinant 
technology. It has many advantages such as having mature technology, market 
presence, low cost, easy to use for end users without education, and stable shelf 
life. Gold nanoparticles (GNPs) are the most commonly used labels in the LFAs 
for the naked-eye analysis. Therefore, Salmonella detection by LFA based on GNPs 
in a rapid and simple way is always open to be developed by new reagents and 
methods.
Keywords: Salmonella, gold nanoparticles, lateral flow, food pathogens, 
rapid detection
1. Introduction
Most of Salmonella infections are typically food-borne illness. It was reported 
that around 15% of salmonellosis cases is caused by pork [1], turkey products, and 
meat [2]. Early detection of pathogens which contaminated the foods or consump-
tion products is a crucial issue especially for the government authorities to ensure 
public health. Thus, many kinds of identification methods are in use, and new 
detection platforms are also being tried to develop for improving the sensitivity and 
selectivity of detection with low cost as rapid tests.
Traditionally, the Salmonella diagnosis in the laboratory is based on common 
cultural techniques [3], biochemical and serological confirmation tests. Along with 
immunomagnetic nanospheres as immunological tools [4], multiplex PCR [5] and 
real-time multiplex PCR [6–9] are other detection methods of Salmonella in chicken 
samples or other sources. However, some of those techniques require 5 or 7 days, 
skilled personnel, sterile working conditions, and sensitive and costly equipment, 
and they are inconvenient for food sector or industrial applications [10] and not 
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portable to perform sensitive and rapid microbial analysis. To develop the fast and 
sensitive method for bacterial antigens, electrochemical [11], optical [12], microflu-
idic [13], and magnetoelastic biosensors are also being developed for the detection 
of Salmonella species. Among those techniques lateral flow assay (LFA) is still the 
most practical and easy to use test and multiple detection tool as an immunosensor 
for end users.
2. Lateral flow assay
LFA, immunochromatographic strip test, which can be developed by Abs, 
aptamer, and nucleic acids, was described in the 1960s [14] and become a popular 
platform for rapid immunoassays since the mid-1980s [15–17]. Depending on their 
formats, LFAs might be expressed as dipstick assay, lateral flow device (LFD), 
point of care (POC) to bedside test, and lateral flow immunochromatographic 
assay (LFIA). LFAs are used to detect the presence or absence of a target analyte in 
sample and allow naked-eye analyses based on accumulation concepts [18]. LFAs 
have many advantages compared to other detection methods. They are established 
mature technology, with processes already developed, relative ease of manufacture, 
and stable shelf lives of 12–24 months often without refrigeration; easily scalable 
to high-volume production; and integrated with various systems, having high 
sensitivity, specificity, relatively low cost, market presence, and minimal education 
required for users and regulators [19]. However, test-to-test reproducibility, unclear 
patent situation, sensitivity issues in some systems, and integration with onboard 
electronics are drawbacks of LFAs. To note LFA market is expected to reach USD 8.7 
billion by 2023 from an estimated USD 6.0 billion in 2018, at a compound annual 
growth rate (CAGR) of 7.7% [20].
The production of typical strip assay includes the preparation of colloidal gold 
conjugates, application of reagents onto the membrane and pads, lamination of the 
strip membranes onto a support backing, cutting the prepared master cards into 
strips of defined length and width, and strip packaging (Figure 1A and B).
Three types of pads, a sample pad, conjugate pad, and absorbent pad, and 
nitrocellulose membrane are used for developing the strip assay. The test sample 
is applied onto the sample pad. Conjugate pad contains Abs, aptamers, or nucleic 
acids specific to the target analyte which are usually conjugated to colored 
particles, gold nanoparticles (GNPs), and latex beads. Capture reagents such as 
anti-target Abs or aptamers are immobilized in a line across the membrane which 
are nitrocellulose or cellulose acetate as a test line. It has also a control line contain-
ing capture reagents such as Abs or complementary nucleic acids specific for the 
conjugate Abs or aptamers present on the conjugate, respectively. The strip compo-
nents are usually fixed to an inert backing material and may be placed in a plastic 
casing with a sample port, and reaction window showing the test and control line 
or strip can be prepared as a simple dipstick format [22]. After soaking of sample 
pad with analyte, it flows through the conjugate pad and nitrocellulose membrane 
via capillary action and ends on an absorbent pad. When the flow is continuing, 
the analyte bound by gold conjugate on conjugate pad is captured and accumulated 
on test line. The excess conjugate is also captured by a control line, and it should 
always be visible. If the test strip works correctly and it is positive, both the test 
and control lines are seen as red. If no colored capture lines or only a red color at 
the test line appears, the strip is invalid, and the test should be repeated [21, 23, 24] 
(Figure 2).
Although LFAs for Salmonella are commonly noncompetitive, the competitive for-
mat of LFA can also be developed for the smaller analytes [25, 26]. The principle of this 
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Figure 1. 
Preparation of LFA strip (a) and schematic representation of it in plastic case [21].
Figure 2. 
Schematic diagram of the immunochromatographic test strip principle for the dipstick assay. CSA Ab, common 
structural antigenic antibody; GNPs, gold nanoparticles [21].
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format is that sample extract is applied onto the sample pad and it flows through the 
absorbent pad. If the analyte is absent, all of the detection reagent would be trapped by 
capture reagent to form an easily visible test line. However, when the analyte is present, 
it competes with the immobilized capture reagent for the limited amount of competi-
tive detection reagent. Thus, it means that the more analyte in the sample, the weaker 
the test line color.
Manufacturing of LFAs developed for Salmonella depends on some significant 
factors. First is the membrane type having suitable flow rate because it plays 
significant role for recognizing the whole bacteria cell. For instance, nitrocellulose 
Millipore membrane, Hi-Flow™ Plus 180 Membrane Card, shows good assay per-
formance in terms of the whole-cell detection, analysis time, no background signal, 
and immobilization of capture reagents such as Abs and aptamers. If the flow rate 
of membrane is very slow, it takes a long time to see the results with the naked 
eye. However, if flow is very fast, capturing process cannot be completed and line 
intensities become unclear. Second is the application of analyte on sample pad. Both 
the dipstick assay and loading of sample as droplets can be preferred. The disadvan-
tage of dipping the strip into bacterial media directly is that flow can be retarded on 
conjugate pad because of the media components. Thus, using the suitable running 
buffer, simple phosphate buffer saline (PBS), may enable conjugate to flow through 
the strip test, efficiently [21, 27]. Third is the immobilization of capture reagents. 
Generally streptavidin-biotin interaction is used for aptamer- or nucleic acid-based 
LFAs, and it sometimes may be required as multiple loading with consistent dura-
tions, while Abs can be directly immobilized once. The last one is the size of GNPs 
used for labeling. Although various studies showed that the size of GNPs between 
15 and 40 nm can be used in LFAs, 35 nm GNPs are preferable. Figure 3 displays the 
Ab-based LFAs for Salmonella when they are alone and present in bacterial mixture 
after optimal conditions are performed [27]. Strips were prepared by common 
structural Ab specific to Salmonella enterica species (S. enteritidis, S. typhimurium, 
Figure 3. 
Dipstick assay for live Salmonella strains alone and in the mixture using M180 membrane. Test line: 
Salmonella Ab. Control line: Antigoat IgG. The strips were dipped into 200 μL of total bacteria with PBS. The 
strips 2–4–6–8–10–12–14–16–19–21 were prepared by naked GNPs. D. soil, dry soil bacteria; Bac, B. cereus; S. 
ent, S. enteritidis; S. typ, S. typhimurium [27].
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S. infantis). Bacteria isolated from the food samples were used. Dry soil bacteria, E. 
coli, Bacillus, and PBS were used as negative control. After culturing, test strips were 
dipped into the bacterial media without any treatment and showed positive results 
with target and nontarget samples. To highlight developed strip assays have high 
sensitivity and selectivity for the targets without non-specific interactions with the 
membrane and other samples.
The sensitivity and susceptibility of LFAs may also be improved by using high-
affinity reagents including recombinant antibodies (Abs), one-step GNPs, or silver 
enhancement and integration of microfluidic papers with onboard electronics. 
Therefore, sensitive detection of Salmonella such as 102 or 102 cfu/mL is achieved for 
multiple recognition. Although cultural techniques associated with biochemical and 
serological confirmation tests and molecular methods are being developed for sensitive 
detection, they are time-consuming processes and not practical for end users. Thus, 
LFAs for Salmonella became attractive to make a rapid and sensitive detection for vari-
ous species without nucleic acid isolation and advanced equipments. It is also open to 
improvement by integrating various detection systems for multiple recognition.
3. Antibodies for LFAs
Abs are more common reagents used for LFAs and available from a number of 
commercial sources. Various kinds of Abs generated by different ways includes 
recombinant protein technology, phage display technology, and hybridoma 
techniques. Although LFAs developed by monoclonal or polyclonal Ab are 
commonly in use, there are highly limited sources of LFA based on single-chain 
variable fragments (scFvs) [28]. Generally, commercial Abs used for sandwich 
assay in LFA might be obtained as prequalified by the vendor in pairs. These pairs 
are most readily available for relatively common and high-volume assays, such as 
tests for pregnancy, infectious disease, cardiac markers, and malignancies. Abs 
specific to various antigens of Salmonella species are in use for the development 
of LFAs [27, 29–31]. The common Ab-based LFAs for Salmonella recognition 
require these steps: (i) coating of GNPs with target specific Abs (detection Abs) 
via chemical or physical adsorption under the optimal pH value, (ii) immobi-
lization of capture Abs on nitrocellulose membrane, and (iii) preparation of 
the pad and running buffers which has the optimal releasing effect through 
the membrane. The first use of Abs with colloidal gold reagent for a diagnostic 
immunoassay was reported in 1981 [32]. The optimal concentration of Abs to 
cover the GNPs and preventing them from agglomeration can be changeable. 
The specificity and selectivity of the strip assay depends on the affinity of used 
Abs. Thus, using high-affinity Abs will increase the sensitivity and decrease the 
limit of detection (LOD) and non-specific interactions with different antigens. 
To achieve this goal, engineered Abs are being continued to generate and adapt 
to LFAs, recently [33, 34]. As it is seen on Figure 3, all the requirements for LFAs 
mentioned above were achieved by Ab-based strip assay. Therefore, it makes 
possible to develop the strip assay for multiple Salmonella detection using both 
the monoclonal or polyclonal Abs on one assay.
4. Aptamers for LFAs
Aptamers are single-stranded DNA or RNA molecules that bind to the specific 
targets. Usage of aptamers in biosensors and development of new diagnostic 
systems based on aptamers become popular since 2000. Because they have high 
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mentioned above were achieved by Ab-based strip assay. Therefore, it makes 
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4. Aptamers for LFAs
Aptamers are single-stranded DNA or RNA molecules that bind to the specific 
targets. Usage of aptamers in biosensors and development of new diagnostic 
systems based on aptamers become popular since 2000. Because they have high 
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affinity to their targets, their generation is rapid and easy compared to the Abs, and 
conjugation with GNPs is chemical which is basically performed by thiol bonds. 
Besides, aptamer conjugates have long shelf life without degradation in comparison 
to Abs. Although they are used for developing LFAs, recently studies have still 
limited numbers in terms of the technical and application. While aptamers can 
be used together with Abs, they are commonly used as pairs for developing LFAs, 
and they should be decided carefully. Recognition aptamers present on GNPs and 
capture aptamers immobilized on the capture lines should have different bind-
ing sites to increase the sensitivity. Some LFAs for Salmonella detection based on 
aptamers are recorded in the literature with various reagents and techniques [35, 
36]. While some aptamers show lower LOD such as 101 colony forming unit (cfu) 
of S. enteritidis [37], some of them show higher. Those variabilities can be caused by 
some reasons which are choosing the aptamer pairs, the distance of aptamers from 
the immobilization zone of membrane, affinity of aptamers [37, 38], and experi-
mental assay conditions. Although large numbers of aptamers were recorded in the 
literature [39–41], there is still a lack of their adaptation to LFAs for the recognition 
of Salmonella species. Because the optimization of test parameters including immo-
bilization procedure of aptamers on capture zones, optimal buffer ingredients, and 
membrane types, the exact size of GNPs has more complexity than Ab-based strip 
assays. Therefore, LFAs should be manufactured by high-affinity aptamers to detect 
whole Salmonella cells.
Nucleic acid-based LFAs using nucleic acid hybridization or amplification 
methods are also developed for Salmonella. However, further experimental steps 
including nucleic acid or genomic DNA isolation, primer design, and PCR are 
required. Due to the poorly suited point-of-care testing of PCR, new methods such 
as isothermal amplification become popular. The most common isothermal ampli-
fication methods are loop-mediated amplification (LAMP) [42, 43], nucleic acid 
sequence-based amplification (NASBA), rolling circle amplification (RCA), nicking 
enzyme-mediated amplification (NEMA), recombinase polymerase amplification 
(RPA), helicase-dependent amplification (HDA), multiple displacement amplifica-
tion (MDA), and transcription-mediated amplification (TMA) depending on the 
detection techniques [44, 45]. Using this type of LFAs, lower detection limit of 
Detection Detection reagent Detection limit Detection type Refs.
S. typhimurium LPS Ab - Multiple [29]
S. typhimurium Whole cell Ab 102 cfu/mL−1 Single [50]
Salmonella typhi Whole cell Ab 3 × 108 cfu Single [30]
S. typhimurium 16S ribosomal 
RNA and DNA
Nucleic acid-Ab 104 cells Single [51]
S. pullorum Salmonella invA 
gene
Nucleic acid-Ab 89 fg/μl Single [52]
S. typhimurium Salmonella 
enterica 
yfiR(375 bp) gene
Nucleic acid-Ab 0.75 pgμL−1 Single [49]
S. enteriditis Out membrane of 
S. enteritidis
Aptamer 10 cfu mL−1 Single [37]
S. typhimurium Whole cell Aptamer 85 cfu mL−1 Multiplex [36]
S. typhimurium Whole cell Aptamer - Single [35]
Table 1. 
LFAs for Salmonella detection by Ab, aptamer, and nucleic acids.
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Salmonella such as 20 fg of target DNA or 1.05 × 101 cfu of bacteria in pure culture 
[46] or 1.3–1.9 cfu/g or 1.3–1.9 cfu/mL of Salmonella in contaminated chicken 
products can be achieved after enrichment [47]. The assay sensitivity may also show 
variety according to the length of amplicon or target [48]. The commonly used 
reagents in this assay are biotin/fluorescein, biotin/digoxigenin tags for ampli-
cons and gold/anti-digoxin Ab or gold/streptavidin conjugate on conjugate pad. 
Depending on the immobilized capture agents such as Abs, labeled nucleic acids, 
or aptamers on test and control line, assay is performed and results become visible 
for Salmonella [49]. Table 1 shows some LFAs for Salmonella detection by using 
reagents mentioned above.
5. Gold nanoparticles for LFAs
Currently the nanoscale properties of GNPs have attracted more attention, and 
they are used in different fields like electronics [53], optics [54], and biosensors 
[55]. A common way to synthesize the nearly monodisperse spherical GNPs is the 
aqueous reduction of HAuCl4 by sodium citrate at boiling point [56]. Other reduc-
ing agents such as borohydrides and amines have also been used [57].
The nature of the surface chemistry of GNPs promotes easy and controlled 
attachment of other molecules especially those with thiol functionalities. 
Following their biocompatibility, high stability, ease of characterization [58, 59], 
and the controllable morphology, GNP-based bioconjugates are found to be good 
candidates for biomedical applications because they are stable with their conju-
gated parts compared to the unbound forms. If sodium chloride is present in the 
solution, repulsive and attractive forces between the particles are imbalanced, due 
to the masking of negative charge of colloidal solution [60]. This resulted with 
collapsing of gold particles after adsorbing one particle onto another, and visu-
alization of this phenomenon is seen as the color change of colloids. However, in 
the presence of coating molecules including proteins, nucleic acids, and aptamers, 
they adsorb onto gold particles and help in preventing them from aggregation by 
inhibiting the binding of other gold particles. To make GNP conjugates, physi-
cal interaction is the simple method, while chemical interaction is also another 
method including covalent conjugation [61] by using thiol derivatives and bifunc-
tional linkers.
LFAs based on GNPs conjugates have become useful innovation in nanotechnol-
ogy. Colloidal gold is the most widely used label today in commercial LFAs for many 
reasons. It is fairly easy and inexpensive to prepare in the laboratory. The color is 
intense, and no development process is needed for visualization. However, assays 
may have varying sensitivity with respect to their target agents [22] in LFAs.
As a conclusion LFA based on GNPs is rapid and sensitive assay for Salmonella 
detection as point-of-care tests compared to other detection methods because it 
is a naked-eye analysis test and does not require the skilled personnel. Once it is 
developed, it can be used for 1 year by the end users without advanced equip-
ments. Adapting different reagents including Abs, aptamers, or nucleic acids onto 
LFAs is another advantage because of their practical immobilization and binding 
steps in terms of the whole-cell detection and also their potential to be adopted to 
enhance LFAs.
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Applications of Genomics in 
Regulatory Food Safety Testing in 
Canada
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Abstract
Recent developments in the field of pathogen genomics herald a new paradigm for 
analytical food microbiology in which pathogenic bacteria will be characterized on the 
basis of their genetic profile rather than traditional approaches relying on phenotypic 
properties. The ability to identify gene markers associated with virulence, antimicro-
bial resistance, and other properties relevant to the identification, risk profiling, and 
typing of foodborne bacterial isolates will play a critical role in informing regulatory 
decisions and tracing sources of food contamination. Here we present several scenarios 
illustrating current and prospective roles for pathogen genomics in food inspection.
Keywords: pathogen genomics, virulence, foodborne pathogens, whole-genome 
sequencing, typing, bioinformatics, food inspection, Escherichia coli, Salmonella, 
Listeria
1. Introduction
The food microbiology testing laboratory has a key role in supporting regula-
tory food safety investigations, whether stemming from a contamination incident 
identified through routine monitoring food inspection programs or a foodborne 
illness outbreak event where human lives and well-being are at risk. While such 
investigations typically involve the concerted actions of food inspection and public 
health authorities at different levels of government, the main role of the regulatory 
testing laboratory is to confirm the presence of a specified hazard in a food vehicle 
and provide data indicating the scope and source of a contamination event. The 
extent to which the laboratory can contribute critical information to an investiga-
tion will to a large degree depend on the application of leading-edge technologies 
for detection and characterization of foodborne pathogens. Approaches capable 
of maximizing the amount of information obtained in the course of conducting 
laboratory testing of inspection samples will foster the most appropriate regulatory 
responses, for example, by informing the health risk assessment process undertaken 
to categorize the degree of risk attending a contamination incident.
The impact of analytical service delivery on public health outcomes depends on 
the ability to process large numbers of investigative samples and produce accurate 
test results in the shortest timeframe possible. While cultural enrichment of food 
samples to amplify pathogens to detectable levels is generally necessary for their 
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1. Introduction
The food microbiology testing laboratory has a key role in supporting regula-
tory food safety investigations, whether stemming from a contamination incident 
identified through routine monitoring food inspection programs or a foodborne 
illness outbreak event where human lives and well-being are at risk. While such 
investigations typically involve the concerted actions of food inspection and public 
health authorities at different levels of government, the main role of the regulatory 
testing laboratory is to confirm the presence of a specified hazard in a food vehicle 
and provide data indicating the scope and source of a contamination event. The 
extent to which the laboratory can contribute critical information to an investiga-
tion will to a large degree depend on the application of leading-edge technologies 
for detection and characterization of foodborne pathogens. Approaches capable 
of maximizing the amount of information obtained in the course of conducting 
laboratory testing of inspection samples will foster the most appropriate regulatory 
responses, for example, by informing the health risk assessment process undertaken 
to categorize the degree of risk attending a contamination incident.
The impact of analytical service delivery on public health outcomes depends on 
the ability to process large numbers of investigative samples and produce accurate 
test results in the shortest timeframe possible. While cultural enrichment of food 
samples to amplify pathogens to detectable levels is generally necessary for their 
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recovery, current approaches often use protracted identification processes relying 
on phenotypic characteristics elucidated by time-consuming cultivation, biochemi-
cal and serological techniques. While effective under certain circumstances, there 
are shortcomings to such a limited approach, when dealing with novel pathogens 
for which analytical parameters may not have been comprehensively worked out or 
in trying to attribute contamination sources.
The exploitation of the genetic blueprint, or known parts thereof, associated 
with a targeted bacterial pathogen is now widely accepted as an effective means for 
the identification of food pathogens. Polymerase chain reaction (PCR) technology 
is now well established as an analytical tool in the regulatory food laboratory [1–4]. 
Its implementation in regulatory testing programs underscores the growing accep-
tance of redefining the terms for the identification and characterization of bacteria 
from a phenotypic to a genotypic basis. Indeed, the advent of leading-edge genom-
ics technologies opens new possibilities for comprehensive analyses of microbial 
isolates recovered from food inspection samples; for example, next-generation 
sequencing technologies (whole-genome sequencing, WGS) can now render a 
bacterial genome much faster (i.e., within 1–3 days) and at a significantly lower cost 
(about 100 dollars) than previously possible, making it feasible to sequence food-
borne isolates within the timeframes of food safety investigations [5–7].
Currently available bioinformatics tools are sufficiently advanced to enable the rapid 
processing of raw sequence data into a usable form for many purposes. Sequencing 
pathogenic bacteria, whether in the context of outbreak investigations or information 
gathering in the course of research, can yield an unprecedented level of information 
regarding the presence of virulence and other marker genes relevant to the identi-
fication and risk characterization of food isolates [6–10]. WGS data can provide an 
exquisite degree of resolution capable of ascertaining differences between strains and 
determining phylogenetic relationships among different bacterial isolates for pinpoint 
precision in the attribution of contamination sources [6, 11]. Finally, the identification 
of strain-specific features such as unique DNA sequences, metabolic properties, and 
antimicrobial resistance will enable testing labs to implement customized tests address-
ing specific strains of interest in determining the scope of contamination events.
While genomics, including WGS technology, already plays a significant role in 
the clinical sciences, its role in regulatory food microbiology inspection programs 
remains to be fully delineated. Currently, methods used to characterize foodborne 
pathogens recovered in regulatory food testing programs aim to answer three ques-
tions: (1) what is it? (2) have we seen it before? and (3) is it dangerous? This work 
describes some of the ways in which characterization of bacterial pathogens using 
genomics technologies has provided or may contribute to faster, more reliable and 
cost-effective results addressing these questions. Our purpose is to present different 
scenarios to illustrate impacts of leading-edge genomics technologies, some imag-
ined, and others already achieved, on food inspection programs.
2.  Impacts of the implementation of genomics in regulatory food 
microbiology
2.1 What is it? Definitive identification of pathogenic bacteria based on genomics 
techniques
2.1.1 In the beginning: detection of genomic markers by PCR
Escherichia coli O157:H7 have been implicated in outbreaks of foodborne illness 
associated with the consumption of contaminated foods such as ground beef and 
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produce [12, 13]. In the event of an outbreak, it is imperative that production lots 
associated with the primary food vehicle are identified as quickly as possible in 
order to recall all contaminated products from the marketplace [14]. Traditional 
techniques for the detection of E. coli O157:H7 in foods rely on a multistep process 
involving pre-enrichment in a selective broth followed by plating to reveal the 
presence of sorbitol-negative colonies, which are then purified and subjected to a 
battery of biochemical and serological tests to confirm their identity [15, 16]. This 
process can take up to 1 week to complete before the contaminant can be defini-
tively identified because of the requirement for growth and phenotypic expression 
of the organism.
As an alternative to classic phenotypic techniques, the identification of food-
borne colony isolates can be achieved on the basis of detection of defining gene 
markers. Detection platforms incorporating PCR techniques are particularly well 
suited for same-day analysis of a primary colony isolate. The CFIA microbiology 
laboratory network has undertaken a program of method development aimed at the 
rapid identification of colonies isolated on plating media at an early stage during the 
enrichment process. A key technology platform adopted by CFIA for this purpose is 
the cloth-based hybridization array system (CHAS) providing for identification of 
pathogens through amplification of key target genes by multiplex PCR, followed by 
rapid hybridization of the amplicons with an array of immobilized capture probes 
on a polyester cloth support [2–4, 17]. This approach enables facile detection of 
many gene markers in a single reaction, with specificity assured through the hybrid-
ization process.
A CHAS method for the identification of E. coli O157:H7 [17] has been validated 
following the guidelines of the Health Canada Compendium of Analytical Methods 
(CAM) (available at [18]). This method has been published in the CAM (MFLP-22: 
Characterization of verotoxigenic Escherichia coli O157:H7 colonies by polymerase 
chain reaction and cloth-based hybridization array system, [2]), enabling its 
implementation for regulatory testing purposes in Canada. It is notable as the first 
instance of a genetic marker-based approach for the definitive identification of a 
foodborne pathogen isolate in our laboratories. The E. coli O157:H7 CHAS was used 
by CFIA laboratories on two separate occasions in 2013 to provide critical evidence 
supporting health risk assessments in connection with foodborne illness outbreaks 
implicating ground beef distributed in Canada. This method enabled the testing 
laboratories to issue official results of analysis a full 2 days ahead of the traditional 
approach, leading to more timely interventions minimizing public exposure to 
the contaminated product. The CHAS technology has now been incorporated into 
routine diagnostic testing schemes in CFIA food testing laboratories.
2.1.2 Enter the next generation: whole-genome sequencing
Non-O157 STEC, particularly strains bearing certain O antigenic determinants 
(O26, O45, O103, O111, O121, O145, and O157), are emerging as a serious food-
borne public health concern [19]. Unlike E. coli O157:H7, there are no biochemical 
features by which these so-called priority STEC strains can be differentiated from 
commensal E. coli or other STEC which are not a public health concern. However, 
it is universally recognized that foodborne STEC posing a public health risk can be 
defined on the basis of possession of certain gene markers, including the Shiga toxin 
genes st1 or st2, the intimin-coding gene eae, and markers for the specific serogroups 
of concern [1, 19, 20]. Thus, priority STEC constitute a striking example illustrat-
ing the benefit of the use of gene markers for pinpointing pathogens otherwise not 
readily amenable to identification by classic means. This in turn has enabled practi-
cal strategies for multiplex gene detection methods for detection of such pathogens 
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presence of sorbitol-negative colonies, which are then purified and subjected to a 
battery of biochemical and serological tests to confirm their identity [15, 16]. This 
process can take up to 1 week to complete before the contaminant can be defini-
tively identified because of the requirement for growth and phenotypic expression 
of the organism.
As an alternative to classic phenotypic techniques, the identification of food-
borne colony isolates can be achieved on the basis of detection of defining gene 
markers. Detection platforms incorporating PCR techniques are particularly well 
suited for same-day analysis of a primary colony isolate. The CFIA microbiology 
laboratory network has undertaken a program of method development aimed at the 
rapid identification of colonies isolated on plating media at an early stage during the 
enrichment process. A key technology platform adopted by CFIA for this purpose is 
the cloth-based hybridization array system (CHAS) providing for identification of 
pathogens through amplification of key target genes by multiplex PCR, followed by 
rapid hybridization of the amplicons with an array of immobilized capture probes 
on a polyester cloth support [2–4, 17]. This approach enables facile detection of 
many gene markers in a single reaction, with specificity assured through the hybrid-
ization process.
A CHAS method for the identification of E. coli O157:H7 [17] has been validated 
following the guidelines of the Health Canada Compendium of Analytical Methods 
(CAM) (available at [18]). This method has been published in the CAM (MFLP-22: 
Characterization of verotoxigenic Escherichia coli O157:H7 colonies by polymerase 
chain reaction and cloth-based hybridization array system, [2]), enabling its 
implementation for regulatory testing purposes in Canada. It is notable as the first 
instance of a genetic marker-based approach for the definitive identification of a 
foodborne pathogen isolate in our laboratories. The E. coli O157:H7 CHAS was used 
by CFIA laboratories on two separate occasions in 2013 to provide critical evidence 
supporting health risk assessments in connection with foodborne illness outbreaks 
implicating ground beef distributed in Canada. This method enabled the testing 
laboratories to issue official results of analysis a full 2 days ahead of the traditional 
approach, leading to more timely interventions minimizing public exposure to 
the contaminated product. The CHAS technology has now been incorporated into 
routine diagnostic testing schemes in CFIA food testing laboratories.
2.1.2 Enter the next generation: whole-genome sequencing
Non-O157 STEC, particularly strains bearing certain O antigenic determinants 
(O26, O45, O103, O111, O121, O145, and O157), are emerging as a serious food-
borne public health concern [19]. Unlike E. coli O157:H7, there are no biochemical 
features by which these so-called priority STEC strains can be differentiated from 
commensal E. coli or other STEC which are not a public health concern. However, 
it is universally recognized that foodborne STEC posing a public health risk can be 
defined on the basis of possession of certain gene markers, including the Shiga toxin 
genes st1 or st2, the intimin-coding gene eae, and markers for the specific serogroups 
of concern [1, 19, 20]. Thus, priority STEC constitute a striking example illustrat-
ing the benefit of the use of gene markers for pinpointing pathogens otherwise not 
readily amenable to identification by classic means. This in turn has enabled practi-
cal strategies for multiplex gene detection methods for detection of such pathogens 
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during routine monitoring of the food supply to verify industry compliance with 
food safety regulations. In fact, such an approach is the basis for the Canadian STEC 
Method which was developed jointly by CFIA and Health Canada for the detection 
of this family of pathogens in meats and produce [3, 4].
The potential of PCR technology to provide informative test results is limited by 
its rather fragmentary nature, that is, the fact that only a relatively small number of 
different DNA markers can be assessed in a single analytical procedure. A consider-
able effort is required to optimize and validate the performance of PCR systems, 
particularly those in which multiple primer pairs are combined (e.g., identification 
of priority Shiga toxigenic E. coli (STEC) using a combination of 11 primer pairs; 
[1]). For all intents and purposes, validated assays are locked into their original 
configurations, and it is not possible to modify them (e.g., add or alter primers) on 
an ad hoc basis without first having to undertake a laborious and time-consuming 
re-evaluation of assay performance characteristics. Thus, novel queries cannot be 
undertaken if, in the course of an active food safety investigation, new questions 
arise regarding the occurrence of an unanticipated assay target. This was the case in 
a 2011 German outbreak involving STEC with an unusual virulence profile [21, 22].
The use of WGS technologies for STEC characterization can provide a more com-
plete picture [8]; however, completion of WGS analyses typically requires 3–5 days. 
As this timeline may be too long in an outbreak situation, we have developed practical 
processes in which genomic DNA isolated from a single STEC colony is sequenced 
using the Illumina MiSeq platform, followed by analysis of the sequence data during 
the course of the sequencing run for the determination of genomic markers for phylo-
genetic identity, virulence profile, serotyping, as well as biological metrics serving as 
quality control features supporting the validity of the process [5]. Identification and 
characterization of isolates can be completed within 9 h, comparable to the current 
method used for characterization of STEC. This real-time WGS approach produces 
high-resolution characterization of bacterial pathogens at a cost and within a time-
frame that are similar to standard microbiological techniques and has the potential 
to replace lengthy biochemical characterization and molecular and serological 
typing procedures widely used in food testing laboratories. Our laboratory is cur-
rently studying strategies for broad implementation of WGS technology in support 
of regulatory food inspection objectives through the detection, identification, and 
characterization of priority bacterial pathogens such as STEC, Salmonella enterica, 
and Listeria monocytogenes [5, 23–25]. We have developed guidelines and implemented 
validated methods and bioinformatics tools for automated analyses of sequence data 
to ensure reliability and reproducibility of WGS-based analyses [24, 26].
2.2 Have we seen it before? Impact of high-resolution molecular typing by 
WGS for distinguishing new isolates from control and historical laboratory 
isolates
Following detection of a pathogen in foods, (sub)typing methods are often used 
to generate a profile of the isolated organism to determine similarity to previously 
characterized isolates from clinical or food sources (reviewed in [27–29]). Typing of 
isolates recovered from food samples can provide important information regarding 
the complexity and source(s) of a given contamination incident, enables tracking of 
foodborne bacterial strains, and is frequently used to support regulatory decisions.
Early methods of typing were based on phenotypic properties, for example, 
 serotyping based on proteins expressed by the organism on surface structures [30–32] 
and phage typing based on susceptibility to reference panels of bacteriophage for 
distinguishing closely related isolates [33]. The development of methods based 
on DNA sequences followed [29]. Methods such as multilocus sequence typing 
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(MLST), involving sequencing of PCR-amplified fragments of a small number (i.e., 
6–9) of housekeeping genes, can be used to infer evolutionary relationships among 
organisms [34, 35]. This portable and highly reproducible method of typing has 
been widely deployed, and MLST schema have been developed for all of the prior-
ity foodborne pathogens [34]. For public health surveillance in Canada, as in other 
jurisdictions, the standard approach for typing of foodborne pathogens for cluster 
identification has been pulsed-field gel electrophoresis (PFGE) and multilocus 
variable-number tandem repeat analysis (MLVA) [27, 28, 36, 37]. In North America, 
data is shared among public health agencies through PulseNet [27, 38]. The selection 
of a typing method depends on a number of factors, including proven utility of the 
method for the pathogen being investigated. Each method requires costly training 
of lab personnel and in many cases the purchase of specialized equipment [39]. 
Furthermore, comparisons of typing data among different strains can only be done 
in cases where the same method has been applied. In some cases, variability in the 
execution of methods by different analysts or different labs significantly impacts the 
comparability of molecular typing data [36].
These typing methods are based on a limited subset of genomic sequences and 
often lack the discriminatory power to differentiate among closely related organ-
isms [39]. DNA typing profiles from two isolates appearing indistinguishable might 
be interpreted as evidence that the bacteria have a common source. However, the 
strength of this type of evidence rests on the extent to which the DNA profile consists 
of a combination of rare traits. When the traits defining a DNA profile are not rare, 
there is the possibility that two isolates are in fact unrelated and that matches are mere 
chance occurrences. In highly clonal strains (e.g., Salmonella) serovar Enteritidis, 
where only a few single-nucleotide changes may be observed among epidemiologi-
cally unrelated strains, most methods are not sufficiently discriminatory [40].
WGS provides a high-resolution molecular typing platform that can be uni-
versally applied to bacterial pathogens [6, 38, 41]. In principle, strains differing 
by even a single nucleotide can be distinguished [42, 43]. Furthermore, WGS can 
now be done more cheaply than lower resolution methods such as MLST and is 
backward-compatible with previous methods since, in some cases, typing data can 
be generated from minimally processed genomic data in silico [8, 9, 44]. Strains 
characterized by WGS can be compared to strains characterized by any other DNA-
based subtyping method, enabling optimal use of historical data. Molecular typing 
data have generally been developed as a surrogate measure of the genetic similar-
ity between bacterial strains. Using databases of WGS information, the utility of 
existing subtyping methods can be rigorously assessed, and improved subtyping 
schemes that reflect true strain relationships can be developed [45].
One advantage of the availability of WGS for typing bacterial isolates is the abil-
ity to evaluate datasets at different levels of resolution as needed to resolve biologi-
cal questions. In this regard, MLST continues to be a valuable approach for tracking 
foodborne pathogens in the genomic era [41, 44]. WGS data can be matched to 
current and historical databases at different levels of resolution including pathogen-
specific MLST (described above), core genome MLST (cgMLST) which uses 
hundreds of genes that are conserved within a species, and whole-genome MLST 
(wgMLST) which considers all genes within a species [38]. Similarly, ribosomal 
MLST (rMLST) is a 53-gene scheme with the advantage of being universally appli-
cable to bacteria typically encountered in a food testing laboratory [46].
The highest-resolution WGS-based analyses such as wgMLST and single-
nucleotide variant (SNV) analyses provide unrivaled DNA fingerprinting capability 
and offer tremendous potential for food safety applications [41, 42, 47]. Still, the 
use of these analyses in a food safety context is in its infancy, and the interpretation 
of genomic data from foodborne pathogens in support of regulatory interventions 
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One advantage of the availability of WGS for typing bacterial isolates is the abil-
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cal questions. In this regard, MLST continues to be a valuable approach for tracking 
foodborne pathogens in the genomic era [41, 44]. WGS data can be matched to 
current and historical databases at different levels of resolution including pathogen-
specific MLST (described above), core genome MLST (cgMLST) which uses 
hundreds of genes that are conserved within a species, and whole-genome MLST 
(wgMLST) which considers all genes within a species [38]. Similarly, ribosomal 
MLST (rMLST) is a 53-gene scheme with the advantage of being universally appli-
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remains challenging [48]. For example, how many SNVs are required to exclude a 
sample from a food safety investigation? This question remains difficult to answer, 
in part because of differences in rates at which DNA accumulates changes within a 
species or among strains within a species. Bacterial strains with a mutator pheno-
type have an elevated mutation rate, typically due to mutations in genes encoding 
components of DNA replication and repair pathways [49]. Mutator phenotypes are 
commonly found in clinical bacterial populations and may contribute significantly 
to the acquisition of antimicrobial resistance [50–52]. For example, the muta-
tor phenotype has been attributed to the development of multidrug-resistant S. 
typhimurium [50]. In E. coli, this phenotype has recently been shown to be induced 
in response to stress conditions [53]. The possibility that environmental stress 
could lead to the development of the mutator phenotype may be highly relevant to 
analyses of foodborne pathogens.
2.2.1 Identification of persistent contamination
Persistent contamination of food manufacturing environments with bacteria 
such as Listeria monocytogenes poses significant public health risks as these events 
serve as a source for the continual contamination of food products, primarily 
because (by definition) persistent contaminators defy attempts to sanitize the 
manufacturing environment using standard protocols [54–56]. Listeria monocy-
togenes is the causative agent of listeriosis, a potentially fatal foodborne illness in 
susceptible populations such as the very young, the elderly, and the immunocom-
promised [57]. The ability of this organism to contaminate food contact surfaces 
(e.g., conveyors, saws, etc.) and survive in the manufacturing environment 
increases the risk of food product contamination, with possible serious public 
health consequences. Routinely monitoring the food manufacturing environment 
for the presence of pathogenic bacteria is a key to preventing contamination of food 
products [56]. The presence of environmental contamination is usually ascertained 
through swabbing and testing of food manufacturing environment surfaces using 
standard microbiology techniques. Transient contamination is of a sporadic nature 
and may be effectively managed through the application of standard sanitation 
regimens followed by testing to ensure treatment efficacy. Persistent contamination 
occurs when a specific strain becomes a permanent resident of specific niches in the 
manufacturing environment. Persistence may be attributable to the incorporation 
of L. monocytogenes into biofilms occurring on equipment surfaces, resistance to 
commonly used sanitizers such as benzalkonium chloride, or through mechanical 
sequestration in hard-to-clean areas (e.g., meat cutting saw arbors, as was the case 
in the 2008 Canadian listeriosis outbreak resulting in many fatalities associated 
with the consumption of contaminated ready-to-eat meats [58]).
The ability to distinguish the two modes of contamination in the analysis of 
environmental isolates recovered during routine monitoring activities would 
constitute an important element to inform the best approach for the management 
of microbial hazards in food manufacturing plants [54, 55]. For example, while 
regular sanitation procedures may be effective in dealing with removal of sporadic 
surface contaminants, a more comprehensive approach requiring equipment tear-
down and aggressive sanitation would be required to deal with persistent contami-
nants, which are by nature highly resistant to sanitizers and cleaning procedures. 
The traditional approach to identify the occurrence of persistent contamination 
in food manufacturing environments involves the characterization of successive 
isolates using typing procedures such as PFGE to determine their relatedness [54]. 
However, PFGE is of limited value for this purpose because it is not sufficiently 
discriminatory to unequivocally establish whether two strains are clonally related 
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(i.e., one being descendant from the other). Depending on the scope of the con-
tamination, there may be multiple related populations within the food production 
environment.
Whole-genome sequencing approaches offer the prospect of determining the 
degree of relatedness among isolates on the basis of very fine base sequence differ-
ences, because more closely or clonally related isolates have fewer SNV differences. 
Therefore, it should be possible to compare two isolates (e.g., recovered on successive 
sampling incursions in the same plant) using high-resolution WGS typing methods 
to ascertain whether they are clonally related or different [55]. In the former case, 
this would be a strong indication that there is either an unresolved source of con-
tamination in the plant, or more likely, a case of persistent contamination, whereas 
the latter case would suggest two independent contamination incidents. Each 
scenario would warrant a different approach to decontamination, and the ability to 
differentiate persistent and sporadic strains on the basis of the relatedness of succes-
sive isolates would constitute a powerful risk assessment and risk management tool 
for the use in the most highly proactive food safety programs. There is one caveat in 
the use of SNV-based typing, and that is the temporal drift which naturally occurs 
in bacteria, resulting in the accumulation of SNVs among the progeny derived from 
a single parent. The question remains under which conditions this occurs for bacte-
rial strains in a food manufacturing environment and how many SNV differences 
constitute a real difference in terms of the provenance of isolates under comparison.
One cause of L. monocytogenes persistence has been identified as resistance to 
sanitizers such as quaternary ammonium compounds (QACs) [59–61]. An impor-
tant determinant of QAC resistance is efflux systems such as those encoded by 
the bcrABC gene cassette [62] or emrE [63]. In a recent study to characterize the 
genomes of L. monocytogenes isolates collected at a pig slaughterhouse to determine 
the molecular basis for their persistence, we found that successive environmental 
isolates (persistent types) linked on the basis of SNV analyses all harbored the 
bcrABC and concluded that high-resolution typing and determination of the 
cassette may serve to distinguish between persistent and sporadic L. monocytogenes 
isolates [59]. This in turn may have important ramifications for risk management 
actions when L. monocytogenes is recovered from a food manufacturing environ-
ment, since the ability of a strain to persist casts doubt on the efficacy of standard 
sanitization protocols, and more intensive cleaning procedures (e.g., equipment 
teardown, use of alternative sanitizers) may be warranted. These types of analyses 
of food inspection isolates are greatly facilitated by WGS technology [55, 59].
2.2.2 Contribution to surveillance programs and outbreak investigations
Although numerous methods are used by food safety and public health agencies 
to support regulatory decisions during outbreak investigations, demonstrating that 
food and clinical isolates originated from the same source can be challenging. As the 
results generated by WGS make their way into situation rooms to guide decision-
makers, concise metrics for the interpretation and contextualization of genomics-
derived data will be required to achieve more precise assessments [64]. The value of 
WGS-based typing for cluster identification has already been demonstrated through 
global surveillance networks such as GenomeTrakr and PulseNet [6, 38, 41]. 
Smaller clusters of cases can be linked through WGS analyses and investigated [65], 
and conversely, unrelated cases can be excluded from an epidemiological investiga-
tion leading to improved outcomes for rapid identification of foods implicated in 
outbreaks [66]. Nonetheless, WGS results should not be interpreted in the absence 
of epidemiological context as some lineage rates of mutation are low and strains 
from different sources may appear to be linked [67].
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remains challenging [48]. For example, how many SNVs are required to exclude a 
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The concepts of “match probability” and “likelihood ratios” are well known in 
human forensic sciences where they facilitate the interpretation of DNA profiles 
in matching individuals to a crime scene [68]. For example, when the DNA profile 
found on a crime scene matches that of a suspect and there is only a one-in-one 
million probability that this DNA profile might be found in another individual, 
there is a strong case linking the suspect to the crime scene. Food inspectors face 
a similar situation during outbreak investigations when trying to establish causal 
links between isolates from different sources [69]. Bacteria may undergo subtle 
changes in their genomes during the course of a foodborne illness outbreak event, 
with possible impacts on the typing profiles of clonally related isolates recovered 
over time. The question arises as to how much change in a genome constitutes a 
significant difference between individual isolates (i.e., different origins or strains). 
Through statistical analyses of comprehensive pathogen genome databases, it 
should be possible to develop a likelihood ratio approach to determine the prob-
ability of finding a given profile in a defined population and, hence, develop criteria 
to measure sequence diversity between isolates with different degrees of relatedness 
and even among clonally related isolates recovered over the course of an outbreak 
event [69]. This in turn would provide a greater degree of confidence in attribut-
ing the origins of isolates, identifying clusters of foodborne illness and their food 
vehicles, and the scope of contamination. This information can also be used to 
revise and adjust detection tools (e.g., PCR primers) to ensure their effectiveness 
in identifying “moving” genomic targets. The development of a forensic likelihood 
ratio approach would provide a valuable tool to assess the reliability of genomic 
information underlying regulatory decision-making.
2.2.3 Attribution of food vehicles through genomic surveillance
The advent of genomic typing augurs well for the creation of highly refined 
databases of bacterial isolates from various sources (foods, production facilities, 
farms, environmental and clinical strains) providing high-resolution characteriza-
tion of individual strains with established linkages to their geographic and temporal 
origins. Historically, the use of low-resolution typing approaches such as MLST 
profiles or serotypes has been valuable for the association of specific lineages with 
a given food type, production environment, or country [70, 71]. Initiatives such as 
the GenomeTrakr and the PulseNet WGS networks represent rich resources from 
which to draw valuable information linking isolates to their origin in the food pro-
duction continuum [6, 38, 72]. For example, an analysis of E. coli O157:H7 identified 
SNVs associated with country of origin [73]. Similarly, an outbreak involving S. 
Bareilly in the United States was tracked to a food originating in India based on 
high-resolution SNV typing [74].
With the aid of bioinformatics tools, databases can be queried to identify 
genomic signatures that are overrepresented in particular head sources for bacterial 
isolates. For example, a study by Thépault et al. [75] identified 15 host-associated  
C. jejuni markers and demonstrated utility of these markers for identifying host 
association of strains with 80% accuracy. The ability to discern this type of informa-
tion would be a tremendous boon for foodborne illness investigations: WGS data 
could be used to determine the “source signature” of clinical isolates, enabling a 
highly proactive approach in rapidly narrowing the field for the attribution of food 
vehicles. Regulatory food inspection agencies such as the CFIA would have an impor-
tant role to play in such a scheme. Ongoing, extensive sampling plans will be required 
to ensure adequate representation of different food production elements, such as food 
types and geographic provenance. Given that most cases of foodborne illness occur 
sporadically, this approach would enable public health authorities to track the causes 
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of a larger proportion of cases of foodborne illness. This would ultimately lead to a 
better understanding of foods commonly implicated in disease and the implementa-
tion of more effective interventions to reduce the burden of foodborne illness.
2.3 Is it dangerous? Rapid identification of virulence, antimicrobial resistance, 
and epidemiological markers through WGS
Genomic information is highly complex, and there are many knowledge gaps 
with respect to the significance of various marker genes to public health [76]. 
Nonetheless, there is a growing body of evidence linking certain well-defined gene 
markers to virulence characteristics of bacteria, for example, the role of intimin 
(coded by the eae gene) in the pathogenesis of STEC, epidemiological associations 
between certain serotype features and outbreaks of serious foodborne illness (e.g., 
L. monocytogenes serogroups 1/2a, 1/2b, and 4b, STEC serogroups O26, O45, O103, 
O111, O121, O145, and O157), and even the type of toxin secreted (e.g., Shiga toxin 2) 
and the attendant severity of illness [77, 78].
In the case of STEC, regulatory food testing programs currently define priority 
target strains as bearing markers for Shiga toxin genes and intimin, in addition to 
markers associated with a narrow family of O serogroups [2]. However, the question 
arises whether in the course of conducting routine monitoring of food inspection 
samples the occurrence of an isolate bearing markers for Shiga toxin and intimin, 
but none of the so-called priority serogroups would be actionable. There are vary-
ing subjective opinions on the matter, ranging from a narrow interpretation of test 
results in which only isolates bearing all the designated factors are considered haz-
ardous to the more precautionary approach whereby any isolate bearing both Shiga 
toxin and intimin factors, regardless of O serogroup, constitutes a public health risk. 
There is also evidence suggesting that severity or likelihood of foodborne illness 
varies with Shiga toxin type and subtype (e.g., STEC strains possessing st2a tend to 
be more frequently implicated in cases of severe foodborne illness [79]) and that this 
should be a factor in determining the appropriate response to the presence of a food 
contaminant. These properties are readily discoverable through the analysis of WGS 
data. For instance, the Shiga toxin subtype can be reliably determined using the 
V-typer tool, which is an automated assembly-independent subtyping module that 
can be integrated in a bioinformatics pipeline for the analysis of foodborne STEC 
isolates [23]. Yet another possibility would be to define priority STEC on the basis of 
contemporary public health data (reviewed periodically) identifying STEC sero-
groups most frequently associated with illness in a given jurisdiction. The serogroup 
of an E. coli isolate can be determined using tools such as SeroTypeFinder [8] which 
can be freely accessed through the Center for Genomic Epidemiology website [80].
Such considerations raise problems for health risk assessment specialists who 
must interpret laboratory results (among other factors) to determine the degree 
of risk informing the course of regulatory interventions [76]. It is tempting to 
speculate that it may be possible to devise an objective scheme for rating the degree 
of hazard associated with a given isolate on the basis of genomic analyses. For 
instance, the public health and food inspection communities could agree on a list 
of key factors relevant to the characterization of a given pathogen (Table 1). For 
organisms such as E. coli, acquired virulence gene databases have been established, 
and isolates may be profiled using tools such as VirulenceFinder [7], accessible 
through the Center for Genomic Epidemiology website [80]. Since not all factors 
have the same impact, it should be possible to develop a weighted index approach in 
which each constituent factor determined by genomic analysis makes up a frac-
tion of a final index value which is proportional to the degree of hazard. Such an 
index value (hazard characterization or HazChar Score), used in conjunction with 
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numerical criteria derived from historical data, could form a basis for attribut-
ing the degree of hazard associated with a particular isolate, which in turn would 
enable an objective categorization of risk to inform the appropriate regulatory 
response.
The antimicrobial resistance profile of pathogenic bacteria, while not a 
virulence attribute per se, remains an important factor in the ultimate public 
health outcomes of foodborne illness events, since a significant fraction of the 
affected population (e.g., the elderly and the immunocompromised) may criti-
cally require antibiotic therapy to recover. Furthermore, antimicrobial use at 
sub-therapeutic levels for growth promotion in food animal production has been 
implicated in the development of antimicrobial resistance (AMR) in animals and 
humans [81, 82], though there is paucity of data to support this claim. Food test-
ing laboratories can play an important role in contributing data on the occurrence 
of AMR bacteria to national and international surveillance initiatives seeking 
to understand the role of production practices in the emergence of these micro-
organisms. As an alternative to labor- and time-consuming phenotypic testing, 
AMR profiles can be predicted from WGS data through the identification of 
genetic markers by querying the subject genome using DNA sequence informa-
tion deposited in curated AMR gene databases, such as well-cataloged AMR gene 
markers. A number of tools are currently available to predict AMR from bacterial 
WGS data (e.g., ResFinder [10, 83], SEAR [84], Resistance Gene Identifier [85], 
and ARMI [86]). These AMR marker prediction tools rely on curated interna-
tional AMR gene databases such as CARD [85], ARDB [87], and ARG-ANNOT 
[88]. WGS-based methods for prediction of AMR phenotype have been shown to 
be highly accurate [86, 89–91].
Key factors Element Relevance
Primary virulence Toxin Presence or absence
Attachment and colonization eae, enteroaggregative factors
Pathogenicity Pathogenesis mechanisms (e.g., 
hemolysin)
Severity modulator Type st1 vs. st2
Subtype st2a vs. st2f
Accessory functions Antibiotic resistance Therapeutic impact
Antimicrobial resistance Sanitizer efficacy
Biofilm formation Persistence
Pathogenicity islands Signatures for novel pathogens
Epidemiological markers Serotype Outbreak vs. sporadic vs. nil association
Phage type Reservoirs, illness outbreaks
Molecular type PFGE/SNV cluster
Phylogenetic markers Genus/species Identity (e.g., Salmonella, E. coli)
Family or group STEC
aA list of key factors is developed for a given pathogen, and each element is assigned a weighted value based on 
its significance in human illness. Genomic analysis of a foodborne isolate by whole-genome sequencing with the 
application of bioinformatics tools to determine the presence of targeted features. The individual weighted values 
are summed giving the HazChar Score, which is then compared against a set of predetermined criteria to categorize 
the degree of risk.
Table 1. 
Proposed concept for hazard characterization: HazChar Scorea.
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3. Future applications
3.1 Deployment of ad hoc methods in support of outbreak investigations
Despite recent efforts of regulatory food safety agencies to implement test 
methods targeting defined serogroups of so-called priority STEC, the history of 
foodborne disease outbreaks is rife with examples of causative strains with unex-
pected characteristics (e.g., the 2011 German outbreak in which the etiologic agent 
belonged to serogroup O104, not a designated priority serogroup, and lacked the 
definitive virulence marker eae [21]), making it difficult to anticipate detection 
methods suiting all contingencies. Detection is further complicated by variability 
among non-O157 STEC strains in resistance to selective agents commonly used in 
enrichment culture techniques, hindering their recovery from foods bearing high 
levels of background microbiota [92–94]. Genomic information garnered from 
clinical bacterial isolates implicated in outbreaks of foodborne illness will be very 
useful in the customization of selective recovery and identification procedures to 
facilitate their detection in food samples during outbreak investigations [86].
The state of the art in WGS technology has reached the point where clinical 
isolates implicated in foodborne disease outbreaks are routinely sequenced in public 
health laboratories at an early stage during these events [38]. With the application of 
appropriate bioinformatics tools to analyze the ensuing data, it should be possible 
to develop customized strain-specific test methods that can be rapidly deployed 
to food testing labs conducting analyses in support of outbreak investigations. 
The availability of WGS information for these strains should make it possible to 
ascertain the presence of traits conferring resistance to antimicrobial agents such as 
antibiotics, quaternary ammonium compounds, and tellurite, suggesting an avenue 
for the formulation of customized selective enrichment media enabling recovery 
of specific outbreak strains [86]. This would be a particular advantage in instances 
where a food matrix (e.g., meats, sprouts, etc.) contains high levels of background 
microbiota, which might otherwise interfere with recovery of the target organism. 
Genomic AMR prediction tools can be used to discern the AMR marker profile of 
a strain of interest (e.g., outbreak strain) to identify an antibiotic resistance trait 
which can be exploited for customization of selective enrichment media favoring 
its recovery from samples with high background bacteria loads [86, 95]. In addi-
tion, WGS data can be analyzed using a pipeline such as SigSeekr [96] designed to 
identify DNA sequences associated with a particular strain for its rapid identifica-
tion by PCR. By combining strain-specific selective enrichment and PCR detection 
tools, it should be possible to deploy custom recovery and identification tools for 
the efficient detection of STEC outbreak strains within the timeframe of an active 
investigation. The feasibility of such an approach has been demonstrated using 
laboratory STEC strains as models, with resistance to a variety of antibiotic classes 
used as the basis for their selective recovery against high backgrounds of commensal 
E. coli bacteria in ground beef samples [86].
3.2 Characterization of food microbiomes in support of improved method 
development
Metagenomic analysis of enrichment dynamics can be used to inform the 
development of improved methods for cultural enrichment of pathogens [97–99]. 
A practical approach for this is to selectively amplify hypervariable regions within 
the 16 s rDNA and to sequence amplicons using WGS technologies. Sequences are 
then mapped to databases to determine composition of microbial communities 
using bioinformatics tools such as QIIME [100] or mothur [101]. Samples from 
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numerical criteria derived from historical data, could form a basis for attribut-
ing the degree of hazard associated with a particular isolate, which in turn would 
enable an objective categorization of risk to inform the appropriate regulatory 
response.
The antimicrobial resistance profile of pathogenic bacteria, while not a 
virulence attribute per se, remains an important factor in the ultimate public 
health outcomes of foodborne illness events, since a significant fraction of the 
affected population (e.g., the elderly and the immunocompromised) may criti-
cally require antibiotic therapy to recover. Furthermore, antimicrobial use at 
sub-therapeutic levels for growth promotion in food animal production has been 
implicated in the development of antimicrobial resistance (AMR) in animals and 
humans [81, 82], though there is paucity of data to support this claim. Food test-
ing laboratories can play an important role in contributing data on the occurrence 
of AMR bacteria to national and international surveillance initiatives seeking 
to understand the role of production practices in the emergence of these micro-
organisms. As an alternative to labor- and time-consuming phenotypic testing, 
AMR profiles can be predicted from WGS data through the identification of 
genetic markers by querying the subject genome using DNA sequence informa-
tion deposited in curated AMR gene databases, such as well-cataloged AMR gene 
markers. A number of tools are currently available to predict AMR from bacterial 
WGS data (e.g., ResFinder [10, 83], SEAR [84], Resistance Gene Identifier [85], 
and ARMI [86]). These AMR marker prediction tools rely on curated interna-
tional AMR gene databases such as CARD [85], ARDB [87], and ARG-ANNOT 
[88]. WGS-based methods for prediction of AMR phenotype have been shown to 
be highly accurate [86, 89–91].
Key factors Element Relevance
Primary virulence Toxin Presence or absence
Attachment and colonization eae, enteroaggregative factors
Pathogenicity Pathogenesis mechanisms (e.g., 
hemolysin)
Severity modulator Type st1 vs. st2
Subtype st2a vs. st2f
Accessory functions Antibiotic resistance Therapeutic impact
Antimicrobial resistance Sanitizer efficacy
Biofilm formation Persistence
Pathogenicity islands Signatures for novel pathogens
Epidemiological markers Serotype Outbreak vs. sporadic vs. nil association
Phage type Reservoirs, illness outbreaks
Molecular type PFGE/SNV cluster
Phylogenetic markers Genus/species Identity (e.g., Salmonella, E. coli)
Family or group STEC
aA list of key factors is developed for a given pathogen, and each element is assigned a weighted value based on 
its significance in human illness. Genomic analysis of a foodborne isolate by whole-genome sequencing with the 
application of bioinformatics tools to determine the presence of targeted features. The individual weighted values 
are summed giving the HazChar Score, which is then compared against a set of predetermined criteria to categorize 
the degree of risk.
Table 1. 
Proposed concept for hazard characterization: HazChar Scorea.
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3. Future applications
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definitive virulence marker eae [21]), making it difficult to anticipate detection 
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among non-O157 STEC strains in resistance to selective agents commonly used in 
enrichment culture techniques, hindering their recovery from foods bearing high 
levels of background microbiota [92–94]. Genomic information garnered from 
clinical bacterial isolates implicated in outbreaks of foodborne illness will be very 
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appropriate bioinformatics tools to analyze the ensuing data, it should be possible 
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ascertain the presence of traits conferring resistance to antimicrobial agents such as 
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a strain of interest (e.g., outbreak strain) to identify an antibiotic resistance trait 
which can be exploited for customization of selective enrichment media favoring 
its recovery from samples with high background bacteria loads [86, 95]. In addi-
tion, WGS data can be analyzed using a pipeline such as SigSeekr [96] designed to 
identify DNA sequences associated with a particular strain for its rapid identifica-
tion by PCR. By combining strain-specific selective enrichment and PCR detection 
tools, it should be possible to deploy custom recovery and identification tools for 
the efficient detection of STEC outbreak strains within the timeframe of an active 
investigation. The feasibility of such an approach has been demonstrated using 
laboratory STEC strains as models, with resistance to a variety of antibiotic classes 
used as the basis for their selective recovery against high backgrounds of commensal 
E. coli bacteria in ground beef samples [86].
3.2 Characterization of food microbiomes in support of improved method 
development
Metagenomic analysis of enrichment dynamics can be used to inform the 
development of improved methods for cultural enrichment of pathogens [97–99]. 
A practical approach for this is to selectively amplify hypervariable regions within 
the 16 s rDNA and to sequence amplicons using WGS technologies. Sequences are 
then mapped to databases to determine composition of microbial communities 
using bioinformatics tools such as QIIME [100] or mothur [101]. Samples from 
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enrichment cultures can be used to evaluate growth of target pathogens relative to 
background food microbiota over time [97, 99]. Such studies can provide valuable 
insight into species that could potentially interfere with target pathogens that can be 
applied to the development of improved methodology.
A modern concept in the study of pathogenic bacteria is the emergence of novel 
pathogens among commensals in a given environment through the acquisition of 
virulence factors by horizontal gene transfers from other bacteria [102–104]. The 
evolutionary trail of the STEC family suggests a priori transformations of benign 
E. coli strains into virulent STEC having acquired exogenous DNA segments such 
as bacteriophage carrying Shiga toxin genes and pathogenicity islands harboring 
host colonization factors [105]. There is evidence that other food pathogens such as 
L. monocytogenes strains implicated in serious outbreaks of foodborne illness may 
have acquired enhanced virulence characteristics through horizontal gene transfer 
processes [106]. This is believed to occur on a relatively short time scale, perhaps 
on the order of weeks or months, making the emergence of novel pathogens in food 
production environments or animal reservoirs in near real time a significant pos-
sibility. Furthermore, food-acquired coinfections may arise in which two or more 
bacterial strains complement each another, for example, a toxigenic strain lacking 
adherence factors might colonize a host by cross-utilizing a factor secreted by 
another strain [107]. It may be possible to predict the probability of emergence of 
novel pathogens with enhanced virulence or antibiotic resistance characteristics in 
the food supply through periodic microbial metagenomic analyses to ascertain the 
presence of key indicators in the background microflora of food commodities (e.g., 
ground beef, trim), food manufacturing environments (e.g., floors, food contact 
surfaces), and animal reservoirs (e.g., cattle, poultry) [108, 109]. A weighted index 
approach much like that described for the HazChar Score above could be employed 
here, with possible inclusion of a more comprehensive catalog of known virulence, 
AMR, and other critical factors relevant to public health.
4. Conclusions
Modern food microbiology research has generated a critical understanding of 
the epidemiology, pathogenic mechanisms, virulence factors, and other salient 
characteristics of the major food pathogens. The convergence of expanded sci-
entific knowledge and sophisticated technological capability create exciting new 
opportunities for the refinement of food microbiology testing programs to meet 
the needs of a comprehensive risk-based inspection approach. Advances in next-
generation sequencing technologies have made it possible for investigators to carry 
out sequencing and processing of bacterial genomes within the time course of a 
typical foodborne illness outbreak investigation. It may reasonably be expected 
that in the near future, analysts will be moving from traditional DNA hybridization 
approaches (e.g., PCR and microarrays) toward rapid whole-genome sequencing 
allowing a much more comprehensive examination of the isolate at hand. This new 
approach will require broad access to leading-edge bioinformatics capability for 
analysis of complex genomics data in silico to ascertain the presence of key genetic 
markers (e.g., presence of virulence genes in bacterial pathogens, completeness and 
functionality of gene products, markers for molecular typing, etc.). The genera-
tion and analysis of WGS information requires the migration of large packets of 
information between laboratory sites involved in the exploitation of this informa-
tion, remote computing sites, and internet databases for data manipulation and 
comparative analyses. There are many ways in which the high-tech needs of the 
future can be met, even for relatively small laboratories with low operating budgets. 
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